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Abstract  
 
 
The oncogenic protein Bcl-2 is overexpressed in many cancers and prevents cells 
from undergoing apoptosis in response to traditional chemotherapeutic agents. Recent 
research has focussed on the development of novel agents that can disrupt the 
function of Bcl-2 and trigger apoptosis in cancer cells. The isothiocyanates are a class 
of naturally-occurring phytochemical with potential for development as both 
chemopreventive and chemotherapeutic agents. This thesis investigated the ability of 
the isothiocyanates to induce apoptosis in cells that overexpressed Bcl-2. 
 
Initially, phenethyl isothiocyanate was shown to be cytotoxic to the Jurkat T-
lymphoma cell line with an LD50 of 7.4 µM. Bcl-2 expression had little protective 
effect, and even greater than 50-fold overexpression only increased the LD50 to 15.1 
µM. Morphological and biochemical assays indicated that death still occurred by 
apoptosis despite overexpression of Bcl-2.  
 
A variety of other isothiocyanates were also screened for cytotoxic activity. While the 
isothiocyanate moiety was crucial for induction of apoptosis, the chemistry of the side 
chain attached to the isothiocyanate moiety also profoundly influenced the ability of 
an isothiocyanate to kill Bcl-2 overexpressing cells. The aromatic isothiocyanates 
were generally far more cytotoxic than aliphatic isothiocyanates. However, within the 
aromatic isothiocyanates tested in this study the length of the carbon linker group, 
between the phenyl ring and the isothiocyanate moiety, also influenced cytotoxic 
activity. Phenethyl isothiocyanate was identified as the most promising compound 
when targeting cells that overexpressed Bcl-2. Given that minor structural alterations 
significantly altered cytotoxic activity it is hypothesised that specific interactions with 
cellular targets may mediate induction of apoptosis by the isothiocyanates.  
 
Finally, using a sensitive proteomic technique to label oxidised thiol proteins a 
preliminary investigation of the targets of the isothiocyanates was performed. A 
number of thiol proteins were selectively modified following exposure to phenethyl 
 isothiocyanate. One thiol protein that consistently changed was identified as 
mitochondrial peroxiredoxin-3. Changes to the oxidation state of peroxiredoxin-3 
occurred well before activation of apoptosis and may play a role in mediating 
induction of apoptosis in cells that overexpress Bcl-2. 
 
The results of this thesis have provided a platform to permit further investigation of 
the chemotherapeutic potential of the isothiocyanates and investigation of the 
mechanisms that allow the isothiocyanates to induce apoptosis in cells that 
overexpress the oncogene Bcl-2. In the future, the identification of primary targets of 
the isothiocyanates may aid the design and testing of novel anticancer drugs, and it 
will also provide novel insight into the regulation of apoptosis. 
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 Chapter 1 
 
Introduction 
 
 
The anti-apoptotic protein Bcl-2 is overexpressed in many cancers. Overexpression of 
this oncogene can abrogate the cytotoxic activities of chemotherapeutic agents 
resulting in multi-drug resistance. Current research is focussed on the identification of 
novel agents to overcome the anti-apoptotic block that overexpression of Bcl-2 
confers. This thesis investigates the potential of a class of phytochemicals, called 
isothiocyanates, to induce apoptosis in cells that overexpress Bcl-2. 
 
1.1 The isothiocyanates  
Epidemiological studies demonstrate a clear relationship between increased 
consumption of fruits and vegetables and reduced occurrence of cancer (Steinmetz 
and Potter 1991; Steinmetz and Potter 1996). In particular, increased consumption of 
cruciferous vegetables from the Brassica genus has been correlated with a decrease in 
the incidence of various cancers (Spitz et al. 2000; Seow et al. 2002; Fowke et al. 
2003; Bianchini and Vainio 2004). Commonly consumed Brassica vegetables include 
cabbage, broccoli, Brussels sprouts and watercress. The chemopreventive activity of 
these vegetables is largely attributed to amino-acid derived secondary products called 
glucosinolates, which are β-thioglucoside N-hydroxysulfates with a variable side 
chain and a sulfur-linked β-D-glucopyranose moiety (Holst and Williamson 2004) 
(Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Chemical structure of the glucosinolates. Glucosinolates exist as N-
hydroxysulfates with a sulfur-linked β-glucose and variable side chain (R) (adapted 
from Fahey et al. 2001). 
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 More than 120 naturally occurring glucosinolates have been reported (Fahey et al. 
2001). As many as fifteen different glucosinolates can be found in the same plant, 
although usually only three or four predominate (Holst and Williamson 2004). 
Watercress (Nasturtium officinale) contains eight glucosinolates, including 
glucoibarin, glucohirsutin, glucotropaeolin, glucosinalbin and, predominantly, 
gluconasturtiin (Daxenbichler et al. 1991; Fahey et al. 2001). On the other hand, the 
glucosinolate content of broccoli (Brassica oleracea) consists almost entirely of 
glucoraphanin, glucoerucin and glucoiberin (Fahey et al. 1997).  
 
Although the glucosinolates are relatively biologically inert, they are converted into 
biologically active isothiocyanates by β-thioglucosidases called myrosinases (Bones 
and Rossiter 1996). In intact plant tissue, the myrosinases are localised in ‘myrosin 
cells’ and are physically separated from glucosinolates, which are located within the 
vacuole of a plant cell (Halkier and Du 1997). When the tissues of such plants are 
damaged, the glucosinolates come into contact with myrosinase, resulting in the 
conversion of the glucosinolate to a highly unstable aglycone which, in turn, 
undergoes spontaneous Lossen rearrangement to form the corresponding 
isothiocyanate (Chen and Andreasson 2001; Conaway et al. 2002) (Figure 1.2). Given 
that cruciferous vegetables are often consumed after being cooked, plant-derived 
myrosinase activity is usually absent; however, the conversion of glucosinolate to 
isothiocyanate can occur in the digestive system, as myrosinases are also present in 
many bacteria that are commonly associated with human gut microflora (Getahun and 
Chung 1999).  
 
 
 
Figure 1.2: Formation of an isothiocyanate by hydrolysis of a glucosinolate 
(adapted from Chen and Andreasson 2001). Isothiocyanates are produced as a result 
of myrosinase-dependent hydrolysis of glucosinolates. An unstable aglycone (a 
thiohydroxamate-O-sulfonate) is the intermediate in the hydrolysis reaction.  
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 Within the plant itself, the isothiocyanates are thought to function as a defence against 
herbivore attack; however, these compounds also demonstrate antibacterial and 
antifungal activity (Manici et al. 1997; Lin et al. 2000; Mithen et al. 2000). More 
recently, the isothiocyanates have attracted much attention for their considerable 
potential as chemopreventive and chemotherapeutic agents. 
 
1.1.1 Metabolism of the isothiocyanates 
Oral administration of isothiocyanates has been shown to lead to rapid cellular 
accumulation in all organs of the body (Conaway et al. 1999; Conaway et al. 2002). 
Once ingested, isothiocyanates rapidly accumulate within cells and intracellular 
concentrations of these phytochemicals can reach millimolar levels (Zhang and 
Talalay 1998). Initially, isothiocyanates cross the plasma membrane by passive 
diffusion (Figure 1.3). Once inside the cell, the enzymatic actions of glutathione S-
transferases (GSTs) catalyse the rapid conjugation of isothiocyanates with glutathione 
(GSH) to produce a dithiocarbamate (Zhang et al. 1995; Zhang 2001). Intracellular 
dithiocarbamates are rapidly depleted by expulsion through both the multidrug 
resistance associated protein-1 and P-glycoprotein-1 (Callaway et al. 2004). Upon 
leaving the cell, the dithiocarbamate can take one of two pathways. In the first 
pathway, the dithiocarbamate is converted back to the parent isothiocyanate by 
removal of GSH. This pathway regenerates the isothiocyanate, which can once again 
enter a cell by passive diffusion (Bruggeman et al. 1986; Zhang and Callaway 2002). 
The second pathway involves the processing of the dithiocarbamate via the 
mercapturic acid pathway, which ultimately allows for urinary excretion of the N-
acetyl cysteine derivative of the dithiocarbamate (Ji and Morris 2003; Vermeulen et 
al. 2003).  
 
  
Figure 1.3: Metabolism of isothiocyanates (adapted from Keum et al. 2004). (1) 
Extracellular isothiocyanates cross the cell membrane by passive diffusion. (2) GSTs 
catalyse the rapid conjugation of intracellular isothiocyanates with GSH. (3) The 
resulting dithiocarbamate is exported from the cell where (4) the parent 
isothiocyanate can be regenerated. Alternatively, the dithiocarbamate may be 
metabolised via the mercapturic acid pathway. Initially, (5) γ-glutamyl-transpeptidase 
converts the dithiocarbamate to a cysteinyl glycine derivative. (6) Cysteinyl-glycinase 
then converts the cysteinyl glycine derivative to a cysteine derivative. Finally, (7) N-
acetyltransferase converts the cysteine derivative to an N-acetylcysteine derivative, 
which can be excreted in the urine. 
 
1.1.2 Intracellular reactions of the isothiocyanates 
The chemistry of the isothiocyanate moiety will mediate the majority, if not all, of the 
physiological effects induced in response to isothiocyanate exposure. The central 
carbon of the isothiocyanate moiety is often highly electrophilic and can react with 
two cellular nucleophilic targets: amines and thiols (Thornalley 2002) (Figure 1.4). It 
is widely believed that the protective activities of the isothiocyanates may be 
mediated primarily via the reaction of the central carbon atom with these targets 
(Zhang et al. 2005). 
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Figure 1.4: Key reactions of isothiocyanates with cellular targets. Upon entering a 
cell an isothiocyanate can react with amines or thiol groups to produce thiourea or 
dithiocarbamate derivatives respectively (adapted from Thornalley 2002).  
 
The reaction of an isothiocyanate with an amine group results in the formation of a 
thiourea derivative. The modification of amines by isothiocyanates is utilised, in 
combination with mass spectrometry or high performance liquid chromatography 
(HPLC), for the sequencing of proteins and peptides (Muramoto et al. 1984; Gu and 
Prestwich 1997; Mo et al. 1997; Liu and Liang 2001). While the reaction of an 
isothiocyanate with an amine group is favoured above pH 9.5 (Maeda et al. 1969; 
Hernandez-Triana et al. 1996), at physiological pH, the predominant reaction is the 
conjugation of an isothiocyanate to a thiol, giving rise to a dithiocarbamate derivative 
(Podhradsky et al. 1979; Zhang et al. 2006). As previously discussed (section 1.1.1), 
this reaction occurs between an isothiocyanate and GSH. The formation of 
isothiocyanate-GSH adducts depletes the cell of its primary redox buffer and this has 
the potential to disrupt the function of sensitive thiol proteins in the cell (Xu and 
Thornalley 2001a). However, the direct modification of cysteinyl thiol groups, to 
form protein dithiocarbamates, is also likely to constitute an important component of 
isothiocyanate action.  
 
While the isothiocyanate moiety itself is central to the biological actions of the 
isothiocyanates, the side chain is likely to influence biological activity. Numerous 
studies have already demonstrated the differing potencies of diverse isothiocyanates 
(Xu and Thornalley 2000b; Tang and Zhang 2004; Jakubikova et al. 2005). It is 
widely believed that the side chains of the isothiocyanates may influence factors such 
as the electrophilicity of the –N=C=S group, altering the steric hindrance to the 
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 central carbon atom and controlling the lipophilicity of the molecule (Zhang et al. 
2005). 
 
1.1.3 Isothiocyanates and cancer prevention 
The chemopreventive potential of the isothiocyanates has been attributed to several 
different actions (Hecht 2000; Zhang et al. 2006). The isothiocyanates are strong 
inhibitors of phase I enzymes, particularly the cytochrome P450 enzymes (Goosen et 
al. 2000; Nakajima et al. 2001), which convert environmental carcinogens into a 
much more toxic form. The isothiocyanates can inhibit cytochrome P450 activity by 
competitive, non-competitive and mechanism-based inhibition (Moreno et al. 1999; 
Goosen et al. 2001; Nakajima et al. 2001; von Weymarn et al. 2005). Such 
inactivation is likely to explain the results obtained in early rodent studies, where 
isothiocyanates could block carcinogenicity of compounds such as N-nitrosobis(2-
oxopropyl)amine (BOP) and 4-(methylnitrosamino)-1-butanone (NNK), which 
require conversion to their active forms by cytochrome P450 enzymes (Smith et al. 
1993; Hecht et al. 1996; Nishikawa et al. 1997). 
 
Another important activity of the isothiocyanates is induction of phase II 
detoxification enzymes. The phase II enzyme family consists of a diverse range of 
enzymes including sulfotransferases, NAD(P)H:quinone oxidoreductases, and N-
acetyltransferases (Xu et al. 2005a). Generally, phase II enzymes catalyse the 
conjugation of carcinogens with endogenous ligands, resulting in the formation of 
hydrophilic conjugates, which are often less toxic and more easily excreted in the 
urine or bile (Holtzclaw et al. 2004). The isothiocyanates activate phase II enzymes 
and consequently reduce carcinogen titre within the body (Rose et al. 2000). 
Activation of phase II enzymes by isothiocyanates also confers protection against 
oxidative insult via the induction of GST and thioredoxin reductase, two key enzymes 
involved in the maintenance of thiol homeostasis (Gao et al. 2001; Ye and Zhang 
2001; Hintze et al. 2003).  
 
The induction of phase II enzymes by isothiocyanates is primarily mediated by 
activation of the transcription factor Nrf2 (nuclear transcription factor erythroid 2p45-
related factor 2) (Ye and Zhang 2001). Normally, Nrf2 is anchored in the cytoplasm 
by Keap1 (Kelch-like ECH-associated protein 1). Under conditions of stress, or 
 following isothiocyanate exposure, Nrf2 dissociates from Keap1 (Itoh et al. 1999) and 
translocates to the nucleus where it can proceed to bind the DNA regulatory 
antioxidant responsive elements (AREs) to induce transcription of phase II enzymes 
(Itoh et al. 1997; Lee and Surh 2005). Oxidation, or covalent modification, of cysteine 
residues within Keap1 is sufficient to disrupt the Nrf2-Keap1 complex (Dinkova-
Kostova et al. 2002; Hong et al. 2005b) (Figure 1.5). The isothiocyanate sulforaphane 
has been demonstrated to activate Nrf2 via the formation of covalent adducts with 
selected cysteine residues in Keap1 (Hong et al. 2005a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Regulation of phase II detoxification enzymes (adapted from Dinkova-
Kostova et al. 2002). The transcription factor Nrf2 is anchored in the cytoplasm by 
binding to Keap1. Inducers, including some isothiocyanates (ITC) disrupt the Keap1-
Nrf2 complex, and Nrf2 migrates to the nucleus where it binds ARE regions of phase 
II genes and accelerates their transcription. 
 
The chemopreventive effects of the isothiocyanates were traditionally attributed to the 
above processes of enhancement of carcinogen detoxification by phase II induction 
and the blocking of carcinogen activation by phase I inhibition (Hecht 1999). Both of 
these actions explain the ability of the isothiocyanates to prevent tumourigenesis 
when administered prior to carcinogen exposure (Morse et al. 1991; Jiao et al. 1997; 
Kassie et al. 2002). However, the isothiocyanates have also been shown to inhibit 
tumour formation when administered after carcinogen insult (Chung et al. 2000; Yang 
et al. 2002). An alternate mechanism to explain the chemopreventive activity of the 
isothiocyanates was revealed when a selection of isothiocyanates were shown to 
 
Nrf-2 Keap1 
SH    
Keap1 
S-ITC 
 
Nrf-2 
ARE 
Phase II 
NUCLEUS 
CYTOPLASM 
Inducer 
e.g. ITC 
 induce a form of cell death termed apoptosis (Yu et al. 1998). It has since been shown 
that a variety of isothiocyanates possess a potent ability to inhibit cell proliferation 
and induce apoptosis in a wide variety of cell types. The ability of compounds to 
trigger apoptosis in precancerous cells is currently being explored as an alternate 
mechanism of chemoprevention (Sun et al. 2004). In addition to the mechanisms 
described above, chemoprevention by the isothiocyanates has been linked to 
inhibition of the NF-κB (nuclear factor-kappa B) signal transduction pathway (Heiss 
et al. 2001; Jeong et al. 2004; Xu et al. 2005b), inhibition of histone deacetylase 
(Myzak et al. 2004; Myzak et al. 2006a; Myzak et al. 2006b), inhibition of free-
radical production by phagocytic cells (Manesh and Kuttan 2003; Miyoshi et al. 2004) 
and inhibition of angiogenesis (Bertl et al. 2006). The focus of this thesis is the ability 
of the isothiocyanates to promote apoptosis. 
 
1.2 Apoptosis 
To protect tissue homeostasis, all dividing cell populations maintain a balance 
between cell production and cell loss. Most cell loss observed during normal turnover 
is attributed to a process known as apoptosis. Apoptosis can be defined as a form of 
programmed cell death that is either developmentally regulated, launched in response 
to specific stimuli or activated in response to various forms of injury or stress 
(Chandra et al. 2000; Kaufmann and Earnshaw 2000; Raghupathi et al. 2000; 
Twomey and McCarthy 2005).  
 
The term apoptosis was first introduced following observations of a morphologically 
distinct type of cell death that occurred primarily under physiological conditions (Kerr 
1971; Kerr et al. 1972). Apoptosis is characterised by the sequential appearance of 
chromatin margination and fragmentation, cellular shrinkage, and a budding 
fragmentation (Saraste and Pulkki 2000). The morphological features of an apoptotic 
cell result from the execution of a genetically controlled autodigestion pathway. The 
key event in this pathway is the activation of endogenous proteases called caspases 
(Cohen 1997; Chang and Yang 2000). Prior to the initiation of apoptosis, the caspases 
exist in a cell as inactive proenzymes. When the apoptotic pathway is initiated, 
procaspases are processed by cleavage at internal aspartate residues to form active 
caspases (Earnshaw et al. 1999). The active caspases then proceed to cleave specific 
 protein substrates to bring about the controlled degradation of a cell (Fischer et al. 
2003).  
 
1.2.1 Apoptotic signalling pathways 
Two distinct, but interconnected, pathways of caspase activation have been 
characterised: the cell surface death receptor (extrinsic) pathway and the 
mitochondria-initiated (intrinsic) pathway.  
 
The extrinsic caspase activation pathway is triggered by binding of cell surface death 
receptors with their specific ligands in response to an extracellular pro-apoptotic 
stimulus. Ligand binding induces receptor oligomerization and the recruitment of 
intracellular receptor-associated proteins. The best characterised member of the death 
receptor superfamily is Fas (Figure 1.6A). Binding of the Fas ligand to the Fas 
receptor induces oligomerization of Fas and formation of the death-inducing 
signalling complex (DISC) (Peter and Krammer 2003). The cytoplasmic region of the 
DISC contains a death domain that binds the adaptor molecule FADD (Fas-
associating protein with death domain), which, in turn, recruits procaspase-8 
(Kaufmanna et al. 2002). The association of procaspase-8 with FADD enables auto-
proteolytic processing to generate active caspase-8 (Nicholson and Thornberry 1997). 
Caspase-8 in turn activates caspase-3, the key executioner of apoptosis responsible for 
the proteolytic cleavage of cellular proteins (Fischer et al. 2003). 
 
The extrinsic signalling pathway diverges following formation of the DISC (Scaffidi 
et al. 1998). In Type I cells, where the activation of procaspase-8 is vigorous, active 
caspase-8 can directly cleave and activate procaspase-3. In contrast, Type II cells are 
characterised by insufficient activation of caspase-8 and subsequent failure to activate 
procaspase-3. Therefore, in Type II cells, apoptosis is dependent on caspase-8 
cleaving the cytosolic Bcl-2 protein Bid to generate a truncated fragment (tBid) 
(Kaufmann and Hengartner 2001). tBid acts at the mitochondria to indirectly activate 
the intrinsic pathway (Li et al. 1998) (Figure 1.6B). This mechanism allows for a 
significant degree of crosstalk between the two pathways and also for amplification of 
the apoptotic response. 
 
  
Figure 1.6: Pathways that lead to caspase activation and apoptosis (reviewed by 
Green 1998). (A) The extrinsic pathway is initiated when an extracellular ligand 
binds to a death receptor. Ligand binding induces the oligomerization of the death 
receptor, which in turn allows for the recruitment of adaptor proteins that contain a 
binding site for procaspase-8. The formation of such a complex induces the auto-
proteolytic activation of the inactive procaspase to active caspase-8. Caspase-8 then 
proceeds to activate caspase-3. (B) The extrinsic pathway can also initiate or amplify 
apoptosis via cleavage of the pro-apoptotic factor Bid by caspase-8. The truncated 
fragment (tBid) then acts at the mitochondria to induce the release of cytochrome c 
(Cyt c). (C) The intrinsic pathway is initiated by the release of pro-apoptotic factors 
including cytochrome c from the mitochondria in response to an intracellular 
stimulus. The binding of cytosolic cytochrome c to Apaf-1 triggers the recruitment of 
procaspase-9 via a caspase recruitment domain. Procaspase-9 is then activated to 
caspase-9 and in turn proceeds to activate caspase-3.  
 
As well as being triggered via activation of the extrinsic pathway, the intrinsic caspase 
activation pathway is induced in response to intracellular apoptotic stimuli, including 
hypoxic stress, chemotherapeutic agents and growth factor withdrawal (Kim and Park 
2003; Bian et al. 2004; Cornelis et al. 2005). The conversion of an intracellular 
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 stimulus into initiation of the intrinsic apoptotic cascade relies on alterations at the 
mitochondria. The critical step in the initiation of the intrinsic pathway is the release 
of cytochrome c from where it normally resides, in the intermembrane space of 
mitochondria, to the cytosol, where it can complex with Apaf-1 (Liu et al. 1996) 
(Figure 1.6C). Apaf-1 will initially bind ATP and hydrolyse it to ADP. This process 
facilitates the formation of a multimeric Apaf-1/cytochrome c complex called the 
apoptosome, which can then recruit and subsequently activate procaspase-9 (Zou et 
al. 1999; Cain 2003). The intrinsic caspase activation pathway culminates in caspase-
9-mediated activation of the executioner caspase, caspase-3 (Kaufmann and 
Hengartner 2001). The activation of the intrinsic caspase activation pathway is 
centred on the regulation of cytochrome c release from the mitochondria, which is 
mediated by the Bcl-2 family of pro- and anti-apoptotic proteins (Kluck et al. 1997; 
Cai et al. 1998; Scorrano and Korsmeyer 2003). 
 
1.3 The Bcl-2 family of pro- and anti-apoptotic proteins 
The Bcl-2 family plays a critical role in whether or not a cell will undergo apoptosis. 
Over twenty-five Bcl-2 family members have been identified, and these can be 
broadly divided into three functional groups (Adams and Cory 1998). Members of the 
first group, which include Bcl-2 and Bcl-XL, are characterized by the presence of four 
Bcl-2 homology (BH) domains (BH1-BH4). All members of this group display anti-
apoptotic activity (Huang et al. 1998). Members of group two, including Bax and 
Bak, have a similar overall structure to the group one proteins but lack the BH4 
domain and display pro-apoptotic activity. Group three covers a diverse collection of 
pro-apoptotic proteins, including Bid, whose only common feature is the presence of 
the BH3 domain. The balance between the expression and activity of pro-apoptotic 
and anti-apoptotic members of the Bcl-2 family provides a critical switch in the 
determination of whether or not a cell will undergo apoptosis (Mirjolet et al. 2000; 
Borner 2003). 
 
1.3.1 Bcl-2 
The founding member of the Bcl-2 family of proteins was the B-cell 
lymphocyte/leukemia-2 (Bcl-2) oncoprotein. Bcl-2 was initially identified at the 
breakpoint of the t(14;18) chromosomal translocation that occurs in a large majority 
of patients with non-Hodgkin’s B-cell lymphoma (Tsujimoto et al. 1984). As a result 
 of this translocation, the expression of bcl-2 comes under the control of the 
immunoglobulin heavy chain enhancer and is therefore constitutively expressed in B 
cells (Graninger et al. 1987; Reed et al. 1987; Seto et al. 1988). Subsequent studies 
demonstrated that deregulation of Bcl-2 markedly prolongs the survival of mature B 
cells, resulting in an immortalized cell population (Vaux et al. 1988; McDonnell et al. 
1989). The biochemical function of Bcl-2 was eventually elucidated in 1990, when it 
was discovered that deregulation of Bcl-2 prevents cell death by blocking apoptosis 
(Hockenbery et al. 1990), although how Bcl-2 achieves this block continues to be a 
matter of controversy (Vander Heiden and Thompson 1999; Belka and Budach 2002; 
Annis et al. 2004). 
 
1.3.2 Structure of Bcl-2 
Bcl-2 is composed of eight α-helices that are connected by loops of varying length 
(Petros et al. 2001; Petros et al. 2004) (Figure 1.7A and B). Two central helices (α5 
and α6) form the core of the protein. The central helices are flanked by helices α3 and 
α4 on one side and, on the other side, by helices α1 and α2. A largely unstructured 
loop exists between α1 and α2. The BH1, BH2 and BH3 domains of Bcl-2 are 
proximal to one another and form the top of an elongated hydrophobic groove, which 
is required for anti-apoptotic activity (Figure 1.7C). The bottom of this groove is 
formed by helices α3 and α4. The carboxy-terminal transmembrane domain is critical 
for the localization of Bcl-2 to the endoplasmic reticulum, nuclear envelope and the 
outer mitochondrial membrane (Krajewski et al. 1993). However, removal of the 
transmembrane domain only partially reduces the anti-apoptotic activity of Bcl-2, 
suggesting that membrane localisation is not absolutely essential for the function of 
Bcl-2 (Hunter et al. 1996). 
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Figure 1.7: Structure of the anti-apoptotic protein Bcl-2. (A) Primary structure of 
Bcl-2 highlighting the Bcl-2 homology (BH) domains the transmembrane domain and 
the positions of the α-helices (adapted from Petros et al. 2004). (B) Ribbon 
representation of the solution structure of Bcl-2 (Petros et al. 2004). (C) The 
Connolly surface model for Bcl-2 is coloured as follows: hydrophobic residues are 
yellow, basic residues are blue and acidic residues are red (Petros et al. 2004).  
 
1.3.3 Inhibition of apoptosis by Bcl-2 
The exact mechanisms by which Bcl-2 can prevent apoptosis are still highly 
controversial; however, it is widely accepted that mitochondrial anchored Bcl-2 can 
maintain the integrity of the mitochondrial outer membrane and thereby prevent the 
 release of pro-apoptotic factors. Given the importance of cytochrome c release in the 
induction of apoptosis, a large collection of data has been presented to support the 
hypothesis that the release of cytochrome c from mitochondria is regulated, either 
directly or indirectly, by Bcl-2 and that overexpression of Bcl-2 can prevent the 
release of such pro-apoptotic factors (Kluck et al. 1997; Yang et al. 1997).  
 
While Bcl-2 can prevent the release of cytochrome c, the pro-apoptotic Bcl-2 family 
member Bax (Bcl-2-associated X protein) can induce the release of cytochrome c 
from mitochondria (Jurgensmeier et al. 1998). Bax was initially identified as a 
heterodimerization partner of Bcl-2 and the ratio of Bcl-2 to Bax has been shown to 
determine the rate of apoptosis (Oltvai et al. 1993). Bax can form pores in the 
mitochondrial outer membrane which permit the release of pro-apoptotic factors from 
the mitochondrial intermembrane space. The ability of Bcl-2 to heterodimerize with 
Bax is thought to constitute a key mechanism of the anti-apoptotic function of Bcl-2. 
The hydrophobic groove formed by the BH1-3 regions of anti-apoptotic Bcl-2 family 
proteins mediates the interaction with the amphipathic, α-helical BH3 domain of pro-
apoptotic counterparts such as Bax (Sattler et al. 1997) (Figure 1.7). Mutations in the 
hydrophobic region of Bcl-2 have been shown to block heterodimerization with other 
family members and, furthermore, abolish the anti-apoptotic activity of Bcl-2 (Yin et 
al. 1994; Minn et al. 1999). However, the sequestration of pro-apoptotic family 
members is likely to be just one of the mechanisms by which Bcl-2 prevents the 
release of pro-apoptotic factors from the mitochondria (Zamzami et al. 1998).  
 
Another potential explanation for the anti-apoptotic activity of Bcl-2 arose when it 
was observed that Bcl-2 knockout mice display pathologies that are associated with 
defects in antioxidant pathways (Veis et al. 1993). This suggested that Bcl-2 plays a 
role in preventing cell death in response to oxidative stress. Further studies examining 
the enforced expression of Bcl-2 clearly demonstrated the ability of Bcl-2 to inhibit 
hydrogen peroxide-induced apoptosis (Hockenbery et al. 1993). The potential 
antioxidant function of Bcl-2 may be explained by the observation that an elevation in 
the cellular levels of Bcl-2 corresponds with a concomitant increase in intracellular 
levels of GSH (Mirkovic et al. 1997). Given that GSH acts as the primary reducing 
equivalent that can buffer and remove free radicals, an increase in GSH would confer 
resistance to oxidative stress-induced apoptosis (Kane et al. 1993; Ellerby et al. 1996; 
 Devadas et al. 2003). This mechanism was broadened to include non-oxidative 
stimuli, particularly because alterations in the redox environment of a cell are 
proposed to be a common feature of the apoptosis pathway; however, this remains a 
controversial area (Steinman 1995; Voehringer and Meyn 1998; Ueda et al. 2002).  
 
1.4 Apoptosis resistance and cancer 
Defects in the apoptotic pathway play an important role in the pathogenesis and 
progression of many cancers (Hanahan and Weinberg 2000). Defective apoptosis is 
necessary for cellular transformation, enabling the survival of damaged and mutated 
cells, and balancing the action of oncogenes that jointly enhance proliferation and 
apoptosis (Green and Evan 2002). In addition, defective apoptosis pathways 
contribute to multi-drug resistance (Johnstone et al. 2002). Many cancer cells possess 
or acquire the ability to resist chemotherapeutic agents, making the successful 
treatment of cancer very difficult. 
 
A landmark study investigating the mechanism of action of several chemotherapeutic 
agents revealed that DNA fragmentation is induced in response to chemotherapy 
(Kaufmann 1989). Given that DNA fragmentation is one of the first features of a cell 
undergoing apoptosis, it was concluded that some chemotherapeutic agents induce 
apoptosis. It is now understood that a chemotherapeutic agent does not directly kill a 
cell but will induce a series of cellular responses that impact on tumour cell 
proliferation and survival (Lowe and Lin 2000). Probably the most important response 
of a cell to a chemotherapeutic agent is the induction of apoptosis. Due to the fact that 
diverse chemotherapeutic agents all act via initiation of the apoptotic pathway, small 
discrepancies in either the activation or execution phases of apoptosis can result in a 
multi-drug resistant phenotype (Ferreira et al. 2002). 
 
1.4.1 Deregulation of Bcl-2 in cancer 
In many forms of cancer, an imbalance between pro- and anti-apoptotic proteins leads 
to accumulation of cells and the inability to respond correctly to apoptotic stimuli. In 
fact, deregulation of such proteins strongly correlates with the incidence of certain 
types of cancer and also with the ability of a cancer patient to enter remission 
(Schimmer et al. 2003; Yang et al. 2003). Besides being overexpressed in a large 
majority of patients with non-Hodgkin’s B cell lymphoma, the anti-apoptotic protein 
 Bcl-2 has been shown to be upregulated in a wide variety of human cancers including 
80% of B-cell lymphomas, 30-60% of prostate cancers, and 90% of colorectal 
carcinomas (Kitada et al. 2003). The overexpression of Bcl-2 has serious 
consequences for cancer chemotherapy and can abrogate the cytotoxic activities of a 
wide variety of standard chemotherapeutic agents by blocking chemotherapy-induced 
apoptosis (Campos et al. 1993; Miyashita and Reed 1993; Park et al. 2001; Kim et al. 
2003). 
 
Direct inhibition or downregulation of Bcl-2 has been shown to be lethal to cancer 
cells and is, therefore, a valid target for cancer therapy (Strasser et al. 1990; Letai et 
al. 2004; Letai 2005). Three key strategies have been employed to target Bcl-2. The 
first strategy involves the development of antisense molecules which degrade mRNA 
and, therefore, downregulate the levels of Bcl-2 (Rudin et al. 2004). The other two 
strategies employ molecules that bind the hydrophobic pocket of Bcl-2 and prevent 
the interaction of the anti-apoptotic protein with pro-apoptotic counterparts. Such 
inhibition sensitizes cells to the effects of death signals. The first of these Bcl-2-
binding strategies utilises BH3-domain peptides from pro-apoptotic Bcl-2 proteins 
including Bax (Finnegan et al. 2001). The second Bcl-2 binding strategy employs 
small-molecule inhibitors of Bcl-2 (Oltersdorf et al. 2005; Milanesi et al. 2006). 
Recent efforts have focussed on the identification and design of small organic 
molecules that are capable of antagonizing Bcl-2 function. Such inhibitors are more 
advantageous than peptide-based drugs as they can be refined for optimal solubility, 
cell permeability, stability, binding affinity and activity (Shangary and Johnson 2003). 
One class of compounds receiving interest as novel cancer therapeutics targeting Bcl-
2 are the naturally occurring plant polyphenols that can bind the BH3 binding pocket 
of anti-apoptotic Bcl-2 proteins with extreme efficiency (Kitada et al. 2003). In 
addition to the plant polyphenols, Pellecchia and Reed (2004) speculated that other 
plant phytochemicals with anticancer properties, including the isothiocyanates, may 
act in a similar way (Pellecchia and Reed 2004).  
 
1.5 Ability of isothiocyanates to trigger apoptosis in cells overexpressing Bcl-2 
Previous work from our laboratory explored the possibility that elevated GSH levels 
played a role in the resistance of Bcl-2 expressing cells to Fas-mediated apoptosis. 
This hypothesis was subsequently disproved when agents that depleted GSH were 
 unable to sensitize the cells to apoptosis. However, one of the compounds used, 
phenethyl isothiocyanate, showed a dramatic ability to sensitize the cells to apoptosis 
(Pullar et al. 2004). Subsequent experiments were undertaken to determine if 
phenethyl isothiocyanate could also sensitize the resistant cells to chemotherapeutic 
drugs. However, these preliminary studies suggested that phenethyl isothiocyanate 
was able to directly trigger apoptosis in the cells overexpressing Bcl-2.  
 
The aim of this thesis was to directly examine this phenomenon by: 
 
1. An investigation of the ability of phenethyl isothiocyanate to induce apoptosis 
in cells overexpressing Bcl-2. The anti-proliferative activity, cytotoxic activity 
and apoptosis-inducing potential of phenethyl isothiocyanate was examined in 
sensitive cells and cells overexpressing varying levels of Bcl-2. 
2. A structure-activity investigation of a selection of isothiocyanates to determine 
the key structural features of the isothiocyanates that confer apoptosis-
inducing properties in cells overexpressing Bcl-2. Sixteen isothiocyanates with 
diverse side chain chemistry were screened for anti-proliferative activity, 
cytotoxic activity and ability to sensitise cells to Fas-mediated apoptosis in 
sensitive cells and Bcl-2 overexpressing cells. 
3. A preliminary investigation into the key cellular targets of the isothiocyanates 
that promote induction of apoptosis. A proteomic technique for labelling 
oxidised thiol proteins was utilised to examine the response of the entire 
cellular complement of thiol proteins to exposure to the isothiocyanates. 
 
 
 
 
 
 
 
 Chapter 2 
 
Materials and Methods 
 
 
2.1 Materials 
Cell culture materials including RPMI-1640, fetal bovine serum (FBS), penicillin, 
streptomycin, and geneticin were purchased from Gibco BRL, Invitrogen (Auckland, 
New Zealand).  
 
Hexyl isothiocyanate, tert-butyl isothiocyanate, 1-methyl allyl isothiocyanate and 1-
methyl butyl isothiocyanate were provided by Dr Rex Munday, AgResearch 
(Ruakura, New Zealand). Allyl isothiocyanate was obtained from Sigma Chemical Co 
(St Louis, MO, USA). All other isothiocyanates were sourced from LKT Laboratories 
(St Paul, MN, USA). 
 
The detergent compatible (DC) protein assay kit, 40% acrylamide/bis solution 37.5:1 
(2.6% C), Micro Bio-Spin® 6 chromatography columns, ReadyStrip 17cm, pH 3-10 
IPG strips, Bio-Lyte® 3/10 ampholytes, mineral oil and electrode wicks were acquired 
from Bio-Rad Laboratories (Hercules, CA, USA).  
 
DNA grade agarose was purchased from Progen Industries Ltd. (Darra, Australia) 
 
Mouse anti-Bcl-2 and activating Fas antibodies were supplied by Zymed Laboratories 
(San Francisco, CA, USA).  
 
Sheep anti-mouse IgG-horseradish peroxidase, Hybond-PVDF membrane and 
enhanced chemiluminescence (ECL™) Western blotting system were obtained from 
Amersham Biosciences (Buckinghamshire, England).  
 
5-Iodoacetamidofluorescein (IAF) was sourced from Molecular Probes (Invitrogen, 
Auckland, New Zealand).  
 
 The cell proliferation ELISA, BrdU (colorimetric) kit, Complete™ protease inhibitors 
and 3[(3-cholamidopropyl)dimethylammonio]propanesulfonic acid (CHAPS) were 
acquired from Roche Diagnostics (Manheim, Germany).  
 
The artificial caspase substrate Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin 
(Ac-DEVD-AMC) was acquired from the Peptide Institute Inc (Osaka, Japan).  
 
All other chemicals and reagents were purchased from Sigma Chemical Co (St Louis, 
MO, USA) and BDH Laboratory Supplies (Poole, England).  
 
All water was deionised and ultrafiltrated using a Milli-Q filtration system. 
 
2.2 Solutions  
2.2.1 Isothiocyanate Stock Solutions 
The isothiocyanates were diluted with DMSO to make 100 mM stock solutions. Stock 
solutions were prepared using known MW and purity values (Table 2.1):   
 
Isothiocyanate MW (g/mol) Purity (%) 
Benzyl thiocyanate 149.21 99 
Benzyl selenocyanate 196.11 99.24 
Phenyl isothiocyanate 135.19 98 
Benzyl isothiocyanate 149.22 98 
Phenethyl isothiocyanate 163.24 99 
3-Phenylpropyl isothiocyanate 177.27 99.2 
4-Phenylbutyl isothiocyanate 191.30 100 
Phenylhexyl isothiocyanate 219.35 98.81 
R(-)-α-Methylbenzyl isothiocyanate 163.24 99.7 
S-(N-benzylthiocarbamoyl)-L-cysteine 270.37 98 
S-(N-3-phenylpropylthiocarbamoyl)-L-cysteine 298.42 99 
t-Butyl isothiocyanate 115.20 100 
Allyl isothiocyanate 99.16 95 
1-Methyl allyl isothiocyanate 113.18 100 
1-Methyl butyl isothiocyanate 129.23 100 
Hexyl isothiocyanate 143.25 100 
Sulforaphane 177.29 99.68 
 
Table 2.1: Molecular weight and percentage purity of various isothiocyanates. 
 
 The appropriate mass of an isothiocyanate was weighed out and DMSO was added to 
bring the final volume to 1 mL. The stock solutions were stored at +4°C for up to two 
months. 
 
Just prior to use, further dilutions of the isothiocyanate stock solutions were prepared 
in order that the final concentration of DMSO added to the cell culture medium was 
maintained at a constant 0.1%. 
 
2.2.2 Cell viability analysis solutions 
Propidium iodide 
The propidium iodide staining solution was prepared by dissolving 5 mg of propidium 
iodide in 5 mL of milliQ water. Aliquots were stored in the dark at +4°C.  
 
2.2.3 Caspase activity analysis solutions 
Caspase buffer 
The caspase buffer was made by combining:  100 mM HEPES 
10% sucrose 
0.1% CHAPS 
0.1% NP-40 
The solution was made to 100mL with milliQ water and the pH adjusted to 7.25 with 
NaOH. The caspase buffer was stored in aliquots at -20°C.  
 
2.2.4 SDS-PAGE solutions 
2 M Tris-HCl, pH 8.8 
A 2 M Tris-HCl, pH 8.8 solution was prepared by dissolving 48 g of Tris base in 100 
mL of milliQ water. The pH was adjusted to 8.8 before the solution was made to a 
final volume of 200 mL. 
 
0.5 M Tris-HCl, pH 6.8 
A 0.5 M Tris-HCl, pH 6.8 solution was prepared by dissolving 6 g of Tris base in 60 
mL of milliQ water. The pH was adjusted to 6.8 before the solution was made to a 
final volume of 100 mL. 
 
 
 20% (w/v) SDS 
A 20% solution of SDS was made by dissolving 20 g of SDS in 100 mL of milliQ 
water. 
 
10% ammonium persulfate 
A fresh 10% solution of ammonium persulphate (APS) was prepared just prior to gel 
preparation by dissolving 100 mg APS in 1 mL of milliQ water.  
 
SDS-polyacrylamide gels 
SDS-PAGE gels were prepared according to Table 2.2. Acrylamide, Tris-HCl and 
water were initially combined before addition of SDS and APS. The solution was 
thoroughly mixed before addition of TEMED. 
 
      Component      15% gel for           4% stacking gel       15% gel for 2-D 
                           Western blotting          for Western           electrophoresis 
         (2 gels)            blotting (2 gels)              (2 gels) 
 
40% acrylamide/bis         3.75 mL       500 µL            37.5 mL 
    solution 37.5:1 
2 M Tris/HCl, pH 8.8 2 mL - 20 mL 
0.5 M Tris/HCl, pH 6.8 - 1.25 mL - 
Water 4.15 mL 3.2 mL 41.5 mL 
20% SDS 50 µL 25 µL 250 µL 
10% APS 50 µL 25 µL 250 µL 
TEMED 15 µL 8 µL 25 µL 
 
Table 2.2: Components of SDS-PAGE gels for Western blotting and 2-D 
electrophoresis. 
 
Sample loading buffer 
Sample loading buffer was prepared by combining: 
 Distilled water     3 mL 
 0.5 M Tris-HCl, pH 6.8   1 mL 
 Glycerol     1.6 mL 
 10% SDS     1.6 mL 
 β-mercaptoethanol    0.4 mL 
 0.5% (w/v) bromophenol blue  0.4 mL 
 
 
 SDS-PAGE running buffer 
The electrode running buffer was made by addition of 25 mM Tris, 192 mM glycine 
and 0.1% SDS to the appropriate volume of milliQ water. 
 
2.2.5 Western Blotting solutions 
Extract buffer 
The extract buffer was made by combining milliQ water with: 40 mM HEPES 
         50 mM NaCl 
         1 mM EDTA 
         1 mM EGTA 
The pH of the solution was adjusted to 7.4. 
 
Sample extract buffer 
To prepare the sample extract buffer, 40 μL of a Complete™ protease inhibitor 
solution and 40 μL of a 25% CHAPS solution were added to every 1 mL of extract 
buffer. The sample extract buffer was prepared just prior to use. 
 
Western blot buffer 
A Tris-glycine Western blot buffer was prepared by dissolving 25mM Tris and 
192mM glycine in milliQ water with 10% methanol.  The buffer was refrigerated for 
at least one hour before use. 
 
10x Tris-buffered saline (TBS) 
A 10x stock solution of TBS was made by addition of 24.2g Tris and 80g NaCl to 1 L 
of milliQ water. The pH of the solution was adjusted to 7.6. 
 
TBST20 
A 1 L preparation of TBST20 was prepared by combining 100 mL of 10x TBS and 
500μL TweenTM 20 with 900 mL milliQ water. 
 
 
 
 
 2.2.6 Two-dimensional electrophoresis solutions 
N-ethyl maleimide (NEM) buffer 
NEM buffer was made by adding 0.0125 g of NEM and 40 μL of a protease inhibitor 
solution to every 1 mL of extract buffer (section 2.2.5). The NEM buffer was 
prepared just prior to use. 
 
IAF solution 
A 10 mM solution of IAF was prepared by dissolving 5.2 mg of IAF in 1 mL of 
DMSO. The IAF solution was stored in the dark at -20°C. A fresh preparation was 
made weekly. 
 
Sample/rehydration solution 
The sample/rehydration solution was prepared by combining: 7 M Urea 
         2 M Thiourea 
         10 mM DTT 
         4% CHAPS 
         0.2% Biolytes 
A few crystals of bromophenol blue were added before the solution was made to a 
final volume of 40 mL by addition of milliQ water.  
 
Equilibration buffer 
The equilibration buffer was prepared by combining: 6 M Urea 
        0.375 M Tris 
        20% glycerol 
        2% SDS 
The final volume was brought to 500 mL with milliQ water. A few crystals of 
bromophenol blue were added to the final solution. 
 
0.5% agarose solution 
The agarose solution was made by combining 2.5 g of agarose with 500 mL of 1x 
SDS-PAGE running buffer. The agarose was dissolved by heating in the microwave. 
A few crystals of bromophenol blue were added to the final solution. Just prior to use 
the agarose solution was heated in the microwave until molten.  
 
 2.2.7 Silver stain solutions 
Solution 1 
Silver stain solution 1 was made by dissolving 0.2 g of anhydrous sodium 
thiosulphate in 1 L of milliQ water. 
 
Solution 2 
Silver stain solution 2 was prepared by addition of 2 g silver AgNO3 and 750 µL of 
formaldehyde to 1 L of milliQ water. A fresh preparation of solution 2 was made just 
prior to use. 
 
Solution 3 
Silver stain solution 2 was made by combining 60 g sodium carbonate, 20 mL of 
silver stain solution 1, 500 µL formaldehyde and 980 mL of milliQ water. 
 
Solution 4 
Silver stain solution 4 was prepared by dissolving 20 g of sodium EDTA in 1 L of 
milliQ water 
 
2.3 Methods 
2.3.1 Cell Culture 
The Jurkat T lymphocyte cell line was obtained from American Type Culture 
Collection (Rockville, MD). Jurkat cells were cultured in RPMI-1640 containing 10% 
fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin. The 
vector control and the Bcl-2 over-expressing lines were maintained in RPMI-1640 
containing 10% FBS and 350 μg/ml geneticin. Cells were maintained at 37°C in a 
humidified atmosphere with 5% CO2.  
 
Cultured cells were collected at optimal growth (~0.8-1x106 cells/ml) and resuspended 
in fresh RPMI 1640 supplemented with 10% FBS at a concentration of 1x106 cells/ml, 
unless otherwise stated. Cells were transferred to 96 well microplates for cell 
proliferation assays, 24 well plates for caspase activity analysis and cell viability 
analysis, or to 6 well plates for two-dimensional electrophoresis. Cells were left to 
 equilibrate for 1 hr at 37°C before exposure to the isothiocyanates. Isothiocyanates 
were added directly to the cell culture medium.  
 
2.3.2 Cell proliferation BrdU ELISA  
A commercially available colorimetric BrdU enzyme linked immunosorbent assay 
(ELISA) kit (Roche Diagnostics, Manheim, Germany) was used to measure cell 
proliferation. The assay is based on measuring the incorporation of the thymidine 
analogue 5-bromo-2-deoxyuridine (BrdU) into the DNA of proliferating cells 
(Hawker 2003). Plates (96 well) were seeded with 100 μL of a 1×106 cell/mL Jurkat 
culture and incubated at 37°C for 1 hr. The cells were then treated with a range of 
concentrations of the appropriate isothiocyanate (section 2.2.1) and incubated at 37°C 
for 30 min, unless otherwise stated. Each sample was then diluted to 5×105 cells/mL 
by taking 50 μL of each sample and transferring it to a new well containing 50 μL of 
fresh media. The diluted cells were immediately treated with 10 μL of the kit BrdU 
labelling reagent and incubated at 37°C for 30 min. The cells were then sedimented 
by centrifugation of the plate at 500 g for 10 min. Media was removed by inverting 
the plate. Cells were washed by addition of 100 µL PBS to each well followed by 
sedimentation by centrifugation of the plate at 500 g for 10 min. PBS was removed by 
inverting the plate and the washing process was repeated. As much PBS as possible 
was removed and the cells were dried using a hair-dryer for 10 min. Cells were 
incubated for 30 min at room temperature with 200 μL of the kit FixDenat solution to 
fix cells to the plate and expose the BrdU-labelled DNA. FixDenat was removed by 
inverting the plate and 100 μL of the kit anti-BrdU-peroxidase was added to each 
sample. The cells were incubated with the antibody solution for 90 min at room 
temperature. Excess antibody was removed by washing wells three times with 200 μL 
of the kit washing solution. The washing solution was removed by inverting the plate 
and gently tapping the plate on a paper-towel. Finally, 100 µL of the kit peroxidase 
substrate solution, containing tetramethyl benzadine, was added to each well and the 
rate of absorbance increase at 370 nm was measured. A blank, containing culture 
medium only, was carried out in each experiment to measure non-specific binding of 
BrdU and anti-BrdU-peroxidase to the wells. Furthermore, a background control, 
containing cells but no BrdU label, was also carried out in each experiment to 
 measure non-specific binding of the anti-BrdU-peroxidase to the cells in the absence 
of BrdU. 
Proliferation was graphed as a percentage of the proliferation measured in cells that 
were not treated with an isothiocyanate. This was calculated according to the 
equation: 
 
Proliferation  =   [ΔA370 (treated sample) –  ΔA370 (blank)]  – ΔA370 (background control) 
 
            [ΔA370 (untreated sample) –  ΔA370 (blank)]  – ΔA370 (background control)                         
                           
 
IC50 values were generated using SigmaPlot (Version 8, Jandel Scientific). Data from 
three individual experiments were pooled and x and y values (for example Table 2.3) 
were fitted into a 4 parameter sigmoid curve equation: 
 
                  y = y0           a          
                            -    x – x0 
                          b 
                   1 + e 
 
            Concentration of   Proliferation (% of control) 
phenethyl isothiocyanate (µM) 
                       0            100 
                       2            80.5 
                       5                                          26.2 
                      10                                          22.9 
                      15                                          20.6 
                      20                                           5.0 
Table 2.3: Example of data used to generate IC50 values 
 
Corresponding values for a, b, x0 and y0 were generated (Figure 2.1) 
 
 
× 100% 
 Figure 2.1: Example of the parameters for generation of IC50 values 
 
To calculate the IC50 (x), y was set at 50 and values for a, b, x0 and y0 were substituted 
into the 4 parameter sigmoid curve equation. The standard error for the IC50 was 
calculated by multiplying the IC50 by the percentage variability about the parameter x0 
(CV%, Figure 2.1). 
 
2.3.3 Cell viability assay 
Propidium iodide (PI) is a dye that is excluded from viable cells but can penetrate the 
membranes of dead or dying cells. When inside a cell, PI binds to the major groove of 
DNA (Hudson, Upholt et al. 1969). This interaction facilitates the formation of a red 
fluorescent adduct. The proportion of cells that produce red fluorescence directly 
correlates to the proportion of cells that are non-viable following treatment with an 
isothiocyanate (Nicoletti, Migliorati et al. 1991). Wells of a 24 well plate were seeded 
with 1 mL of a 1×106 cell/mL culture and incubated at 37°C for 1 hr. The cells were 
then treated with a range of concentrations of the appropriate isothiocyanate (section 
2.2.1) and incubated at 37°C for 24 hr. Cell samples were transferred to 5 mL plastic 
test tubes before 5 μL of a 1 mg/mL PI solution (section 2.2.2) was added directly to 
the culture medium. Samples were briefly vortexed, placed on ice and kept in the dark 
for 10 min. The proportion of PI-positive cells in a 10,000 cell sample was analysed 
using a FACSCalibre flow cytometer (Becton Dickinson, Mountain View, CA). Cells 
with PI fluorescence intensity over 20 units were counted as non-viable (Figure 2.2). 
 
A      B 
          
Figure 2.2: Representative graphs following PI analysis for loss of cell viability. (A) 
Untreated sample and (B) sample treated with an isothiocyanate.  
 
Non-viable Non-viable 
 Percentage loss of cell viability was adjusted in order that loss of cell viability in 
untreated samples was always equal to zero. Loss of cell viability was adjusted 
according to the equation below, where (a) represents the number of dead cells in 
treated samples and (b) represents the number of dead cells in the control sample: 
 
Percentage loss of cell viability = (a-b/100-b) × 100 
 
LD50 values were generated using SigmaPlot (Version 8, Jandel Scientific), as 
outlined in section 2.3.2 for IC50 calculation. 
 
2.3.4 Caspase activity assay 
Caspase activation was monitored by measuring the fluorescence of amino-4-
methylcoumarin (AMC) released following cleavage of the artificial caspase substrate 
Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC) (Nicholson, Ali et al. 1995; 
Thornberry, Rano et al. 1997; Gorman, Hirt et al. 1999). Wells of a 24 well plate were 
seeded with 0.5 mL of a 1×106 cell/mL suspension and incubated at 37°C for 1 hr. 
Cells were treated with a range of concentrations of phenethyl isothiocyanate (section 
2.2.1) and incubated for the desired time period at 37°C. Samples were transferred to 
1.5 mL Eppendorf tubes and sedimented by centrifugation at 10,000 g for 15 sec. 
Culture medium was removed and the cell pellet stored at -80°C. Immediately prior to 
running the assay cell pellets were thawed and resuspended in 10 μL of PBS. The 
resuspended cells were transferred to a 96 well plate before addition of 90 μL of 
caspase buffer (section 2.2.3) containing 50 µM Ac-DEVD-AMC. The rate of release 
of fluorescent AMC was monitored for 30 min at 37°C using a POLARstar 
fluorescent platereader (BMG Labtechnologies Pty. Ltd. Mt Eliza, Australia) with an 
excitation wavelength of 390 nm and an emission/detection wavelength of 460 nm. 
 
Caspase activity was expressed as a fold increase over the rate of caspase activity that 
could be detected in control cells. Immediately prior to treating cells with phenethyl 
isothiocyanate, a single control sample was removed in order to detect basal caspase 
activity in cultured cells. The fold increase in caspase activity was determined by 
dividing the rate of caspase activity in treated samples by the rate of caspase activity 
observed in control cells. 
 
 2.3.5 Induction of Fas-mediated apoptosis 
The Fas-mediated extrinsic caspase activation pathway is induced by binding of Fas 
ligand to the corresponding Fas death receptor. Bcl-2 overexpressing cells are 
resistant to the induction of Fas-mediated apoptosis but can be sensitized by exposure 
to phenethyl isothiocyanate (Pullar, Thomson et al. 2004). The ability of other 
isothiocyanates to sensitize cells to Fas-mediated apoptosis was examined. Wells of a 
24 well plate were seeded with 500 µL of a 5×106 cell/mL B9 culture and incubated at 
37°C for 1 hr. Cells were treated with a range of concentrations of the appropriate 
isothiocyanate and incubated at 37°C for 1 hr. Isothiocyanate-treated cells were then 
either exposed to 4 µL of a 5 µg/mL activating Fas antibody solution or left without 
Fas antibody treatment. Cells were incubated for a further 4 hr at 37°C. Samples were 
transferred to 1.5 mL Eppendorf tubes and sedimented by centrifugation at 10,000 g 
for 15 sec. Culture medium was removed and the cell pellet stored at -80°C. 
Immediately prior to running the assay cell pellets were thawed and resuspended in 10 
μL of PBS. The resuspended cells were transferred to a 96 well plate before addition 
of 90 μL of caspase buffer (section 2.2.3) containing 50 µM Ac-DEVD-AMC. The 
rate of release of fluorescent AMC was monitored for 30 min at 37°C using a 
POLARstar fluorescent platereader (BMG Labtechnologies Pty. Ltd. Mt Eliza, 
Australia) with an excitation wavelength of 390 nm and an emission/detection 
wavelength of 460 nm. 
 
Caspase activity was expressed as a fold increase over caspase activity that could be 
detected in control cells. Immediately prior to treating cells with the isothiocyanates a 
single control sample was removed in order to detect basal caspase activity in cultured 
cells. The fold increase in caspase activity was determined by dividing caspase 
activity in treated samples by the caspase activity observed in control cells 
 
2.3.6 Western Blotting for Bcl-2 
The amount of Bcl-2 in Jurkat cells and Jurkat cells transfected with pCI-Neo/Bcl-2 
cDNA was estimated by Western blotting (Burnette 1981), for Bcl-2. Two million 
cells were transferred to 1.5 mL Eppendorf tubes and sedimented by centrifugation at 
10,000 g for 20 sec. Culture medium was removed before washing by addition of 1 
mL PBS and centrifugation at 10,000 g for 20 sec. PBS was removed and cell pellets 
were resuspended in 60 µL of sample extract buffer (section 2.2.5). Samples were 
 incubated for 30 min at 4°C with occasional vortexing. Cellular debris was removed 
by centrifugation at 12,000 g for 3 min. A protein assay (section 2.3.7) of the resulting 
supernatant was carried out before samples were stored at –80°C until required.  
 
The cell lysates were resolved by discontinuous SDS-PAGE (Laemmli 1970). Twenty 
μg of protein was combined with enough sample loading buffer (section 2.2.4) to 
bring the final volume to 35 μL. Samples were loaded onto a 4% stacking gel and 
resolved with a 15% separating gel (section 2.2.4). Electrophoresis was performed for 
45 min at 200 V using the BioRad Mini Protean 3 system with a BioRad Powerpack 
300 (Bio-Rad Laboatories, Hercules, CA, USA).  
 
At the conclusion of SDS-PAGE the proteins were electotransferred for 50 min at 100 
V to polyvinyldene difluoride (PVDF) membrane using a Bio-Rad Transblot 
apparatus (Bio-Rad Laboatories, Hercules, CA, USA). Non-specific antibody-binding 
sites were blocked by incubating the PVDF membranes with 5% milk powder (w/v) 
in Tris buffered saline with 0.1% TweenTM 20 (TBST20) (section 2.2.5) for 1 hr. The 
blots were incubated overnight at 4°C with a primary antibody against Bcl-2 diluted 
by a factor of 20,000 in TBST20 containing 2% milk powder (w/v). The PVDF 
membranes were thoroughly washed with TBST20 and then incubated for 1 hr with 
HRP-conjugated sheep anti-mouse antibody diluted by a factor of 20,000 in TBST20 
containing 2% milk powder (w/v). Secondary antibody was thoroughly washed off 
with TBST20. Antibodies bound to the membrane were detected using an enhanced 
chemiluminescence system (ECL) (Amersham Biosciences), according to 
manufacturer’s instructions and visualized using a Chemidoc FX imager (BioRad 
Laboratories, Hercules, CA, USA). Western blotting for β-actin was also carried out 
to ensure even protein loading between lanes. Following detection of Bcl-2 the ECL 
reagent was removed by thorough washing of the membranes in TBST20. Non-
specific antibody-binding sites were blocked by incubating the PVDF membranes 
with 5% milk powder (w/v) in TBST20. The membranes were then incubated for 2 hr 
with a primary antibody against β-actin diluted by a factor of 5,000 in TBST20 
containing 2% milk powder (w/v). The membranes were thoroughly washed with 
TBST20 and then incubated for 1 hr with HRP-conjugated sheep anti-mouse antibody 
diluted by a factor of 20,000 in TBST20 containing 2% milk powder (w/v). Secondary 
 antibody was thoroughly washed off with TBST20. Antibodies bound to the membrane 
were detected using an enhanced chemiluminescence system (ECL) (Amersham 
Biosciences), according to manufacturer’s instructions and visualized using a 
Chemidoc FX imager (BioRad Laboratories, Hercules, CA, USA). 
  
2.3.7 Protein assay 
Sample protein concentration was estimated using a Bio-Rad Detergent Compatible 
(Dc) protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). A standard curve 
containing 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 μg bovine serum albumin (BSA) was 
transferred into a microplate along with 2 μL of sample lysates. Twenty-five μL of 
reagent S was added to each well, followed by 200 μl of reagent B. Wells were 
incubated at room temperature for 15 min before absorbance was read at 750 nm 
using a MRX microplate reader (Dynatech Laboratories). Sample protein 
concentration was calculated by comparison to the BSA standard curve. 
 
2.3.8 Detection of oxidised thiol proteins by two-dimensional electrophoresis 
Oxidised thiol proteins were monitored by using a proteomic technique developed by 
Dr James Baty (Baty, Hampton et al. 2002). Ten million B9 cells (1×106 cells/mL) 
were seeded into three wells of a six-well culture plate. Cells were left to incubate for 
1 hr at 37°C. Cells were subsequently treated with either 15 µM phenethyl 
isothiocyanate or 15 µM sulforaphane (section 2.2.1) while 10 μL (0.1%) DMSO was 
added to control cells. Cells were incubated for 30 min at 37°C. Cells were harvested 
and pelleted by centrifugation at 1,000 g for 5 min. Culture medium was removed and 
the remaining pellet resuspended in 1 mL of ice-cold PBS. Suspended cells were 
centrifuged at 10,000 g for 15 sec. The PBS was aspirated and another 1 mL of ice-
cold PBS was added to the resulting pellet. Once again cells were pelleted by 
centrifugation at 10,000 g for 15 sec and PBS was removed. The washed cell pellet 
was resuspended in 200 μL of NEM buffer (section 2.2.6) (final concentration 5×106 
cells/mL) and kept on ice for 15 min. Cells were subsequently lysed by addition of 8 
μL of a 25% CHAPS solution (final concentration of 1%). Cells were incubated with 
CHAPS for 15 min, with vortexing every 5 min. The lysed cell preparation was then 
centrifuged at 16,000 g for 4 min. Spin columns that had been pre-equilibrated with 
sample extract buffer (section 2.2.5) were loaded with 90 μL of the resulting 
 supernatant. Two spin columns were used for each sample. The spin columns were 
centrifuged at 1,000 g for 4 min and the resulting eluent was pooled. A protein assay 
(section 2.3.7) was carried out on the pooled samples. The extracts were then treated 
with 1 μL of a 1 M DTT preparation (final concentration of 5 mM) and kept on ice for 
10 min. Four μL of a 10 mM IAF solution (section 2.2.6) (final concentration of 200 
µM) was subsequently added and samples were incubated in the dark, at room 
temperature, for 10 min. The IAF-labelled samples were loaded onto spin columns 
that had been pre-equilibrated with sample extract buffer (section 2.2.5). Two spin 
columns were used for each sample. A maximum of 70 µL sample was loaded onto 
each column with the amount of protein kept constant between samples. The samples, 
containing a maximum of 500 μg protein, were made up to 300 μL with 
sample/rehydration solution (section 2.2.6) and delivered into the channels of a 
rehydration/equilibration tray. Immobilized pH gradient (IPG) strips (17 cm, pH 3-10) 
were placed directly over each sample. The IPG strips were overlayed with mineral 
oil to prevent evaporation. The sample was absorbed into the IPG strips overnight in 
the dark. Rehydrated strips were then transferred to the channels of a focussing tray. 
Pre-wetted electrode wicks were used to ensure good contact between the IPG strips 
and the electrodes of the focussing tray. The strips were overlaid with mineral oil and 
isoelectric focussing (IEF) was carried out on a Bio-Rad Protean IEF Cell (Bio-Rad 
Laboratories, Hercules, CA, USA) with the voltage increasing in a stepwise fashion 
(Table 2.4). 
 
 Step Voltage (V)  Time (hr) 
 1 300   1 
 2 1000   1 
 3 3000   1 
 4 6000   12.5 (75,000 Vhr) 
 5 500   HOLD 
 
Table 2.4: Conditions for isoelectric focussing.  
 
The focussed IPG strips were transferred to a rehydration/equilibration tray and 
prepared for the second dimension by soaking for 15 min in equilibration buffer 
(section 2.2.6). The strips were transferred into clean channels of the tray and fresh 
 equilibration solution applied for another 15 min. For the second dimension, the strips 
were placed on 15% large-format SDS-PAGE gels (section 2.2.4). Strips were kept in 
place by overlaying with a 0.5% agarose solution (section 2.2.6). Electrophoresis was 
carried out for 16-18 hr in the dark with a constant current of 12 mA per gel using a 
Protean 2 Xi cell (Bio-Rad Laboratories, Hercules, CA, USA) with an Ephortec 3000 
power supply. Gels were scanned using a Bio-Rad Molecular Imager® FX (Bio-Rad 
Laboratories, Hercules, CA, USA) with an excitation wavelength of 488 nm and an 
emission/detection wavelength of 530 nm. 
 
2.3.9 Two-dimensional (2-D) gel image analysis 
Gel images of resolved IAF-labelled thiol proteins were analysed with PDQuest™ 
version 7.1.1 2-D electrophoresis gel analysis software (Bio-Rad Laboratories, 
Hercules, CA, USA). Background fluorescence was filtered from the images using the 
software’s default settings and the majority of spots were automatically detected. 
Manual editing of the detected spots was carried out to ensure that all spots were 
identified. Reference spots in a gel were matched with spots in the corresponding 
gels. The PDQuest™ analysis software was used to generate a list of spots with at 
least a two-fold increase or decrease in fluorescence in response to isothiocyanate 
exposure. Each spot that the software nominated was visually inspected to determine 
if the change was authentic or an artefact of spot detection. A consistent change was 
defined as a change that occurred in at least two out of three experiments. An 
estimation of spot molecular weights (MW) and isoelectric point (pI) was made by 
comparison with the positions of proteins with known MW and pI. 
 
2.3.10 Silver stain procedure 
Following visualization of IAF fluorescence, total protein content was visualized by 
silver staining. Gels were fixed with a 50% ethanol, 10% acetic acid solution for 30 
min and then washed with a 5% ethanol, 1% acetic acid solution for 15 min. Gels 
were washed three times with milliQ water for 5 min each before addition of solution 
1 (section 2.2.7) for 2 min. Gels were thoroughly washed three times with milliQ 
water for 30 sec and then incubated with solution 2 (section 2.2.7) for 30 min. Gels 
were washed twice with milliQ water for 20 sec each before addition of solution 3. 
Solution 3 (section 2.2.7) was quickly washed off with milliQ water as soon as colour 
development reached the desired intensity. Colour development was stopped by 
 addition of solution 4 (section 2.2.7). Gel images were acquired using a BioRad 
Fluor-S™ MultiImager (Bio-Rad Laboratories, Hercules, CA, USA). 
 
 
 Chapter 3 
 
The ability of phenethyl isothiocyanate 
to induce apoptosis in cells 
overexpressing Bcl-2. 
 
 
Results reported in this section are published in: 
Thomson, S.J.*, Brown, K.K.*, Pullar, J.M. and Hampton M.B. (2005) Phenethyl 
isothiocyanate triggers apoptosis in Jurkat cells made resistant by the overexpression 
of Bcl-2. Cancer Research 66: 6772-6777 *Joint first authors 
 
3.1 Introduction  
The isothiocyanate family constitutes a large class of compounds that are abundant in 
a wide variety of cruciferous vegetables and possess potent cytotoxicity against 
cancer cells in vitro and in vivo. Phenethyl isothiocyanate (PEITC) (Figure 3.1) in 
particular has received much attention as a potential chemopreventive and 
chemotherapeutic agent (Chen et al. 2002; Solt et al. 2003; Kim et al. 2005; Yang et 
al. 2005; Khor et al. 2006).  
Figure 3.1: Chemical structure of PEITC (adapted from Xu and Thornalley 2000a). 
 
PEITC is a major phytochemical constituent of watercress, generated upon enzymatic 
hydrolysis of the glucosinolate precursor gluconasturtiin. It is also present in many 
other cruciferous vegetables and is one of the most prominent isothiocyanates 
consumed in the human diet (Rose et al. 2005). PEITC is one of the most extensively 
studied isothiocyanates with respect to chemopreventive activity because of its high 
potency against a variety of tumours, and tumour cell lines, and also because of its 
low in vivo toxicity (Hecht 1995; NCI 1996; Rose et al. 2003; Zhang et al. 2003; 
Conaway et al. 2005).  
CH2 - CH2 - N=C=S
  
Previous work from our laboratory has demonstrated that PEITC possesses an ability 
to sensitize Bcl-2 overexpressing cells to Fas-mediated apoptosis (Pullar et al. 2004). 
Subsequent experiments were undertaken to determine if PEITC could also sensitize 
the Bcl-2 overexpressing cells to chemotherapeutic drugs. However, these preliminary 
studies suggested that PEITC could directly trigger apoptosis in the resistant cells. 
The aim of this chapter was, therefore, to fully characterise the effect of PEITC on 
cell viability, induction of apoptosis and proliferation of cells over-expressing the 
anti-apoptotic protein Bcl-2. 
 
3.2 Experimental approach 
3.2.1 The experimental system – Bcl-2 overexpressing Jurkat T cells 
A Jurkat T lymphoma cell line and Jurkat cells that had previously been stably 
transfected to express varying levels of the anti-apoptotic protein Bcl-2 were utilised 
(Bcl-2 overexpressing Jurkat clones were generated by Dr Susan Thomson). Briefly, 
the Bcl-2 coding region was subcloned from human Bcl-2 cDNA (pICbcl-2 obtained 
from Professor Suzanne Cory, Melbourne, Australia) into a pCIneo vector (Figure 
3.2). The pCIneo vector carried the human cytomegalovirus (CMV) 
enhancer/promoter region to promote constitutive expression of the Bcl-2 DNA insert 
(Schmidt et al. 1990). A simian virus 40 (SV40) enhancer/promoter region regulated 
the expression of a neomycin phophotransferase gene. Expression of the neomycin 
gene in mammalian cells confers resistance to the antibiotic geneticin (G-418) 
(Davies and Jimenez 1980) and was therefore used as a marker for successful 
transfection. Jurkat cells were transfected with the pCIneo/bcl-2 construct and 
successfully transfected cells were selected using G-418.  
 
 
 
Figure 3.2: Schematic of the pCI-neo/bcl-2 cDNA construct used to generate Bcl-2 
overexpressing Jurkat cells (adapted from Brondyk 1994). Abbreviations: 
CMV=cytomegalovirus, polyA=polyadenylation signal, SV40= simian virus 40. 
 
 
 
CMV           Bcl-2 cDNA                             polyA                            SV40    Neomycin  polyA 
 3.2.2 Monitoring cell proliferation with a BrdU ELISA assay 
Proliferation is the process by which cells divide to expand a population. Cellular 
proliferation requires the replication of DNA; therefore, DNA synthesis provides a 
parameter by which the rate of cell proliferation can be measured. DNA synthesis was 
quantified using a commercially available enzyme linked immunosorbent assay 
(ELISA) kit (section 2.3.2). The assay is based on the incorporation of the pyrimidine 
analogue 5-bromo-2’-deoxyuridine (BrdU) (Figure 3.3), in place of thymidine, into 
the DNA of proliferating cells, and the quantification of BrdU incorporation by 
ELISA (Hawker 2003).  
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Figure 3.3: Chemical structure of BrdU (adapted from Iball et al. 1966). 
 
Briefly, cells were incubated with PEITC before addition of BrdU. Actively 
replicating cells incorporated BrdU into newly synthesised DNA. DNA was then 
denatured to facilitate the binding of a peroxidase-conjugated anti-BrdU antibody. 
The amount of DNA-antibody complex was quantified by addition of the peroxidase 
substrate tetramethyl-benzidine (TMB). The developed colour directly correlated to 
the amount of DNA synthesis and hence to the number of proliferating cells in a 
population (Heil and Reifferscheid 1992; Maghni et al. 1999). 
 
3.2.3 Measurement of loss of cell viability using propidium iodide 
During cell death, the integrity of the cellular membrane is lost. While playing a 
crucial role in the breakdown of a cell, this process also allows the entry of otherwise 
membrane-impermeant compounds. Propidium iodide (PI) (Figure 3.4) is a polar dye 
that is excluded from viable cells but can penetrate the membranes of dead or dying 
cells (Wrobel et al. 1996).  
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Figure 3.4: Chemical structure of PI (adapted from Hudson et al. 1969). 
 
When inside a cell, PI binds to the major groove of DNA (Hudson et al. 1969). This 
interaction facilitates the formation of a red fluorescent adduct that can subsequently 
be visualised by flow cytometry (Nicoletti et al. 1991) (section 2.3.3). The proportion 
of cells that produce red fluorescence then directly correlates to the proportion of cells 
that are non-viable. 
 
3.2.4 Measurement of caspase activity to determine induction of apoptosis 
The caspases play a critical role in apoptosis. Caspase-mediated destruction of a cell 
is brought about by proteolytic cleavage of cellular targets C-terminal to specific 
aspartic acid residues. Caspase activity can be monitored by measuring the release of 
the fluorescent compound amino-4-methylcoumarin (AMC) from the artificial 
caspase substrate Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC) (Nicholson et al. 
1995; Gorman et al. 1999) (Figure 3.5).  
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Figure 3.5: Chemical structure of the artificial caspase substrate Ac-DEVD-AMC 
(adapted from Thornberry et al. 1997). 
 
Active caspases cleave the substrate to release Ac-DEVD and free AMC. The release 
of AMC can be measured by monitoring fluorescence intensity (section 2.3.4). The 
degree of fluorescence correlates to the amount of caspase activity. 
 
 3.3 Results 
3.3.1 Inhibition of proliferation by PEITC 
Initially, the proliferation of Jurkat cells in response to treatment with PEITC was 
examined. PEITC effectively inhibited the proliferation of Jurkat cells (Figure 3.6). 
After 1 hour of exposure to 2 µM PEITC, there was a small but significant inhibition 
of BrdU incorporation, increasing to 95% inhibition at 20 μM. The concentration of 
PEITC required to inhibit proliferation to 50% of control levels (IC50) was 3.5 μM.  
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Figure 3.6: Inhibition of Jurkat cell proliferation in response to PEITC. Cells were 
treated for one hour with PEITC. Cell proliferation was measured by monitoring the 
incorporation of BrdU into the DNA of proliferating cells using an ELISA (section 
2.3.2). Plotted values represent mean ± standard error of three experiments. * 
Indicates a significant difference (P<0.05) from untreated cells (One Way Repeated 
Measures ANOVA with Bonferroni multiple comparison [SigmaStat, Jandel 
Scientific]). 
 
At later time points, the response of cells to concentrations above and below the IC50 
was dramatically different (Figure 3.7). At 5 μM PEITC, the cells showed signs of 
recovery, with proliferation increasing two and three hours after treatment. However, 
this recovery did not occur at 15 μM PEITC, suggesting sustained growth arrest at 
higher concentrations. 
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Figure 3.7: Inhibition of Jurkat cell proliferation in response to 5 μM or 15 μM 
PEITC. Jurkat cells were treated for with 5 μM (●) or 15 μM (○) PEITC. Cell 
proliferation was measured by monitoring the incorporation of BrdU into the DNA of 
proliferating cells using an ELISA (section 2.3.2). Plotted values represent mean ± 
standard error of three experiments. * Indicates a significant difference (P<0.05) 
from cells treated for one hour (One Way Repeated Measures ANOVA with 
Bonferroni multiple comparison [SigmaStat, Jandel Scientific]). 
 
3.3.2 The effect of PEITC on Jurkat cell viability 
A sustained decrease in cell proliferation can be associated with a loss in cell 
viability. For this reason, the viability of Jurkat cells following 24 hours treatment 
with PEITC was examined. Complete loss of Jurkat cell viability was induced upon 
exposure to 15 μM PEITC (Figure 3.8). The concentration of PEITC required to kill 
fifty percent of Jurkat cells (LD50) was 7.4 μM. 
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Figure 3.8: Viability of Jurkat cells in response to treatment with PEITC. Jurkat 
cells were treated with varying concentrations of PEITC for 24 hours. Cell viability 
was then assessed by flow cytometric determination of the uptake of PI (section 2.3.3). 
Plotted values represent mean ± standard error of four experiments. 
* * 
 3.3.3 Induction of apoptosis by phenethyl isothiocyanate  
Although PEITC was shown to be completely cytotoxic towards Jurkat cells (section 
3.3.2) the mechanism by which the cells were induced to undergo cell death was not 
identified. Controlled cell death by apoptosis is favourable; however, PEITC may 
induce Jurkat cell death by triggering an apoptosis-independent mechanism, such as 
necrosis (Majno 1995; Zeiss 2003). Normally, Jurkat cells present with a roughly 
spherical morphology (Figure 3.9). Following treatment with 10 µM PEITC, 
extensive cell shrinkage and budding of apoptotic bodies was evident (Figure 3.10), 
indicating induction of apoptosis in response to isothiocyanate exposure. Treatment of 
Jurkat cells with 40 µM PEITC resulted in cells with a swollen and granular 
appearance, which are characteristic morphological features of necrosis (Kerr 1971) 
(Figure 3.11). 
 
 
          
 
Figure 3.9: Jurkat cell morphology. A zoom image of a normal Jurkat cell is shown. 
Image is representative of Jurkat morphology in three experiments. Image obtained 
using an inverted phase contrast microscope (Olympus Optical Ltd, Tokyo, Japan) at 
200× magnification. 
 
      
 
Figure 3.10: Apoptotic cell morphology following treatment with 10 µM PEITC. 
Jurkat cells were treated with 10 µM PEITC for 3 hours. A zoom image of an 
apoptotic Jurkat cell is shown. Image is representative of Jurkat morphology in three 
experiments. Image obtained using an inverted phase contrast microscope (Olympus 
Optical Ltd, Tokyo, Japan) at 200× magnification. 
 
          
 
Figure 3.11: Necrotic cell morphology following treatment with 40 µM PEITC. 
Jurkat cells were treated with 40 µM PEITC for 3 hours. A zoom image of a necrotic 
Jurkat cell is shown. Image is representative of Jurkat morphology in three 
experiments. Image obtained using an inverted phase contrast microscope (Olympus 
Optical Ltd, Tokyo, Japan) at 200× magnification. 
 
 To confirm that PEITC could induce apoptosis in Jurkat cells, caspase activity was 
monitored. PEITC induced a time- and concentration-dependent caspase activation 
(Figure 3.12). Maximum caspase activity was measured with 10 μM PEITC and after 
four hours of treatment with PEITC. A sharp decrease in Jurkat caspase activity after 
8 hours treatment with PEITC was evident, which is most likely due to a loss of cell 
viability. 
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Figure 3.12: The time course of Jurkat caspase activity in response to PEITC. Cells 
were treated with PEITC and samples were removed for caspase activity analysis 2, 
4, 6, 8, 12, and 24 hours after treatment. Caspase activity was monitored by 
measuring the release of AMC from the artificial caspase substrate Ac-DEVD-AMC 
(section 2.3.4). Symbols represent: no PEITC (●), 5μM PEITC (○), 10 μM PEITC 
(▼) and 15μM PEITC (□). Plotted values represent mean ± standard error of at least 
four experiments. Caspase activity is expressed as a fold increase over the caspase 
activity that could be detected in control cells. 
 
It is interesting to note that PEITC concentrations found to be completely cytotoxic to 
the Jurkat cell line induce cell death via caspase activation and apoptosis (Figure 
3.12). When the cells were treated with higher concentrations of PEITC (40 μM and 
60 μM) caspase activity dropped back to control levels but maximum cell death was 
still induced. This result suggests that high concentrations of PEITC will cause a 
degree of damage that will induce cell death by necrosis, rather than via activation of 
the apoptotic pathway. 
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Figure 3.13: Loss of Jurkat cell viability is mediated via apoptosis at low 
concentrations of PEITC but by necrosis at high concentrations. PEITC-treated 
Jurkat cells were removed for caspase activity analysis after 4 hours and for cell 
viability analysis following 24 hours of treatment. Cell viability (●) was assessed by 
flow cytometric determination of the uptake of PI (section 2.3.3) while caspase 
activity (○) was monitored by measuring the release of AMC from the artificial 
caspase substrate Ac-DEVD-AMC (section 2.3.4). Plotted values represent mean ± 
standard error of at least three experiments. 
 
3.3.4 The effect of PEITC on the viability of cells overexpressing Bcl-2 
As discussed in Chapter One (section 1.4.1), overexpression of the anti-apoptotic 
protein Bcl-2 blocks apoptosis in response to numerous stimuli. The ability of PEITC 
to induce apoptosis in cells overexpressing Bcl-2 was examined using Jurkat clones 
that overexpressed varying levels of the anti-apoptotic protein Bcl-2 (section 3.2.1). 
Two control cell lines (the Jurkat cell line and an empty vector clone Neo2) and three 
Bcl-2 overexpressing cell lines (Bcl-2 #1, Bcl-2 #9 and Bcl-2 #38) were used. 
Western blotting for Bcl-2 protein demonstrated that the Bcl-2 #9 cell line 
(subsequently referred to as B9) expressed the highest amount of Bcl-2, with an 
approximately sixty-fold relative increase in Bcl-2 expression compared to the 
parental Jurkat cell line (Figure 3.14). The empty vector clone Neo1 was excluded 
due to relatively high apparent expression of Bcl-2 (Figure 3.14A). 
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Figure 3.14: Bcl-2 overexpression in Jurkat T cells. (A) Cell lysates from six clones 
were analysed by SDS-PAGE and immunoblotted for Bcl-2 and for β-actin as a 
loading control (section 2.3.6). Three experiments were performed and a 
representative blot is shown. (B) Quantification of the amount of Bcl-2 in the cell 
clones used during this study. The relative levels of Bcl-2 were assessed by 
densitometric analysis of Western Blots for Bcl-2 using Quantity One software. The 
amount of Bcl-2 is expressed as a fold increase over the amount of Bcl-2 detected in 
the Jurkat cell line. Plotted values represent the mean ± standard error of three 
experiments. 
 
The five cell lines were treated with PEITC for 24 hours before assessment of cell 
viability. The most significant outcome of the cell viability analysis was that all cell 
populations, regardless of the extent of Bcl-2 overexpression, could be induced to 
undergo complete loss of cell viability (Figure 3.15A). This is in contrast to previous 
experiments examining the effect of Bcl-2 expression on the efficacy of the standard 
chemotherapeutic drugs etoposide, cytosine arabinoside and melphalan (Thomson et 
al. 2005) (Figure 3.15B). Intermediate expression of Bcl-2 (Bcl-2#1 and Bcl-2#38) 
was shown to confer some resistance to the cytotoxicity of these chemotherapeutic 
 Bcl-2 
β-actin 
 agents, whereas the degree of Bcl-2 expression in the B9 clone completely abrogated 
the cytotoxic potential of these agents. 
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Figure 3.15: Cell viability of Jurkat clones expressing varying levels of Bcl-2 in 
response to treatment with PEITC and melphalan. (A) All of the cell lines were 
treated with varying concentrations of (A) PEITC for 24 hours or (B) melphalan for 
48 hours. Cell viability was then assessed by flow cytometric determination of the 
uptake of PI (section 2.3.3). Symbols represent Jurkat (●), Neo-2 (▼), Bcl-2 #1 (■), 
Bcl-2 #9 (○) and Bcl-2 #38 (▲). The experimental data for Figure B were generated 
by Dr Susan Thomson and Dr Juliet Pullar. Plotted values represent mean ± standard 
error of at least three experiments.  
 
The Jurkat clones that expressed intermediate levels of Bcl-2 (Bcl-2 #1 and Bcl-2 
#38) demonstrated a slight resistance to PEITC, which is reflected by the raised LD50 
values of 8.8 μM and 8.6 μM respectively, compared with an LD50 of 7.4 μM for the 
Jurkat cell line (Table 3.1). The cell line that expressed the highest amount of Bcl-2 
 had an LD50 value of 15.1 μM, approximately double the LD50 of the parental Jurkat 
cell line. A statistically significant correlation between the amount of Bcl-2 and the 
LD50 with PEITC was observed (Pearson correlation, P=0.01) (Figure 3.16); however, 
it would appear that only very large increases in the levels of Bcl-2 can confer any 
real degree of resistance against PEITC, given that the Bcl-2 #38 cells, which have 
approximately 27 times more Bcl-2 than the Jurkat control, have an LD50 that is raised 
by only 1.1 µM (Table 3.1). 
 
Jurkat T cell clone Amount of Bcl-2 LD50 with PEITC (μM) 
Jurkat 1 7.4 ± 0.1 
Neo 2 1 ± 0.5 6.7 ± 0.2 
Bcl-2 #1 11 ± 3 8.8 ± 0.2 
Bcl-2 #9 60 ± 19 15.1 ± 0.2 
Bcl-2 #38 27 ± 9 8.6 ± 0.3 
 
Table 3.1: The concentration of PEITC required to induce 50% loss of cell viability 
(LD50) in Jurkat cells expressing varying levels of Bcl-2. LD50 values were generated 
using Sigmaplot (Jandel Scientific). All values represent the mean ± standard error of 
at least three experiments. 
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Figure 3.16: Correlation between the amount of Bcl-2 and the concentration of 
PEITC required to induce 50% loss of cell viability (LD50). Values from Table 3.1 
are plotted. Pearson correlation, r2=0.96, P=0.01 (SigmaStat, Jandel Scientific). 
 
3.3.5 The effect of Bcl-2 overexpression on induction of apoptosis by PEITC 
Like the parental Jurkat cells, the Bcl-2 overexpressing cell lines were susceptible to 
the cytotoxic effects of PEITC. To confirm that PEITC was also capable of inducing 
apoptosis in cells that overexpress Bcl-2, caspase activation in the most resistant B9 
cells was examined.  
 While the overexpression of Bcl-2 did reduce detectable caspase activity in response 
to PEITC, it could not prevent caspase activation (Figure 3.17). At all time points and 
concentrations of PEITC tested, the detectable caspase activity in the B9 cells did not 
reach the levels induced in the Jurkat cells (Figure 3.12 and Figure 3.17). Not only 
was the degree of caspase activity reduced, but the time of maximal caspase activation 
differed between the Jurkat and B9 cells. A maximum 6-fold increase in B9 caspase 
activity occurred between 8 and 12 hours after treatment with 15 μM PEITC. This is 
in contrast to a maximum 13-fold increase in Jurkat caspase activity after only 4 hours 
treatment with 10 µM PEITC. 
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Figure 3.17: The time course of B9 caspase activity in response to PEITC. Cells 
were treated with varying concentrations of PEITC and samples were removed for 
caspase activity analysis 2, 4, 6, 8, 12 and 24 hours after treatment. Caspase activity 
was monitored by measuring the release of AMC from the artificial caspase substrate 
Ac-DEVD-AMC (section 2.3.4). Symbols represent: no PEITC (●), 10 μM PEITC (▼) 
and 15μM PEITC (□). Plotted values represent mean ± standard error of at least four 
experiments. Caspase activity is expressed as a fold increase over the caspase activity 
that could be detected in control cells. 
 
Given that overexpression of Bcl-2 appeared to delay the onset of caspase activation, 
the concentration dependence of PEITC treatment on caspase activation at four hours, 
the time of peak caspase activity in Jurkat cells, and eight hours, the time of peak 
caspase activity in B9 cells, was examined. PEITC was able to induce caspase 
activation in all of the cell lines (Figure 3.18). In all cell lines, aside from the B9 cells, 
an approximately fifteen-fold increase in caspase activation was observed. The extent 
of Bcl-2 overexpression in the B9 cells decreased the maximum caspase activation to 
an approximately six-fold increase over control cells. Interestingly, the Bcl-2 #38 cell 
 line (Figure 3.18E), with a 27-fold increase in Bcl-2 expression, displayed a very 
similar profile of caspase activation to the Jurkat control cell line (Figure 3.18A). As 
was the case with cell viability (section 3.3.4), only a massive increase in Bcl-2 
expression could alter the response of a cell towards PEITC (Figure 3.18D).  
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Figure 3.18: Caspase activity of Jurkat clones in response to four and eight hours 
of treatment with PEITC. Cells were treated with increasing concentrations of 
PEITC and samples were removed after four (○) and eight (●) hours for caspase 
activity analysis. Caspase activity was monitored by measuring the release of AMC 
from the artificial caspase substrate Ac-DEVD-AMC (section 2.3.4). Graphed are (A) 
Jurkat, (B) Neo-2, (C) Bcl-2 #1, (D) B9 and (E) Bcl-2 #38. Plotted values represent 
mean ± standard error of at least four experiments. Caspase activity is expressed as a 
fold increase over the caspase activity that could be detected in control cells. 
A B 
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 Despite a reduction in the degree of caspase activation that could be induced in the B9 
cells, the presence of caspase activity in response to PEITC is significant, given that 
previous studies demonstrated these cells to be completely resistant to the induction of 
apoptosis in response to traditional chemotherapeutic agents, including melphalan 
(Thomson et al. 2005) (Figure 3.19). 
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Figure 3.19: Induction of apoptosis by melphalan. All cell lines were treated with 
increasing concentrations of melphalan. Samples were removed after 24 hours 
treatment for caspase activity analysis. Caspase activity was monitored by measuring 
the release of AMC from the artificial caspase substrate Ac-DEVD-AMC (section 
2.3.4). Symbols represent Jurkat (●), Neo-2 (▼), Bcl-2 #1 (■), Bcl-2 #9 (○) and Bcl-2 
#38 (▲). Plotted values represent mean ± standard error of three experiments. 
Caspase activity is expressed as a fold increase over the caspase activity that could be 
detected in control cells. Experimental data were generated by Dr Susan Thomson 
and Dr Juliet Pullar.  
 
As was the case with the Jurkat cells (Figure 3.13) the concentrations of PEITC found 
to be completely cytotoxic to the highly resistant B9 cells induced cell death via 
caspase activation and apoptosis (Figure 3.20). Once again, high concentrations of 
PEITC did not trigger caspase activation suggesting that cell death was a result of 
necrosis rather than through activation of the apoptotic pathway. 
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Figure 3.20: Loss of B9 cell viability is mediated via apoptosis at low concentrations 
of PEITC but by necrosis at high concentrations. PEITC-treated B9 cells were 
removed for caspase activity analysis after eight hours and for cell viability analysis 
following twenty-four hours of treatment. Cell viability (●) was assessed by flow 
cytometric determination of the uptake of PI (section 2.1.3) while caspase activity (○) 
was monitored by measuring the release of AMC from the artificial caspase substrate 
Ac-DEVD-AMC (section 2.3.4). Plotted values represent mean ± standard error of at 
least three experiments. 
 
3.4 Discussion 
In this section of the study, the ability of PEITC to inhibit cell proliferation, trigger 
caspase activation and kill target cells was investigated. PEITC was initially observed 
to rapidly inhibit proliferation of Jurkat cells. Very low concentrations of PEITC 
inhibited cell proliferation within one hour of exposure, suggesting that inhibition of 
proliferation is an early event mediated by the isothiocyanate. At concentrations less 
than 5 μM, this was a reversible effect, and cells continued proliferating at later times. 
Therefore, low doses of PEITC may trigger transient growth arrest but do not appear 
to induce progression to cell death. At doses of 5 µM to 20 µM, the inhibition of 
proliferation appeared to be a permanent effect and was closely associated with 
subsequent induction of apoptosis and loss of cell viability. At doses in excess of 20 
µM, the loss in cell viability was predominantly caspase independent, and associated 
with necrosis.  
 
Few studies have directly examined the ability of the isothiocyanates to inhibit cell 
proliferation by monitoring inhibition of DNA synthesis. PEITC has been shown to 
dramatically reduce DNA synthesis in human acute promyelocytic leukemia HL-60 
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 and human myeloblastic leukemia ML-1 cells with IC50 values of 2.24 μM and 2.42 
μM respectively (Xu and Thornalley 2000b). Inhibition of DNA synthesis has also 
been demonstrated  in human colon adenocarcinoma CaCo2 cells with an IC50 of 2.4 
μM (Visanji et al. 2004). An in vivo study has also shown that the N-acetyl cysteine 
conjugate of PEITC (PEITC-NAC) can reduce the number of actively proliferating 
cells in tumour tissue samples by as much as 75% (Chiao et al. 2004). In the cell lines 
described above, the inhibition of DNA synthesis was examined at much later time 
points than investigated in this study. We have demonstrated, for the first time, that 
low doses of PEITC can significantly reduce cell proliferation within one hour of 
treatment. 
 
The majority of studies relating to the anti-proliferative efficacy of the isothiocyanates 
have focussed on monitoring inhibition of cell cycle progression. Generally, 
isothiocyanate administration results in G2/M cell cycle arrest, which is the point in 
the cell cycle that is most often bypassed by cancerous cells (Malumbres and 
Barbacid 2001; Jackson and Singletary 2004; Singh et al. 2004; Srivastava and Singh 
2004; Tang and Zhang 2004; Visanji et al. 2004). Such an arrest prevents mitosis and, 
therefore, the successful division of daughter cells. G2/M arrest by the isothiocyanates 
has also been demonstrated in vivo (Srivastava et al. 2003). Interestingly, G2/M phase 
arrested cells have been shown to be more sensitive to undergoing apoptosis in 
response to continued exposure to isothiocyanates (Miyoshi et al. 2004b). The exact 
mechanism by which the isothiocyanates can block cell cycle progression remains 
elusive; however, the expression and activity of numerous proteins that play a key 
role in the progression of the cell cycle have been shown to be modulated upon 
treatment with various isothiocyanates (Powolny et al. 2003; Xiao et al. 2003; 
Fimognari et al. 2004b). 
 
While capable of inhibiting the proliferation of Jurkat cells, a dramatic loss of cell 
viability via the induction of apoptosis was also demonstrated following exposure to 
PEITC. A collection of studies suggest that induction of cell death by PEITC is not 
cell line specific (Table 3.2).  
 
 
 
 
 Cell type Description LD50 Reference 
  PEITC 
  (μM) 
Jurkat  T-cell leukemia 7.4 This study 
  25 Chen, et al. 1998 
HL-60 Acute promyelocytic leukemia 2.9 Adesida, et al. 1996 
  5 Xu & Thornalley 2000b 
  3.6 Zhang, et al. 2003 
  1 Jakubikova, et al. 2005 
HL-60/AR Doxorubicin-resistant leukemia 4.9 Zhang, et al. 2003 
HL-60/ADR Multidrug-resistant leukemia 3.8 Jakubikova, et al. 2005 
HL-60/VCR  2.1 Jakubikova, et al. 2005 
8226 Myeloma 3.1 Zhang, et al. 2003 
8226/Dox40 Doxorubicin-resistant myeloma 4.6 Zhang, et al. 2003 
ML-1 Myeloblastic leukemia 3.3 Xu & Thornalley 2000b 
PC-3 Prostate cancer 10 Xu, et al. 2005b 
DU145  7 Xiao, et al. 2005a 
LNCaP  7 Xiao, et al. 2005a 
UM-UC-3 Bladder carcinoma 11.6 Tang & Zhang 2004 
HepG2 Hepatoma 20 Rose, et al. 2005 
  15 Rose et al. 2003 
  11.2 Zhang, et al. 2003 
PLC/PRF/5  4 Wu, et al. 2005 
HT-29  Colorectal cancer 25 Hu, et al. 2003 
  9.6 Zhang, et al. 2003 
CaCo2 Colon adenocarcinoma 12 Bonnesen, et al. 2001 
LS-174  20 Bonnesen, et al. 2001 
HeLa Cervical squamous carcinoma 7.5 Yu, et al. 1998 
MCF-7 Breast cancer 11 Zhang, et al. 2003 
HaCaT Transformed epidermal keratinocytes 6.1 Zhang, et al. 2003 
 
Table 3.2: Summary of previous studies examining cell death in response to 
treatment with PEITC. 
 
In contrast to results from this investigation, an LD50 of 25 μM was previously 
measured in Jurkat cells treated with PEITC (Chen et al. 1998). However, in this 
study, cell viability was crudely measured by a trypan blue exclusion assay, which is 
far less sensitive to loss of cell viability than monitoring incorporation of PI by flow 
cytometry (Altman et al. 1993). Interestingly, PEITC is equally effective in cell lines 
derived from either solid or haematological malignancies, highlighting its potential 
application to the treatment of a wide variety of cancers. 
 
In this study, PEITC also demonstrated a powerful ability to induce cell death despite 
extensive overexpression of the anti-apoptotic protein Bcl-2. Importantly, the loss of 
cell viability that was triggered by PEITC could be attributed to induction of 
apoptosis. The finding that PEITC could induce apoptosis and death of cells 
overexpressing Bcl-2 is in agreement with a recent study which showed that the 
isothiocyanate sulforaphane can directly induce apoptotic cell death in human prostate 
 cancer PC-3 cells that overexpress Bcl-2 (Singh et al. 2005). On the other hand, the 
results disagree with a study by Chen and colleagues showing that overexpression of 
Bcl-2 could prevent the induction of apoptosis by PEITC (Chen et al. 1998). As the 
study was carried out in embryonic kidney 293 cells, this disparity may reflect a 
difference in cell types. However, this study examined a single concentration of 20 
µM PEITC. At the chosen concentration, control cells had lost 40% viability but there 
was no killing observed in the Bcl-2 overexpressing cells. Results from this study 
suggest that overexpression of Bcl-2 can shift the dose-response curve rather than 
confer protection against PEITC. For example, it was shown that 10 μM PEITC can 
kill 40% of Jurkat cells but can induce loss of cell viability in less than 20% of B9 
cells. If this was the only concentration of PEITC examined the incomplete 
conclusion would be that Bcl-2 protects against induction of cell death by PEITC.  
 
The results of this section of the study suggest that isothiocyanates may be useful for 
targeting cells that overexpress Bcl-2. To provide further insight into the mechanism 
of action of PEITC, an investigation of the cytotoxic activity of a selection of 
isothiocyanates was undertaken and is reported in Chapter Four. 
  
 
 
 
 
 Chapter 4 
 
Structure-activity relationships of the isothiocyanates 
 
 
Results reported in this section are published in: 
Thomson, S.J.*, Brown, K.K.*, Pullar, J.M. and Hampton M.B. (2005) Phenethyl 
isothiocyanate triggers apoptosis in Jurkat cells made resistant by the overexpression 
of Bcl-2. Cancer Research 66: 6772-6777 *Joint first authors 
 
4.1 Introduction  
More than 120 naturally occurring isothiocyanates have been identified (Fahey et al. 
2001). As discussed in Chapter One (section 1.1.2) there is considerable structural 
diversity in the side chains that can be associated with the isothiocyanate group. This 
diversity arises during the biosynthesis of glucosinolate precursors. Glucosinolate 
biosynthesis involves four key processes: 1) chain elongation of the amino acids 
alanine, leucine, isoleucine, valine, phenylalanine, tyrosine or tryptophan; 2) oxidative 
decarboxylation of these amino acids to generate an aldoxime; 3) conversion of the 
oxime into the basic glucosinolate structure; and (4) secondary modification of the 
glucosinolate by processes including oxidation, hydroxylation, sulfation and 
glucosylation (Halkier and Du 1997; Chen and Andreasson 2001). The processes of 
chain elongation and secondary modification allow for a vast variety of structures and 
a multitude of potentially biologically active compounds. Furthermore, a number of 
synthetic isothiocyanates have been produced in an attempt to improve 
chemopreventive activity (Morse et al. 1991; Fuke et al. 1997).  
 
The electrophilic carbon residue of the isothiocyanate moiety is primarily responsible 
for mediating the biological effects of the isothiocyanates. However, the side chain 
attached to the functional group will also play a role in biological activity. The 
isothiocyanate side chain will influence electrophilicity of the –N=C=S group, steric 
hindrance, and lipophilicity (Zhang et al. 2005).  
 
Many studies have already highlighted the different potencies of structurally diverse 
isothiocyanates both in vitro and in vivo (Hecht 2000; Conaway et al. 2002). The 
purpose of this section of the thesis was to carry out a structure-activity investigation 
 of a selection of isothiocyanates to determine key structural features that confer 
apoptosis-inducing properties in cells overexpressing Bcl-2. 
 
4.2 Results 
4.2.1 Requirement of the isothiocyanate moiety for cytotoxic activity 
The cytotoxicity of PEITC was demonstrated in Chapter Three. To confirm that the 
isothiocyanate moiety is required for cytotoxic activity, benzyl isothiocyanate, benzyl 
thiocyanate and benzyl selenocyanate were compared (Figure 4.1). Although benzyl 
isothiocyanate (Ph-CH2-N=C=S) and benzyl thiocyanate (Ph-CH2-S=C=N) have the 
same chemical formula, they differ in the orientation of the –NCS atoms, an alteration 
that has a significant effect on the reactivity of the central carbon atom. The carbon 
between the nitrogen and the sulfur in benzyl isothiocyanate is more electrophilic than 
the corresponding carbon in benzyl thiocyanate (personal communication with Prof. 
Margaret Brimble, Department of Chemistry, University of Auckland). Benzyl 
selenocyanate (Ph-CH2-Se=C=N) differs from benzyl isothiocyanate in that the sulfur 
atom of benzyl isothiocyanate is replaced by a selenium atom and the functional 
group is in the thiocyanate conformation. Although both selenium and sulfur are 
nucleophilic, this alteration abolishes the isothiocyanate functional group and changes 
the chemistry of the thiocyanate moiety (Jacob and Sies 2003). 
 
CH2NCS
                                        
CH2SCN
                                       
CH2SeCN
 
 
Figure 4.1: Structures of (A) benzyl isothiocyanate, (B) benzyl thiocyanate, and (C) 
benzyl selenocyanate.  
 
Similar to PEITC (section 3.3.4), benzyl isothiocyanate was able to induce complete 
loss of cell viability in both the parental Jurkat cells and in the Bcl-2 overexpressing 
B9 cells, although it was less effective against the B9 cells than PEITC (Figure 4.2A). 
However, benzyl thiocyanate was only partially toxic towards the Jurkat cells and 
completely ineffective against the B9 cells (Figure 4.2B). Although benzyl 
thiocyanate demonstrated some cytotoxic activity towards the Jurkat cells, the profile 
of cell death was unusual in that maximum loss of cell viability (30% non-viable) was 
     A                                                      B                                                     C 
 observed when cells were treated with 10 µM benzyl thiocyanate and did not differ 
with concentrations up to 60 μM. This suggests that the mechanism of cytotoxicity of 
benzyl thiocyanate is different from that of benzyl isothiocyanate. Interestingly, 
benzyl selenocyanate displayed a relatively similar cell death profile to benzyl 
isothiocyanate in both the Jurkat and B9 cells (Figure 4.2C). The fact that benzyl 
thiocyanate has limited cytotoxicity while benzyl selenocyanate is highly cytotoxic 
suggests that cell death may be a result of the inherent cytotoxicity of seleno-
compounds (Weiller et al. 2004).  
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Figure 4.2: The cytotoxicity of benzyl isothiocyanate, benzyl thiocyanate and benzyl 
selenocyanate. Both Jurkat (●) and B9 (○) cells were treated for 24 hours with either 
benzyl isothiocyanate (A), benzyl thiocyanate (B) or benzyl selenocyanate (C) before 
analysis of cell viability by flow cytometric determination of the uptake of PI (section 
2.3.3). Plotted values represent the mean ± standard error values of at least three 
experiments. LD50 values were generated using Sigmaplot Version 8.  
 
4.2.2 Structure-activity relationship of aromatic isothiocyanates 
The cytotoxicities of a selection of aromatic isothiocyanates (Figure 4.3) were 
examined in order to determine the length of the carbon linker group, between the 
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 phenyl ring and the isothiocyanate moiety that confers the most potent cytotoxic 
activity. R(-)-α-Methylbenzyl isothiocyanate (Figure 4.3G), which is closely related to 
PEITC, was also chosen to determine how the orientation of the isothiocyanate 
moiety with respect to the aromatic ring can affect cytotoxic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Structures of aromatic isothiocyanates. (D) Phenyl isothiocyanate, (A) 
benzyl isothiocyanate, (E) PEITC, (F) 3-phenylpropyl isothiocyanate, (G) 4-
phenylbutyl isothiocyanate, (H) phenylhexyl isothiocyanate and (I) R(-)-α-
methylbenzyl isothiocyanate. 
 
Strikingly, phenyl isothiocyanate was incapable of inducing cell death in either the B9 
cells or the sensitive Jurkat cells at concentrations up to 60 μM (Figure 4.4A). As 
highlighted earlier, benzyl isothiocyanate and PEITC (Figure 4.4B and 4.4C) 
displayed a very similar cell death profile in both Jurkat and B9 cells although, while 
benzyl isothiocyanate was more cytotoxic to Jurkat cells, PEITC was better at killing 
the B9 cells. Increasing the length of the carbon linker group beyond two CH2 units 
adversely affected the ability of the isothiocyanates to induce cell death, although to a 
minimal extent considering the resistance of the B9 cells (Figure 4.4D-4.4F). Finally, 
altering the conformation of PEITC to give R(-)-α-methylbenzyl isothiocyanate 
significantly decreased cytotoxic activity in the B9 cells but did not dramatically 
reduce activity in the Jurkat cells (Figure 4.4G). These results emphasise the 
requirement for quite rigid structural features when targeting cells overexpressing 
Bcl-2. 
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Figure 4.4: The cytotoxicity of aromatic isothiocyanates. Jurkat (●) and B9 (○) cells 
were treated for 24 hours with phenyl (A), benzyl (B), phenethyl (C), 3-phenylpropyl 
(D), 4-phenylbutyl (E), phenylhexyl (F) or R(-)-α-methylbenzyl (G) isothiocyanate 
before analysis of cell viability by flow cytometric determination of the uptake of PI 
(section 2.3.3). Plotted values represent the mean ± standard error of at least three 
experiments. LD50 values were generated using Sigmaplot Version 8. 
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 4.2.3 Cytotoxicity of the products of aromatic isothiocyanate metabolism 
Upon entering a cell, an isothiocyanate will rapidly react with intracellular GSH 
giving rise to a dithiocarbamate (Zhang et al. 1995). This reaction initiates the cellular 
efflux and metabolism of the isothiocyanate via the mercapturic acid pathway. 
Following conjugation with GSH, the enzymatic actions of γ-glutamyl-transpeptidase 
and cysteinyl glycinase convert the dithiocarbamate to a cysteinyl glycine derivative 
and a cysteine derivative respectively (Keum et al. 2004).  
 
 
 
Figure 4.5: Formation of isothiocyanate-cysteine conjugates. Intracellular 
isothiocyanates rapidly conjugate with GSH to form a dithiocarbamate (1). The 
enzymatic activity of γ-glutamyl-transpeptidase then converts the dithiocarbamate to 
a cysteinyl glycine derivative (2). Cysteinyl-glycinase then catalyses the conversion of 
the cysteinyl glycine derivative to a cysteine derivative (3). 
 
Cysteine derivaties of isothiocyanates have been used in previous chemoprevention 
studies and may even be more clinically useful as they are proposed to be less toxic 
(Zheng et al. 1992). Two such cysteine derivatives, S-(N-benzylthiocarbamoyl)-L-
cysteine, which is derived from benzyl isothiocyanate, and S-(N-3-
phenylpropylthiocarbamoyl)-L-cysteine, which is derived from 3-phenylpropyl 
isothiocyanate, were examined for cytotoxic activity (Figure 4.6). 
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Figure 4.6: Structures of the products of aromatic isothiocyanate metabolism. (J) S-
(N-benzylthiocarbamoyl)-L-cysteine which is derived from benzyl isothiocyanate and 
(K) S-(N-3-Phenylpropylthiocarbamoyl)-L-cysteine which is derived from 3-
phenylpropyl isothiocyanate. 
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 The cytotoxic activities of the isothiocyanate-cysteine conjugates (Figure 4.7) were 
greatly diminished when compared with their respective parent compounds (Figure 
4.4B and 4.4D); however, high concentrations of S-(N-benzylthiocarbamoyl)-L-
cysteine were able to induce complete loss of cell viability (Figure 4.7A). Although 
the cysteine derivatives were not as cytotoxic as the isothiocyanates that they are 
derived from, they did retain the ability to induce death of Bcl-2 overexpressing cells. 
 
A      B 
S-(N-benzylthiocarbamoyl)-L-cysteine (μM)
0 10 20 30 40 50 60
%
 P
I p
os
iti
ve
 c
el
ls
0
20
40
60
80
100
     S-(N-3-phenylpropylthiocarbamoyl)-L-cysteine (μM)
0 5 10 15 20 25 30
%
 P
I p
os
iti
ve
 c
el
ls
0
20
40
60
80
100
 
 
Figure 4.7: The cytotoxicity of S-(N-benzylthiocarbamoyl)-L-cysteine and S-(N-3-
phenylpropylthiocarbamoyl)-L-cysteine. Both Jurkat (●) and B9 (○) cells were 
treated for 24 hours with either S-(N-benzylthiocarbamoyl)-L-cysteine (A) or S-(N-3-
phenylpropylthiocarbamoyl)-L-cysteine (B) before analysis of cell viability by flow 
cytometric determination of the uptake of PI (section 2.3.3). Plotted values represent 
the mean ± standard error of at least three experiments. LD50 values were generated 
using Sigmaplot Version 8. 
 
4.2.4 Structure-activity relationship of aliphatic isothiocyanates 
Along with aromatic and indoyl isothiocyanates, a large number of naturally 
occurring aliphatic isothiocyanates have been identified. A selection of such 
compounds (Figure 4.8) was analysed to determine the efficacy of aliphatic 
isothiocyanates as cytotoxic compounds in the Bcl-2 overexpressing cells. Allyl 
isothiocyanate and sulforaphane (Figure 4.8M and 4.8Q) were of particular interest, as 
numerous studies have demonstrated the potent chemopreventive properties of these 
particular isothiocyanates (Conaway et al. 2002; Fimognari et al. 2002b; Munday and 
Munday 2004). 
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Figure 4.8: Structures of aliphatic isothiocyanates. (L) tert-Butyl isothiocyanate, 
(M) allyl isothiocyanate, (N) 1-methyl allyl isothiocyanate, (O) 1-methyl butyl 
isothiocyanate, (P) hexyl isothiocyanate and (Q) sulforaphane [1-isothiocyanato-4-
(methylsufinyl)-butane]. 
 
tert-Butyl isothiocyanate, 1-methyl allyl isothiocyanate, 1-methyl butyl isothiocyanate 
and hexyl isothiocyanate were completely devoid of any ability to induce cell death in 
the B9 cells (Figure 4.9A and 4.9C-E). Of these compounds, only hexyl 
isothiocyanate was able to appreciably affect the viability of the Jurkat cells; however, 
at 20 μM, greater than 80% of cells were still viable. At high concentrations, allyl 
isothiocyanate was cytotoxic to the Jurkat cells, but only induced a minimal amount 
of B9 cell death at concentrations as high as 60 μM (Figure 4.9B). The response of the 
B9 and Jurkat cells to sulforaphane was particularly interesting (Figure 4.9F). In all 
other dose-response curves, the isothiocyanates have demonstrated greater 
cytotoxicity towards the Jurkat cells than towards the B9 cells. Sulforaphane 
displayed a uniquely similar cell death profile in both cell lines.  
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Figure 4.9: The cytotoxicity of aliphatic isothiocyanates. Both Jurkat (●) and B9 (○) 
cells were treated for 24 hours with either  tert-butyl isothiocyanate (A),  allyl 
isothiocyanate (B), 1-methyl allyl isothiocyanate (C), 1-methyl butyl isothiocyanate 
(D), hexyl isothiocyanate (E) or sulforaphane (F) before analysis of cell viability by 
flow cytometric determination of the uptake of PI (section 2.3.3). Plotted values 
represent the means ± standard error of at least three experiments. LD50 values were 
generated using Sigmaplot Version 8. 
 
4.2.5 Isothiocyanates and sensitisation to Fas-mediated apoptosis 
Bcl-2 overexpressing cells have previously been demonstrated to be resistant to the 
induction of Fas-mediated apoptosis (Kawahara et al. 1998), a property that can be 
reversed by addition of PEITC (Pullar et al. 2004). Due to the fact that Jurkat cells are 
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 type II cells and rely on the cleavage of Bid and activation of the mitochondrial 
caspase-activation pathway, apoptosis induction in Jurkat cells is primarily mediated 
via the mitochondria (Cuvillier et al. 2000). Therefore, overexpression of Bcl-2 has a 
profound effect on the ability of the Fas ligand to induce apoptosis in Jurkat cells. 
 
Various isothiocyanates were examined for their ability to sensitize the Bcl-2 
overexpressing B9 cells to Fas-mediated apoptosis (Figure 4.10). Cells were treated 
with 15 µM of each aromatic isothiocyanate, corresponding to the LD50 of PEITC in 
B9 cells.  Sulforaphane and allyl isothiocyanate were administered at a concentration 
of 40 µM, reflecting the LD50 of sulforaphane in B9 cells. Caspase activity was 
assessed after 4 hours, a time when PEITC alone had very little effect on caspase 
activation in B9 cells (section 3.3.5). Only PEITC and benzyl isothiocyanate (BITC) 
were able to sensitize the cells to Fas stimulation. Phenyl isothiocyanate did not affect 
the ability of the anti-Fas antibody to induce apoptosis. Sulforaphane (SFN) and allyl 
isothiocyanate (AITC) were also incapable of sensitising the Bcl-2 overexpressing 
cells to Fas-mediated apoptosis. 
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Figure 4.10: Sensitisation to Fas-mediated apoptosis by a selection of 
isothiocyanates. B9 cells were treated for one hour with the appropriate 
isothiocyanate before 4 hours exposure to anti-Fas antibody. Caspase activity was 
analysed by measuring the release of AMC from the artificial caspase substrate Ac-
DEVD-AMC (section 2.3.5). Plotted values represent the mean ± standard error of at 
least three experiments. * Indicates a significant difference (P<0.05) from control 
cells treated with Fas (One Way Repeated Measures ANOVA with Bonferroni 
multiple comparison [SigmaStat]). 
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 4.2.6 The antiproliferative activity of various isothiocyanates 
Due to the fact that inhibition of proliferation is tightly linked with apoptosis and loss 
of cell viability, the anti-proliferative activities of a selection of isothiocyanates were 
determined. Screening of the ability of the isothiocyanates to induce cell death 
identified differential potencies, depending on structure. However, it is possible that 
an isothiocyanate may be able to inhibit proliferation, but not proceed to induce cell 
death. 
 
Both aliphatic and aromatic isothiocyanates were shown to be capable of inhibiting 
Jurkat cell proliferation, but to varying degrees (Figure 4.11 and Figure 4.12). The 
aromatic isothiocyanates (Figure 4.12) displayed more potent anti-proliferative 
activity than the aliphatic isothiocyanates (Figure 4.11). The only exception was 
phenyl isothiocyanate which demonstrated the weakest anti-proliferative activity and 
only reduced proliferation to a maximum of 20%. The strongest anti-proliferative 
compounds were PEITC and benzyl isothiocyanate with IC50 values of 3.2 µM and 
3.5 µM respectively. The products of aromatic isothiocyanate metabolism (Figure 
4.13) demonstrated weaker anti-proliferative activity than their respective parental 
compounds (Figure 4.12B and 4.12D); however, they still dramatically reduced the 
proliferation of Jurkat cells after 1 hour of exposure. 
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Figure 4.11: The antiproliferative activity of aliphatic isothiocyanates. Jurkat cells 
were treated for one hour with (A) allyl isothiocyanate, or (B) sulforaphane. Cell 
proliferation was then measured by monitoring the incorporation of BrdU into the 
DNA of proliferating cells using an ELISA (section 2.3.2). Plotted values represent 
mean ± standard error of at least three experiments and are expressed as a 
percentage of the proliferation observed in untreated cells. Dose-response curves for 
loss of cell viability are overlayed in each graph (dashed line). 
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Figure 4.12: The antiproliferative activity of aromatic isothiocyanates. Jurkat cells 
were treated for one hour with (A) phenyl isothiocyanate, (B) benzyl isothiocyanate, 
(C) PEITC, (D) 3-phenylpropyl isothiocyanate, or (E) R(-)-α-methylbenzyl 
isothiocyanate. Cell proliferation was then measured by monitoring the incorporation 
of BrdU into the DNA of proliferating cells using an ELISA (section 2.3.2). Plotted 
values represent mean ± standard error of at least three experiments and are 
expressed as a percentage of the proliferation observed in untreated cells. Dose-
response curves for loss of cell viability are overlayed in each graph (dashed line). 
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Figure 4.13: The antiproliferative activity of products of aromatic isothiocyanate 
metabolism. Jurkat cells were treated for one hour with (A) S-(N-
benzylthiocarbamoyl)-L-cysteine, or (B) S-(N-3-phenylpropylthiocarbamoyl)-L-
cysteine. Cell proliferation was then measured by monitoring the incorporation of 
BrdU into the DNA of proliferating cells using an ELISA (section 2.3.2). Plotted 
values represent mean ± standard error of at least three experiments and are 
expressed as a percentage of the proliferation observed in untreated cells. Dose-
response curves for loss of cell viability are overlayed in each graph (dashed line). 
 
A relationship between anti-proliferative activity and ability to induce loss of cell 
viability was observed (Figure 4.14). A statistically significant correlation between 
the LD50 values for loss of cell viability in Jurkat cells and IC50 values for inhibition 
of proliferation was observed (Pearson correlation, P=0.02).  
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Figure 4.14: Correlation between LD50 and IC50 values for different 
isothiocyanates. BITC=benzyl isothiocyanate, PPITC=3-phenylpropyl 
isothiocyanate, MBITC=R(-)-α-methylbenzyl isothiocyanate, BTC-Cys=S-(N-
benzylthiocarbamoyl)-L-cysteine, AITC=allyl isothiocyanate, SFN=sulforaphane,  
PPTC-Cys=S-(N-3-phenylpropylthiocarbamoyl)-L-cysteine. r2=0.794, P=0.02 
(Sigmastat, Jandel Scientific). 
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 4.2.7 The cytotoxic and anti-proliferative activities of various isothiocyanates 
 
 
Table 4.1: Summary of isothiocyanate concentrations required to induce 50% loss 
of cell viability (LD50) in Jurkat and B9 cells and 50% inhibition of proliferation 
(IC50) in Jurkat cells. LD50 and IC50 values were generated using Sigmaplot Version 
8 based on replicate data from Figures 4.2, 4.4, 4.7, and 4.9 for cell viability and 
Figures 4.11, 4.12 and 4.13 for proliferation. All values represent the mean ± 
standard error of at least three experiments. 
 
4.3 Discussion 
This investigation represents the first large scale screening of isothiocyanates for 
chemotherapeutic potential. The cytotoxic activities of aromatic isothiocyanates, 
products of aromatic isothiocyanate metabolism and aliphatic isothiocyanates were 
investigated. This is also the first time that a selection of isothiocyanates has been 
screened for cytotoxic activity towards drug-resistant Bcl-2 overexpressing cells.  
 
Results from this section of the study highlight the critical role that intrinsic structural 
differences of various isothiocyanates play in affording biological activity towards 
cells that overexpress Bcl-2. PEITC displayed the most potent activity in inducing 
loss of cell viability, inhibiting proliferation and sensitising Bcl-2 overexpressing cells 
to Fas-mediated apoptosis. Benzyl isothiocyanate was the other most promising 
compound identified. Previous studies have also identified PEITC and benzyl 
Isothiocyanate     Cell Viability Proliferation         
LD50 (µM)    IC50 (µM)  
 Jurkat B9 Jurkat 
Benzyl thiocyanate > 60 > 60  
Benzyl selenocyanate 11 ± 0.4 18 ± 0.2  
Phenyl isothiocyanate > 60 > 60 >20 
Benzyl isothiocyanate 6.1 ± 0.1 23 ± 6 3.2 ± 0.6 
Phenethyl isothiocyanate 7.4 ± 0.1 15 ± 0.2 3.5 ± 0.9 
3-Phenylpropyl isothiocyanate 11 ± 0.1 21 ± 0.3 4.6 ± 0.1 
4-Phenylbutyl isothiocyanate 10 ± 2 23 ± 0.2  
Phenylhexyl isothiocyanate 11 ± 0.6 25 ± 0.3  
R(-)-α-Methylbenzyl isothiocyanate 11 ± 2 32 ± 2 7.7 ± 0.3 
S-(N-benzylthiocarbamoyl)-L-cysteine 17 ± 0.5 37 ± 2 8.9 ± 1 
S-(N-3-phenylpropylthiocarbamoyl)-L-cysteine 18 ± 2 42 ± 7 10-20 
t-Butyl isothiocyanate >20 > 20  
Allyl isothiocyanate 42 ± 3 > 60 10-20 
1-Methyl allyl isothiocyanate > 20 > 20  
1-Methyl butyl isothiocyanate > 20 > 20  
Hexyl isothiocyanate > 20 > 20  
Sulforaphane 43 ± 3 45 ± 0.6 13 ± 2 
 isothiocyanate as two extremely promising compounds with respect to the ability to 
induce apoptotic cell death (Jakubikova et al. 2005; Tang and Zhang 2005).  
 
The isothiocyanate moiety was clearly identified as being absolutely required for 
cytotoxic activity in our system. The importance of the isothiocyanate group was also 
recognised in a study comparing the inhibition of mitochondrial respiration by benzyl 
isothiocyanate (BITC) and the methyl-thiocarbamate analogue of benzyl 
isothiocyanate (BITC-OMe) (Kawakami et al. 2005).  While BITC potently inhibitied 
respiration, BITC-OMe displayed no activity. Due to the greater electrophilicity of the 
carbon between the nitrogen and sulfur, benzyl isothiocyanate can act as an 
electrophilic trapping agent for a nucleophile derived from a biological target, such as 
a protein (personal communication with Prof. Margaret Brimble, Department of 
Chemistry, University of Auckland). Given that isothiocyanate reactivity confers 
biological activity, in our system the reactions of cellular nucleophiles with the 
electrophilic isothiocyanate moiety is implicated in the induction of cell death in cells 
overexpressing Bcl-2. 
  
The side chain attached to the isothiocyanate group also profoundly influenced 
cytotoxic and anti-proliferative activity. Generally, the aromatic isothiocyanates were 
more potent than the aliphatic isothiocyanates in all three biological activities 
assessed. The only aromatic isothiocyanate that showed a complete absence of 
activity was phenyl isothiocyanate. The lack of a carbon spacer group between the 
aromatic ring and the isothiocyanate moiety rendered phenyl isothiocyanate 
completely ineffective at inducing cell death and inhibiting proliferation. The 
inactivity of phenyl isothiocyanate has been observed in previous studies with 
significant cytotoxicity only presenting at concentrations in excess of 700 μM (Lui et 
al. 2003). Addition of a single CH2 unit, giving rise to benzyl isothiocyanate, was 
sufficient to confer strong cytotoxic and anti-proliferative activity in both the Jurkat 
and B9 cells. The absence of a carbon spacer group promotes electron withdrawal by 
the phenyl ring which increases the electrophilicity of the central carbon of the 
isothiocyanate moiety. The increased reactivity of phenyl isothiocyanate means that it 
could react with constituents in the culture media or react with other cellular proteins 
before reaching the intracellular site(s) critical for promotion of apoptosis (personal 
communication with Dr Yuesheng Zhang, Roswell Park Cancer Institute). This is 
 supported by studies which have shown that phenyl isothiocyanate is inactive in 
assays using cultured cell systems but displays inhibitory activity when used to inhibit 
the respiration of isolated mitochondria (Zhang and Talalay 1998; Kawakami et al. 
2005). However, when either the Jurkat or B9 cells were suspended in PBS, phenyl 
isothiocyanate remained inactive (data not shown), suggesting that phenyl 
isothiocyanate will react with GSH or other non-essential thiols in cells. 
 
Studies on the inhibition of the enzyme papain by various isothiocyanates identified 
an alternate explanation for differences in biological activity and provides an 
interesting perspective as to why the small structural differences between phenyl 
isothiocyanate and BITC affect biological activity (Tang and Tang 1976). A large 
number of isothiocyanates with diverse structural characteristics were examined but 
BITC was identified as the lead compound. The authors proposed formation of a 
thiocarbamic linkage between the active site sulfhydryl group of papain and the 
isothiocyanate moiety of benzyl isothiocyanate as the mechanism for inhibitory 
activity. The sulfhydryl residue of papain exists in the vicinity of an aromatic binding 
site which is hypothesised to interact with the aromatic ring of BITC. The 
isothiocyanate moiety can then be aligned for nucleophilic attack by the carbon linker 
group; therefore, the length of the linker group plays a role in inhibitory activity.  
 
The target molecules in our system may be modified by a similar reaction and the 
structural features of an isothiocyanate may influence inhibitory or activating 
potential in a similar fashion. This will only become apparent upon identification of 
the primary target(s) responsible for enabling apoptosis in the cells overexpressing 
Bcl-2. Chapter Five outlines our initial investigations to address this issue. 
 Chapter 5 
 
An investigation of the molecular 
targets of the isothiocyanates 
 
 
5.1 Introduction  
A number of proteins that are involved in cell signalling pathways, including kinases, 
phosphatases and transcription factors, contain critical thiol residues. Oxidation of 
such thiol residues can dramatically alter the function of a protein by disrupting its 
structure and conformation, or by directly inhibiting catalytic activity (Saitoh et al. 
1998; Korn et al. 2001; Buzek et al. 2002; Chiarugi and Cirri 2003; Sun et al. 2003; 
Cross and Templeton 2004a). Due to the dramatic consequences of such a 
modification, thiol oxidation is believed to play a critical role in controlling the 
equilibrium between cell survival and induction of apoptosis by activating 
proapoptotic signals or by inhibiting cell survival pathways (Cross and Templeton 
2004b; Biswas et al. 2005).  
 
Upon entering a cell, an isothiocyanate can participate in two principal reactions, both 
involving intracellular thiol-containing molecules. Firstly, glutathione S-transferases 
catalyse the rapid conjugation of intracellular isothiocyanates with the cells most 
abundant thiol-containing molecule, glutathione (GSH) (Zhang et al. 1995). 
Alternatively, intracellular isothiocyanates can react with protein thiol residues to 
form dithiocarbamate derivatives (Zhang et al. 2006) (Figure 5.1).  
 
 
 
 
 
Figure 5.1: Reaction of an isothiocyanate with a protein thiol residue. The reaction 
of an isothiocyanate with a protein thiol (R′SH) results in the formation of a 
dithiocarbamate derivative (adapted from Thornalley 2002). 
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 The intracellular reactions of the isothiocyanates have the potential to promote 
indirect oxidation of thiol proteins by decreasing intracellular levels of GSH (Xu and 
Thornalley 2001a), and by inactivation of other cellular reductants, thereby promoting 
an oxidising environment. A decline in cellular reductants would allow accumulation 
of thiol proteins oxidised by endogenous reactive oxygen species (ROS) produced 
during normal cell metabolism (Balaban et al. 2005). Generation of ROS and loss of 
GSH also occur as a consequence of apoptosis (van den Dobbelsteen et al. 1996; 
Macho et al. 1997; Cai and Jones 1998); however, we are interested in the early stages 
of apoptosis and initial targets of the isothiocyanates that are modified, well before 
activation of the apoptotic pathway. 
 
It seems extremely likely that the mechanism by which the isothiocyanates promote 
apoptosis in cells is due to their ability to alter protein function through indirect 
oxidative modification of thiol residues or direct modification of thiol proteins, via the 
formation of dithiocarbamates. Therefore, the aim of this section of the study was to 
identify global changes in oxidised thiol proteins in response to isothiocyanate 
treatment.  
 
PEITC and sulforaphane were chosen as the compounds of interest. The 
isothiocyanate of most interest was PEITC, which was identified as having the 
greatest potential to induce apoptosis in cells that overexpress Bcl-2 (Chapter Three 
and section 4.2.7). On the other hand, sulforaphane was not capable of killing Bcl-2 
overexpressing cells unless administered at high concentrations (section 4.2.4). 
Furthermore, at high concentrations, sulforaphane did not sensitize cells to Fas-
mediated apoptosis (section 4.2.5), suggesting that it is incapable of overcoming the 
anti-apoptotic block that overexpression of Bcl-2 confers. However, sulforaphane is 
known to potently modulate the activities of some phase I and phase II enzymes 
through modification of thiol proteins (Hong et al. 2005a). By comparing the response 
of B9 cells to PEITC with the response of B9 cells to sulforaphane, the goal is to 
distinguish between proteins whose thiol residues are oxidised as a general response 
to isothiocyanate treatment (and therefore should change with both PEITC and 
sulforaphane), or, specifically, due to treatment with PEITC. By utilising the two 
isothiocyanates, the identification of specific proteins that may play a crucial role in 
the induction of apoptosis by PEITC can be identified.  
 5.2 Experimental approach 
Most intracellular protein thiol groups exist in a reduced form (Schafer and Buettner 
2001); therefore, it is easier to detect an increase in oxidised thiol proteins rather than 
a loss of reduced thiol proteins. Oxidised thiol proteins were monitored by utilising a 
sensitive proteomic technique previously developed in our laboratory (Baty et al. 
2002). 
 
Initially, cells are treated with an isothiocyanate for 30 minutes before addition of N-
ethylmaleimide (NEM), which blocks the remaining reduced thiol residues (Figure 
5.2). Cells are then lysed, and the oxidised thiols reduced with dithiothreitol (DTT), 
before addition of the thiol-specific fluorescent probe 5-iodoacetamidofluorescein 
(IAF). 
 
 
Figure 5.2: Fluorescent labelling of oxidised thiol proteins. Whole cells are 
incubated with NEM to block reduced thiols (P1) before being lysed with CHAPS. 
DTT is then added to reduce oxidised thiols (P2-4) which are then labelled with IAF 
(P-S-F). P1SH represents reduced thiol proteins, P2S-S represents intramolecular 
disulfides, P3S-SP3 represents intermolecular disulfides and P3S-SG represents a 
mixed disulfide with glutathione (Baty et al. 2002).  
 
The resulting protein lysates are separated by two-dimensional (2-D) electrophoresis, 
which separates proteins according to their respective isoelectric points and molecular 
weight values (Garfin 2003). Fluorescence scanning of the resulting gels enables the 
visualisation of the cellular complement of oxidised thiol proteins and changes to the 
fluorescence intensity of individual proteins in response to treatment with the 
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 isothiocyanates. Three independent experiments were performed and only thiol 
proteins with a consistent two-fold increase or decrease in IAF fluorescence intensity 
in at least two experiments were selected. 
 
5.3 Results 
Oxidation of protein thiol residues in response to isothiocyanate exposure was 
examined in the Bcl-2 overexpressing B9 cells. B9 cells were treated with 15 µM of 
either PEITC or sulforaphane, corresponding to the LD50 for PEITC in B9 cells 
(section 3.3.4) (Figure 5.3A). At this concentration, sulforaphane kills less than 5% of 
B9 cells (section 4.2.4). Cells were treated for 30 minutes, a time point long before 
PEITC can trigger caspase activation and induce apoptosis in B9 cells (section 3.3.5) 
(Figure 5.3B). Therefore, any differences to IAF labelling of thiol proteins represent 
very early changes, occurring upstream of activation of the apoptotic pathway.  
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Figure 5.3: Loss of B9 cell viability in response to treatment with PEITC or 
sulforaphane and the time course of B9 caspase activity in response to 15 µM 
PEITC. (A) B9 cells were treated with PEITC (●) or sulforaphane (○) for 24 hours 
before assessment of cell viability by flow cytometric determination of the uptake of 
PI (section 2.3.3). Plotted values represent mean ± standard error of at least three 
experiments. (B) B9 cells were treated with 15 μM PEITC and samples were removed 
for caspase activity analysis 2, 4, 6, 8, 12 and 24 hours after treatment. Caspase 
activity was monitored by measuring the release of AMC from the artificial caspase 
substrate Ac-DEVD-AMC (section 2.3.4). Plotted values represent mean ± standard 
error of at least four experiments. Caspase activity is expressed as a fold increase 
over the caspase activity that could be detected in control cells. 
 
The pattern of fluorescent labelling was quite different from the pattern of total 
protein distribution, as determined by a silver stain (Figure 5.4). A large number of 
proteins easily visible following silver staining were not detected by fluorescence 
 scanning (Figure 5.4, Box 1). Conversely, regions with no visible silver staining were 
clearly visible when imaged for IAF-labelled oxidised thiol proteins (Figure 5.4, Box 
2). The IAF-labelling protocol can therefore permit visualisation of changes to low 
abundance thiol proteins. 
 
A       B 
          
Figure 5.4: Silver stain and IAF fluorescence labelling of untreated B9 cells. An 
untreated B9 protein lysate was analysed by 2-D electophoresis (section 2.3.8). (A) A 
representative silver stain (section 2.3.10) of total protein content and (B) the 
corresponding fluorescence scan for IAF-labelled oxidised thiol proteins. A region of 
high protein content but no IAF fluorescence is highlighted in Box 1. A region of low 
protein content but visible IAF fluorescence is highlighted in Box 2. Images are 
representative of gels from three experiments.  
 
The pattern of thiol oxidation following exposure to PEITC was also very different to 
that observed following treatment with the oxidant hydrogen peroxide (H2O2) (Baty et 
al. 2005). Most notably there was no change in the oxidation state of the various 
isoforms of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in response to 
isothiocyanate exposure (Figure 5.5, Box 1). GAPDH is a thiol-containing protein that 
is particularly sensitive to oxidation and a strong increase in IAF labelling of GAPDH 
has been observed when cells are treated with 20 µM H2O2 (Baty et al. 2005). 
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Figure 5.5: Pattern of IAF fluorescence labelling of untreated B9 cells and B9 cells 
treated with 15µM PEITC. B9 cells were either left untreated (A) or treated with 15 
μM PEITC for 30 minutes (B) before labelling of oxidised thiol proteins with IAF. 
IAF-labelled samples were analysed by two-dimensional electrophoresis (section 
2.3.8). Images are representative of gels from three experiments. GAPDH isoforms 
are highlighted in Box 1. 
 
Changes to the intensity of IAF labelling of individual proteins were analysed with 
PDQuest™ 2-D electrophoresis gel analysis software (version 7.1.1, Bio-Rad 
Laboratories, Hercules, CA, USA) (section 2.3.9). Three separate experiments were 
performed and only thiol proteins with a two-fold increase or decrease in fluorescence 
in at least two of the three experiments were selected. A total of 390 thiol protein 
spots were detected following IAF labelling of B9 cells. A comparison of untreated 
B9 cells with PEITC-treated B9 cells revealed 35 spots with consistent changes to 
fluorescence intensity following exposure to PEITC (Figure 5.6 and zoom images for 
each spot in the appendix). The fluorescence intensities of 11 thiol proteins (31%) 
decreased as a result of exposure to PEITC (Figure 5.6A). The majority of thiol 
proteins altered in response to treatment with PEITC demonstrated an increase in the 
degree of IAF fluorescence (Figure 5.6B). A consistent increase in fluorescence was 
observed for 24 of the 35 spots (69%).  
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Figure 5.6: Oxidation of protein thiols following exposure to PEITC. Untreated B9 
cells (A) and B9 cells treated with 15 μM PEITC for 30 minutes (B). Protein lysates were 
separated by 2-D electrophoresis (section 2.3.8). Gels are representative of three 
experiments. Spots with a two-fold decrease in fluorescence are highlighted in (A) while spots 
with a two-fold increase in fluorescence are highlighted in (B).  
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 The 35 spots that changed with PEITC were compared with the location of proteins 
previously identified in our laboratory as having changed following H2O2 treatment 
(Baty et al. 2005). In this earlier work, protein spots were identified by peptide mass 
fingerprinting using MALDI-TOF MS (matrix assisted laser desorption/ionization 
time-of-flight mass spectrometry). Briefly, spots were excised from gels and treated 
with trypsin to digest the protein. The peptides were then eluted and analysed by 
MALDI-TOF MS. The resulting peptide mass fingerprints, estimated molecular 
weight (MW) and isoelectric point (pI) values were then used to search online protein 
databases to identify the excised protein (Beranova-Giorgianni 2003).  
 
The only thiol protein that was similar to thiol protein changes observed in previous 
experiments (Baty et al. 2005), constituted spot number 10 and spot number 11 
(Figure 5.7). Spot number 10, with a molecular weight of 26.1 kDa and isoelectric 
point of 5.5, and spot number 11, with a molecular weight of 26.6 kDa and isoelectric 
point of 5.5 (Appendix) represent peroxiredoxin-3. A consistent increase in the 
fluorescence intensity of this thiol protein was observed when B9 cells were treated 
with PEITC (Figure 5.7B). A change in the extent of IAF labelling of spot number 10 
or 11 was not observed when B9 cells were treated with sulforaphane (Figure 5.7C). 
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Figure 5.7: Changes in IAF-labelling of spot number 10 and spot number 11 in 
response to treatment with 15 µM PEITC but not 15 µM sulforaphane. 
Fluorescence intensity of spot number 10 (MW=26.1, pI=5.5) and spot number 11 
(MW=26.6, pI=5.5) in untreated B9 cells (A), B9 cells exposed to 15 µM PEITC for 
30 minutes (B) and B9 cells exposed to 15 µM sulforaphane for 30 minutes (C). 
Shown are zoom images of spot number 10 and 11 from Figure 5.6 and Figure 5.8. 
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 A comparison of untreated B9 cells with sulforaphane-treated B9 cells revealed 27 
thiol proteins with a consistent two-fold increase or decrease in fluorescence intensity 
(Figure 5.8 and zoom images for each spot in the appendix). Thirteen of the 27 thiol 
proteins (spot numbers 23-35) were also found to consistently change when B9 cells 
were treated with PEITC. The fluorescence of the remaining 14 thiol proteins (spot 
numbers 36-49) changed exclusively in response to treatment with sulforaphane. 
Fourteen of the 27 (52%) thiol proteins altered in response to exposure to 
sulforaphane experienced a decrease in the degree of IAF labelling (Figure 5.8A). A 
consistent increase in fluorescence was observed for the remaining 13 spots (48%) 
(Figure 5.8B).  
 
 
 
 
 
       
 
  
 
 
 
 
 
Figure 5.8: Oxidation of protein thiols following exposure to sulforaphane. 
Untreated B9 cells (A) and B9 cells treated with 15 μM sulforaphane for 30 minutes (B). 
Protein lysates were separated by 2-D electrophoresis (section 2.3.8). Gels are representative 
of three experiments. Spots with a two-fold decrease in fluorescence are highlighted in (A) 
while spots with a two-fold increase in fluorescence are highlighted in (B).  
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In summary, 49 thiol proteins were modified following exposure to either PEITC or 
sulforaphane (Figure 5.9). Thirty-five protein thiol spots consistently changed in 
response to exposure to PEITC, whereas 27 thiol proteins consistently changed in 
response to exposure to sulforaphane. Thirteen of the 27 spots that changed with 
sulforaphane were also observed to change when B9 cells were treated with PEITC. 
Overall, the fluorescence intensities of 21 of the 49 spots (43%) decreased with 
isothiocyanate treatment. The remaining 28 thiol proteins (57%) demonstrated an 
increase in fluorescence. A large majority of thiol proteins altered in response to both 
sulforaphane and PEITC treatment, or in response to PEITC treatment only, 
demonstrated an increase in the degree of IAF labelling (69% and 68% respectively). 
In contrast, only 29% of thiol proteins that were modified by exposure to sulforaphane 
demonstrated an increase in fluorescence with most of the spots (71%) decreasing in 
fluorescence. 
 Spot  MW    pI        Decrease          Increase 
1     12.8     4.8
2     24.2     4.9
3     14.0     5.0
4     19.0     5.0
5     30.3     5.3
6     30.9     5.2
7     49.4     5.4
8     19.0     5.5
9     31.2     5.6
10   26.1     5.6
11   26.6     5.5
12   42.9     5.5
13   68.7     5.5
14   35.8     5.7
15   31.7     6.0
16   66.5     6.1
17   16.4     6.2
18   46.1     6.3
19   31.9     6.5
20   48.2     6.6
21   35.1     7.3
22   55.9     OR
23   21.8     OR
24   31.5     5.1
25   71.9     5.0
26   15.7     5.3
27   46.8     5.4
28   12.2     5.5
29   15.3     5.4
30   12.3     5.9
31   40.7     5.9
32   40.5     6.1
33   24.4     6.1
34   16.4     6.1
35   14.7     6.2
36   14.8     4.7
37   14.4     4.7
38   24.2     5.0
39   28.4     5.0
40   37.3     5.1
41   19.0     5.6
42   61.9     5.4
43   19.5     6.0
44   18.8     5.9
45   35.5     6.1
46   19.2     6.3
47   49.0     6.0
48   33.3     6.4
49   53.4     6.9
            
Figure 5.9: Summary of the changes in IAF labelling when B9 cells were treated 
with PEITC or sulforaphane. OR=out of range 
 
Thiol proteins that changed 
only with 15 µM PEITC. 
Thiol proteins that changed 
only with 15 µM 
sulforaphane.  
Thiol proteins that changed 
with 15 µM PEITC and 15 
µM sulforaphane. 
 5.4 Discussion 
Previous studies investigating the mechanisms that underlie the induction of apoptosis 
by the isothiocyanates have focussed on the modulation of particular components of 
signal transduction pathways known to influence activation of apoptosis (Chen et al. 
1998; Xu and Thornalley 2001b; Jeong et al. 2004; Singh et al. 2004). Although these 
studies have identified changes in the activities of particular pathways in response to 
isothiocyanate exposure, there is no evidence as to whether such alterations are a 
primary response, key to mediating isothiocyanate activity, or just a secondary effect, 
downstream of a more critical pathway. It is also more than likely that the induction 
of apoptosis by the isothiocyanates is not achieved by blocking or activating a single 
signalling pathway but, instead, via the modulation of multiple cellular events. In this 
study, the response of the entire cellular complement of proteins to isothiocyanate 
treatment was monitored. Using a fluorescence labelling technique, changes in the 
pattern of oxidised thiol proteins in Bcl-2 overexpressing cells, induced by 
isothiocyanate exposure, have been detected. While a total of 390 thiol protein spots 
were detected, only 49 spots consistently changed when cells were treated with 
PEITC or sulforaphane.  
 
Changes in the oxidation state of protein thiol residues were observed as either an 
increase or decrease in the intensity of IAF labelling. The nature of the change 
provides some insight into the type of modification that occurs in response to 
isothiocyanate treatment. Oxidation of protein thiol residues can result in the 
formation of a number of products. These include intra- or intermolecular disulfide 
bonds, mixed disulfides with GSH or sulfenic acids, all of which are readily reversed 
by DTT. Alternatively sulfinic or sulfonic acids can be produced, but these changes 
are irreversible (Ghezzi 2005).  
 
An increase in IAF labelling of a thiol protein will result from reversible oxidation in 
response to isothiocyanate treatment (Figure 5.10A). Alternatively, a loss of IAF 
labelling can result from irreversible oxidation of a cysteine residue, of which some 
fraction occurs as being reversibly oxidised before treatment (Figure 5.10B). A 
decrease in IAF labelling will also occur with a protein whose oxidation leads to a 
positional change in the gel. 
 
    
Figure 5.10: IAF labelling of protein thiol residues. (A) If a thiol residue is 
reversibly oxidised in response to isothiocyanate treatment an increase in IAF 
labelling will be observed. (B) A loss of IAF labelling can result from irreversible 
oxidation of a cysteine residue, of which some fraction occurs as being reversibly 
oxidised before treatment  
 
Changes in the fluorescence intensity of thiol proteins may also potentially result from 
the thiocarbamoylation reaction between an isothiocyanate and a protein thiol residue. 
If the dithiocarbamate linkage is disrupted after NEM treatment, but prior to addition 
of IAF, an increase in fluorescence will be observed, as the isothiocyanate will block 
the reaction of the thiol with NEM (Figure 5.11A). If the stability of the 
dithiocarbamate linkage is sufficient to withstand the labelling procedure, then a 
decrease in IAF fluorescence will be observed in treated samples, as long as a fraction 
of the protein is in a reversibly oxidised state prior to treatment (Figure 5.11B). 
Alternatively, dithiocarbamate formation could result in a decrease in fluorescence if 
the thiocarbamoylation reaction were to disrupt an inter- or intramolecular disulfide 
linkage. 
Figure 5.11: The influence of dithiocarbamate formation on IAF labelling of 
protein thiol residues. (A) If the dithiocarbamate linkage is disrupted after NEM 
treatment but prior to addition of IAF, an increase in fluorescence will be observed. 
(B) If the stability of the dithiocarbamate linkage is sufficient to withstand the 
labelling procedure then a decrease in IAF fluorescence will be observed in treated 
samples, as long as a fraction of the protein is in a reversibly oxidised state prior to 
treatment 
 
A large majority of thiol proteins altered in response to both sulforaphane and PEITC 
treatment, or in response to PEITC treatment only, experienced an increase the degree 
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 of IAF labelling (69% and 68% respectively). In contrast, only 29% of thiol proteins 
that were modified by exposure to sulforaphane demonstrated an increase in 
fluorescence with most of the spots decreasing in fluorescence (71%). The reason for 
this difference is not immediately apparent but it warrants further investigation. 
 
The modification of thiol proteins that resulted from exposure to sulforaphane 
occurred at a concentration that is incapable of inducing B9 cell death. This suggests 
that the changes to thiol proteins identified in response to sulforaphane, or in response 
to either sulforaphane or PEITC treatment, represent potential targets that may 
mediate other known biological effects of the isothiocyanates, including modulation 
of phase I and phase II enzymatic activity. Conversely, the changes that occurred 
specifically in response to treatment with PEITC may be involved in the activation of 
apoptosis. 
 
Two changes that were documented exclusively following exposure to PEITC were to 
spot number 10 and spot number 11. Based on the identification of thiol proteins 
sensitive to H2O2-induced oxidation (Baty et al. 2005), spot 10 and spot 11 appear to 
represent peroxiredoxin-3 (Prx-3). An increase in fluorescence labelling was observed 
following PEITC treatment, indicating that the cysteine residues of this protein may 
become oxidised as a result of exposure to PEITC, but not in response to sulforaphane 
treatment. Prx-3 contains two conserved cysteine residues, both of which are required 
for activity (Rhee et al. 2005). The peroxiredoxins, and a number of other 
peroxidases, protect cells against ROS-induced damage by scavenging H2O2. Prx-3 is 
localised exclusively to the mitochondrial matrix, where it is required to maintain 
normal mitochondrial function and where it can protect cells from oxidant-induced 
apoptosis (Araki et al. 1999; Wonsey et al. 2002; Nonn et al. 2003). The significance 
of the oxidation of Prx-3 in terms of the induction of apoptosis by PEITC remains to 
be elucidated, but demonstrates that proteins involved in the regulation of apoptosis 
are modified following a short exposure to this isothiocyanate. 
 
Interestingly, the pattern of thiol oxidation in response to isothiocyanate treatment 
was very different to changes observed when Jurkat cells were treated with H2O2 and 
the thiol alkylating agent diamide or 1-chloro-2,4-dinitrobenzene (DNCB) that 
disrupts thiol reduction pathways (Baty et al. 2005). This suggests that the changes 
 observed in this investigation are not the result of general oxidative stress. Studies 
have suggested that Bcl-2 overexpressing cells might be more resilient to H2O2-
induced damage (Ellerby et al. 1996); therefore, the disparity between experiments 
may simply reflect the differences between the cell lines utilised in each experiment. 
However, studies in our lab have shown that GAPDH and the peroxiredoxins are 
equally susceptible to H2O2-induced oxidation, regardless of the extent of Bcl-2 
overexpression (experimental work performed by Andrew Cox). This indicates that 
we have been able to identify thiol proteins that are exclusively sensitive to oxidative 
modification in response to isothiocyanate exposure.  
 
 
 Chapter 6 
 
Summary and future directions 
 
 
Because the relation between cancer and deregulation of apoptosis is so strong 
(Martin and Green 1995; Brown and Attardi 2005), any therapeutic strategy aimed at 
specifically triggering apoptosis in cancer cells might have potential therapeutic 
efficacy. The identification of agents that are able to induce apoptosis in cancer cells, 
regardless of the cells’ status of resistance, is now recognised as a key step in the 
continuing struggle against the cancer epidemic (Fesik 2005). 
 
The isothiocyanates are emerging as a class of compounds that have potential 
application to both the prevention and treatment of cancer. The biological activities of 
the isothiocyanates include inhibition of phase I carcinogen activating enzymes and 
induction of phase II detoxification enzymes (Hecht 1995; Hecht 2000). Furthermore, 
these naturally occurring phytochemicals have been shown to inhibit cell cycle 
progression and induce apoptosis (Conaway et al. 2002; Zhang et al. 2006). The 
primary aim of this thesis was to directly examine the ability of the isothiocyanates to 
induce apoptosis in cells overexpressing the anti-apoptotic protein Bcl-2.  
 
Initially, the cytotoxic activity of PEITC was examined. PEITC rapidly inhibited 
proliferation of Jurkat cells within 1 hour. At low concentrations, this was a 
temporary growth arrest; however, at higher concentrations (greater than 5 µM) 
caspase activation was observed after 2 hours, leading to apoptotic cell death. At the 
highest concentrations tested (40 µM to 60 µM) no caspase activation was observed, 
but the cells died by necrosis. It was also demonstrated that PEITC was able to 
overcome the anti-apoptotic block that overexpression of Bcl-2 confers. The presence 
of Bcl-2 expression had very little effect on the cytotoxicity of PEITC, with only a 
shifting of the dose-response curve at the highest levels of Bcl-2 expression. 
Furthermore, the isothiocyanates were still able to trigger apoptosis in these cells.  
 
The key structural features of the isothiocyanates that confer an ability to overcome 
Bcl-2 overexpression were also identified. Of the sixteen isothiocyanates screened in 
 this study, PEITC was identified as the most promising compound for targeting Bcl-2 
positive cells. While the isothiocyanate moiety ultimately determined cytotoxic 
activity, the chemistry of the side chain played a key role in the ability of an 
isothiocyanate to kill Bcl-2 overexpressing cells. The aromatic isothiocyanates were 
generally far more efficacious than aliphatic isothiocyanates; however, minor 
structural changes between the aromatic isothiocyanates significantly reduced 
cytotoxic activity. The requirement for rigid structural features suggests that the 
isothiocyanates may specifically interact with cellular targets that are involved in 
activation of apoptosis.  
 
The other important property of the aromatic isothiocyanates is that they caused a 
complete loss of cell viability, in contrast to the phenomenon observed with standard 
chemotherapeutic agents, including melphalan. Complete loss of cancer cell viability 
is important. If any cells within a transformed population are able to resist a cytotoxic 
compound, they will continue to proliferate and reform a more resistant population. 
Results from this in vitro study suggest that such a phenomenon would not occur 
following exposure to PEITC. However, many non-aromatic isothiocyanates 
investigated in this study were only capable of killing a proportion of Bcl-2 
overexpressing cells, and at much higher concentrations than PEITC required.  
 
The final aim of the thesis was to identify the molecular targets of the aromatic 
isothiocyanates that enable these compounds to overcome the anti-apoptotic function 
of Bcl-2. Fluorescent labelling of modified thiol proteins combined with 2-D 
electrophoresis enabled a preliminary investigation of some of the targets of the 
isothiocyanates. A number of protein thiols were selectively modified when Bcl-2 
overexpressing cells were exposed to PEITC. The modifications were observed 
following only thirty minutes exposure to PEITC, indicating that such changes may 
play a role in mediating activation of apoptosis. One such modified thiol protein was 
identified as peroxiredoxin-3. As yet the significance of this modification is unknown.  
 
The ability of PEITC to induce apoptosis and loss of cell viability in cells that 
overexpress Bcl-2 suggests that this compound can either activate an alternate route to 
bypass the apoptotic block that overexpression of Bcl-2 confers, or directly interfere 
with the anti-apoptotic properties of Bcl-2.  
 A potential explanation for the inability of Bcl-2 to prevent apoptosis is that the 
PEITC may induce apoptosis via the receptor-mediated apoptotic pathway. 
Modification of proteins that are associated with the DISC, and subsequent promotion 
of caspase-8 activation, has been suggested as a mechanism by which isothiocyanates 
trigger apoptosis (Thornalley 2002). However, Jurkat cells are type II cells (Cuvillier 
et al. 2000) and overexpression of Bcl-2 blocks the receptor-mediated pathway in our 
cell system. In direct contrast to this hypothesis, many studies support the induction of 
the mitochondria-dependent apoptotic pathway, characterised by activation of 
caspase-9, in response to isothiocyanate exposure (Nakamura et al. 2002; Hu et al. 
2003; Gingras et al. 2004; Rose et al. 2005; Zhang et al. 2005)). Several 
isothiocyanates have been shown to cause direct perturbations to the mitochondrial 
membrane, which induce the release of cytochrome c and allow for the subsequent 
activation of caspase-9 (Rose et al. 2005; Wu et al. 2005; Zhang et al. 2005). By 
directly affecting the permeability of the mitochondrial membrane, the 
isothiocyanates may be able to overcome Bcl-2 overexpression by directly bypassing 
this apoptotic block. 
 
While the isothiocyanates may induce apoptosis via a mechanism that is not reliant on 
the expression of Bcl-2, a large collection of evidence supports a direct role for 
members of the Bcl-2 family in isothiocyanate-induced apoptosis. Several studies 
have demonstrated upregulation of the expression of pro-apoptotic Bcl-2 family 
members, in particular Bax (Gamet-Payrastre et al. 2000; Fimognari et al. 2004b; 
Srivastava and Singh 2004; Wu et al. 2005; Xiao et al. 2005b). The upregulation of 
Bax that occurs in response to isothiocyanate exposure may be sufficient to push the 
equilibrium between pro- and anti-apoptotic factors towards favouring the induction 
of apoptosis. Furthermore, the isothiocyanates have been shown to induce the 
activation and translocation of Bax to the mitochondrial membrane and also to 
prevent the heterodimerization of Bcl-2 with Bax at the mitochondrial membrane 
(Miyoshi et al. 2004b; Rose et al. 2005; Zhang et al. 2005). A key role for pro-
apoptotic Bcl-2 family members in the induction of apoptosis by isothiocyanates has 
been further implicated as a result of studies with Bax and Bak double knockout mice, 
which are significantly more resistant to the cytotoxic activity of PEITC (Xiao et al. 
2005b). Interestingly, in vitro and in vivo evidence has demonstrated down-regulation 
of Bcl-2 expression in response to treatment with isothiocyanates (Srivastava et al. 
 2003; Singh et al. 2004; Srivastava and Singh 2004; Wu et al. 2005), although this is a 
late event and, therefore, unlikely to explain the results obtained in this study  
 
Although potential targets of PEITC, that may play a role in triggering apoptosis, 
have been identified in this research, the protocol probably identified thiol protein 
targets that are indirectly modified in response to isothiocyanate exposure. Given that 
a key reaction of intracellular isothiocyanates is conjugation with protein thiols to 
form dithiocarbamates, it seems reasonable to hypothesise that such 
thiocarbamoylation reactions may play a key role in isothiocyanate-induced apoptosis. 
If dithiocarbamate formation is crucial to the ability of PEITC to induce apoptosis in 
cells that overexpress Bcl-2, a technique to identify the direct formation of a 
dithiocarbamate between PEITC and a thiol protein target must be developed.  
 
Due to the instability of the dithiocarbamate linkage, supporting evidence for the 
conjugation of an isothiocyanate with cysteinyl thiol groups is sparse. A direct 
interaction of benzyl isothiocyanate with Cys25 of papain was hypothesised to be key 
in isothiocyanate-mediated inhibition of enzymatic activity, although no direct 
evidence was available (Tang and Tang 1976). A recent study with Keap1 clearly 
demonstrated the modification of thiol residues by directly monitoring adduct 
formation with sulforaphane (Hong et al. 2005). By regulating the activity of the 
ARE-binding transcription factor Nrf-2, Keap-1 prevents the induction of phase II 
enzymes and antioxidant enzymes that play a key role in chemoprevention (Itoh et al. 
1999). Modification of Keap1 by isothiocyanates therefore leads to transcription of 
ARE-regulated genes, which explains the potent induction of phase II enzymes in 
response to isothiocyanate treatment. Furthermore, isothiocyanate-induced 
mitochondrial damage and cytochrome c release have recently been hypothesised to 
result from an ITC-moiety-dependent reaction with critical thiol groups in the adenine 
nucleotide translocase, which forms part of the mitochondrial permeability transition 
pore (Kawakami et al. 2005).  
 
The need to monitor the formation of dithiocarbamates becomes even more evident 
when considering a potential mechanism to explain the ability of PEITC to induce 
apoptosis, regardless of the extent of Bcl-2 overexpression. On the basis of this 
research it is hypothesised that PEITC may directly bind to, and adversely affect, the 
 anti-apoptotic function of Bcl-2. The primary structure of Bcl-2 contains two cysteine 
residues, Cys158 and Cys229 which lie in the α5 helix and the transmembrane 
domain respectively (Petros et al. 2004) (section 1.3.2). Whereas Cys229 is largely 
sequestered due to the membrane localisation of Bcl-2, Cys158 is free to react with 
thiol-reactive compounds. Although Cys158 is removed from the hydrophobic 
binding groove of Bcl-2, and does not play a role in heterodimerization between Bcl-2 
and pro-apoptotic family members, disruption of this residue has been shown to 
reduce the ability of Bcl-2 to prevent apoptosis (Maser et al. 2000). Binding of PEITC 
to Cys158 may, therefore, at least partially abrogate the anti-apoptotic function of 
Bcl-2 and allow progression of the apoptotic pathway following isothiocyanate 
exposure.  
 
Site-directed mutagenesis of the cysteine residues in Bcl-2 would allow for direct 
insight into the importance of dithiocarbamate formation between PEITC and Bcl-2 
and the ability to overcome overexpression of Bcl-2. This technique could also be 
applied to peroxiredoxin 3, to gain an insight into the importance of oxidation of this 
thiol protein in the activation of PEITC-induced apoptosis. If the isothiocyanates do 
interact with thiol residue(s) of proteins such as Bcl-2, the rigid structural features that 
govern cytotoxicity in Bcl-2 overexpressing cells might become clearer. Furthermore, 
if Bcl-2 or any other apoptosis-regulatory proteins are identified as targets of PEITC, 
the structural features of the compound can be optimised to maximise induction of 
apoptosis in drug-resistant cells. 
 
Although this study has identified that some isothiocyanates possess an ability to 
induce apoptotic cell death, it is also crucial to identify whether the isothiocyanates 
are selectively toxic to cancerous cells. Selective targeting and low toxicity for normal 
tissues are fundamental requisites for proposed chemopreventive agents. If the 
isothiocyanates are to be applied in a clinical setting, it would be advantageous if 
populations of non-transformed cells could remain untouched, while transformed cells 
are eliminated by the compound. Preliminary studies have demonstrated that PEITC, 
allyl isothiocyanate and 4-(methylthio)butyl isothiocyanate are significantly more 
toxic to transformed cells (Musk and Johnson 1993; Adesida et al. 1996; Xu and 
Thornalley 2000b; Fimognari et al. 2004a; Fimognari et al. 2004c; Xiao et al. 2005). 
In contrast, sulforaphane displays selectivity for colon carcinoma cells but adversely 
 affects the viability of both non-transformed T lymphocytes and Jurkat cells 
(Fimognari et al. 2002; Fimognari et al. 2004a). While most of these studies have 
investigated selectivity in cultured cell systems, it would be beneficial to investigate 
transformed and non-transformed cells taken directly from cancer patients. 
 
In summary, the results of this thesis have provided a platform to permit further 
investigation of the chemotherapeutic potential of the isothiocyanates and 
investigation of the mechanisms that allow the isothiocyanates, in particular PEITC, 
to induce apoptosis in cells that overexpress the oncogene Bcl-2. In the future, the 
identification of primary targets of the isothiocyanates will form the basis for drug 
design and will also provide a novel insight into the regulation of apoptosis. 
  
 
 
 
 
 Appendix 
 
Enlarged images of individual spot 
changes identified in Chapter 5 
 
 
Changes to the intensity of IAF labelling of individual proteins were analysed with 
PDQuest™ 2-D electrophoresis gel analysis software (version 7.1.1, Bio-Rad 
Laboratories, Hercules, CA, USA). Thiol proteins with a two-fold increase or 
decrease in IAF fluorescence in response to isothiocyanate exposure were selected. 
Only thiol proteins that consistently changed in at least two of the three experiments 
are shown. Spot numbering is consistent with highlighted spots in Figure 5.6 and 
Figure 5.8. Squares indicate the position of thiol proteins that changed. An estimation 
of molecular weight (MW) and isoelectric point (pI) values for each spot was made by 
comparison with the positions of proteins with known MW and pI values. 
  
1 Spot 1105 MW=12.8  pI=4.8 Increased fluorescence 
    
 Control   PEITC         Sulforaphane 
2 Spot 1110 MW=24.2  pI=4.9 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 
 
 
 3 Spot 1118 MW=14.0  pI=5.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
4 Spot 2102 MW=19.0  pI=5.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
5 Spot 3201 MW=30.3  pI=5.3 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
6 Spot 3308 MW=30.9  pI=5.2 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
7 Spot 3405 MW=49.4  pI=5.4 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 8 Spot 4103 MW=19.0  pI=5.5 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
9 Spot 4206 MW=31.2  pI=5.6 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
10 Spot 4207 MW=26.1  pI=5.6 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
11 Spot 4212 MW=26.6  pI=5.5 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 
12 Spot 4411 MW=42.9  pI=5.5 Increased fluorescence 
                        
Control   PEITC         Sulforaphane 
 13 Spot 4606 MW=68.7  pI=5.5 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
14 Spot 5301 MW=35.8  pI=5.7 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
15 Spot 5312 MW=31.7 pI=6.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
16 Spot 5508 MW=66.5  pI=6.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 
17 Spot 6111 MW=16.4  pI=6.2 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 18 Spot 6304 MW=46.1  pI=6.3 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
19 Spot 7313 MW=31.9  pI=6.5 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
20 Spot 7518 MW=48.2  pI=6.6 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
21 Spot 8309 MW=35.1  pI=7.3 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 
22 Spot 8405 MW=55.9  pI=O.R. Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 23 Spot 0103 MW=21.8  pI=O.R. Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
24 Spot 2311 MW=31.5  pI=5.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
25 Spot 2717 MW=71.9  pI=5.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
26 Spot 3107 MW=15.7  pI=5.3 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 
27 Spot 3306 MW=46.8  pI=5.4 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 28 Spot 4107 MW=12.2  pI=5.5 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
29 Spot 4110 MW=15.3  pI=5.4 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
30 Spot 5102 MW=12.3  pI=5.9 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
31 Spot 5411 MW=40.7  pI=5.9 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 
32 Spot 5412 MW=40.5  pI=6.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 33 Spot 6101 MW=24.4  pI=6.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
34 Spot 6114 MW=16.4  pI=6.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
35 Spot 6117 MW=14.7  pI=6.2 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
36 Spot 1121 MW=14.8  pI=4.7 Decreased fluorescence 
     
Control   PEITC         Sulforaphane 
 
37 Spot 1122 MW=14.4  pI=4.7 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 38 Spot 2101 MW=24.2  pI=5.0 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
39 Spot 2210 MW=28.4  pI=5.0 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
40 Spot 3408 MW=37.3  pI=5.1 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
41 Spot 4113 MW=19.0  pI=5.6 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 
42 Spot 4501 MW=61.9  pI=5.4 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 43 Spot 5108 MW=19.5  pI=6.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
44 Spot 5112 MW=18.8  pI=5.9 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
45 Spot 5315 MW=35.5  pI=6.1 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
46 Spot 6115 MW=19.2  pI=6.3 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
47 Spot 6410 MW=49.0  pI=6.0 Increased fluorescence 
    
Control   PEITC         Sulforaphane 
 48 Spot 7201 MW=33.3  pI=6.4 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
49 Spot 8509 MW=53.4  pI=6.9 Decreased fluorescence 
    
Control   PEITC         Sulforaphane 
 
 
 
  
 
References 
 
 
Adams, J. M. and Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. 
Science 281: 1322-1326. 
Adesida, A., Edwards, L. G. and Thornalley, P. J. (1996). Inhibition of human 
leukaemia 60 cell growth by mercapturic acid metabolites of phenethyl 
isothiocyanate. Food and Chemical Toxicology 34: 385-392. 
Altman, S. A., Randers, L. and Rao, G. (1993). Comparison of trypan blue dye 
exclusion and fluorometric assays for mammalian cell viability determinations. 
Biotechnology Progress 9: 671-674. 
Annis, M. G., Yethon, J. A., Leber, B. and Andrews, D. W. (2004). There is more to 
life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. 
Biochimica et Biophysica Acta 1644: 115-123. 
Araki, M., Nanri, H., Ejima, K., Murasato, Y., Fujiwara, T., Nakashima, Y. and Ikeda, 
M. (1999). Antioxidant function of the mitochondrial protein SP-22 in the 
cardiovascular system. The Journal of Biological Chemistry 274: 2271-2278. 
Balaban, R. S., Nemoto, S. and Finkel, T. (2005). Mitochondria, oxidants and aging. 
Cell 120: 483-495. 
Baty, J. W., Hampton, M. B. and Winterbourn, C. C. (2002). Detection of oxidant 
sensitive thiol proteins by fluorescence labeling and two-dimensional electrophoresis. 
Proteomics 2: 1261-1266. 
Baty, J. W., Hampton, M. B. and Winterbourn, C. C. (2005). Proteomic detection of 
hydrogen peroxide-sensitive thiol proteins in Jurkat cells. Biochemical Journal 389: 
785-795. 
Belka, C. and Budach, W. (2002). Anti-apoptotic Bcl-2 proteins: structure, function 
and relevance for radiation biology. International Journal of Radiation Biology 78: 
643-658. 
Beranova-Giorgianni, S. (2003). Proteome analysis by two-dimensional 
electrophoresis and mass spectrometry: strengths and limitations. Trends in Analytical 
Chemistry 22: 273-281. 
Bertl, E., Bartsch, H. and Gerhauser, C. (2006). Inhibition of angiogenesis and 
endothelial cell functions are novel sulforaphane-mediated mechanisms in 
chemoprevention. Molecular Cancer Therapeutics 5: 575-585. 
 
 Bian, X., Giordano, T. D., Lin, H.-J., Solomon, G., Castle, V. P. and Opipari, A. W. 
(2004). Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires 
caspase-9 and is augmented by CD95/Fas stimulation. The Journal of Biological 
Chemistry 279: 4663-4669. 
Bianchini, F. and Vainio, H. (2004). Isothiocyanates in cancer prevention. Drug 
Metabolism Reviews 36: 655-667. 
Biswas, S., Chida, A. S. and Rahman, I. (2005). Redox modifications of protein–
thiols: emerging roles in cell signaling. Biochemical Pharmacology 71: 551-564. 
Bones, A. M. and Rossiter, J. T. (1996). The myrosinase-glucosinolate system, its 
organisation and biochemistry. Physiologia Plantarum 97: 194-208. 
Bonnesen, C., Eggleston, I. M. and Hayes, J. D. (2001). Dietary indoles and 
isothiocyanates that are generated from cruciferous vegetables can both stimulate 
apoptosis and confer protection against DNA damage in human colon cell lines. 
Cancer Reseach 61: 6120-6130. 
Borner, C. (2003). The Bcl-2 protein family: sensors and checkpoints for life-or-death 
decisions. Molecular Immunology 39: 615-647. 
Brondyk, B. (1994). pCI and pSI mammalian expression vectors. Promega Notes 
Magazine 49: 7-11. 
Brown, J. M. and Attardi, L. D. (2005). The role of apoptosis in cancer development 
and treatment response. Nature Reviews Cancer 5: 231-237. 
Bruggeman, I. M., Temmink, J. H. M. and van Bladeren, P. J. (1986). Glutathione- 
and cysteine-mediated cytotoxicity of allyl and benzyl isothiocyanates. Toxicology 
and Applied Pharmacology 83: 349-359. 
Burnette, W. N. (1981). Western blotting - electrophoretic transfer of proteins from 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels to unmodified 
nitrocellulose and radiographic detection with antibody and radioiodinated protein-A. 
Analytical Biochemistry 112: 195-203. 
Buzek, J., Latonen, L., Kurki, S., Peltonen, K. and Laiho, M. (2002). Redox state of 
tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged 
cells by cysteine 277. Nucleic Acids Research 30: 2340-2348. 
Cai, J., Yang, J. and Jones, D. P. (1998). Mitochondrial control of apoptosis: the role 
of cytochrome c. Biochimica et Biophysica Acta 1366: 139-149. 
Cai, J. J. and Jones, D. P. (1998). Superoxide in apoptosis - mitochondrial generation 
triggered by cytochrome c loss. The Journal of Biological Chemistry 273: 11401-
11404. 
Cain, K. (2003). Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. 
Drug Metabolism Reviews 35: 337-363. 
 Callaway, E. C., Zhang, Y., Chew, W. and Chow, H.-H. S. (2004). Cellular 
accumulation of dietary anticarcinogenic isothiocyanates is followed by transporter-
mediated export as dithiocarbamates. Cancer Letters 204: 23-31. 
Campos, L., Rouault, J.-P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., 
Archimbaud, E., Jean-Pierre, M. and Guyotat, D. (1993). High expression of Bcl-2 
protein in acute myeloid leukemia cells is associated with poor response to 
chemotherapy. Blood 81: 3091-3096. 
Chandra, J., Samali, A. and Orrenius, S. (2000). Triggering and modulation of 
apoptosis by oxidative stress. Free Radical Biology and Medicine 29: 323-333. 
Chang, H. Y. and Yang, X. (2000). Proteases for cell suicide: functions and regulation 
of caspases. Microbiology and Molecular Biology Reviews 64: 821-846. 
Chen, S. and Andreasson, E. (2001). Update on glucosinolate metabolism and 
transport. Plant Physiology and Biochemistry 39: 743-758. 
Chen, Y.-R., Wang, W., Kong, A.-N. T. and Tan, T.-H. (1998). Molecular 
mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by 
anticarcinogenic isothiocyanates. The Journal of Biological Chemistry 273: 1769-
1775. 
Chen, Y.-R., Han, J., Kori, R., Kong, A.-N. T. and Tan, T.-H. (2002). Phenylethyl 
isothiocyanate induces apoptotic signaling via suppressing phosphatase activity 
against c-Jun N-terminal kinase. The Journal of Biological Chemistry 277: 39334-
39342. 
Chiao, J. W., Wu, H., Ramaswamy, G., Conaway, C. C., Chung, F.-L., Wang, L. and 
Liu, D. (2004). Ingestion of an isothiocyanate metabolite from cruciferous vegetables 
inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle 
arrest. Carcinogenesis 25: 1403-1408. 
Chiarugi, P. and Cirri, P. (2003). Redox regulation of protein tyrosine phosphatases 
during receptor tyrosine kinase signal transduction. Trends in Biochemical Sciences 
28: 509-514. 
Chung, F.-L., Conaway, C. C., Rao, C. V. and Reddy, B. S. (2000). Chemoprevention 
of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl 
isothiocyanate. Carcinogenesis 21: 2287-2291. 
Cohen, G. M. (1997). Caspases: the executioners of apoptosis. Biochemical Journal 
326: 1-16. 
Conaway, C. C., Jiao, D., Kohri, T., Liebes, L. and Chung, F.-L. (1999). Dispostion 
and pharmacokinetics of phenethyl isothiocyanate and 6-phenylhexyl isothiocyanate 
in F344 rats. Drug Metabolism and Disposition 27: 13-20. 
Conaway, C. C., Yang, Y.-M. and Chung, F.-L. (2002). Isothiocyanates as cancer 
chemopreventive agents: their biological activities and metabolism in rodents and 
humans. Current Drug Metabolism 3: 233-255. 
 Conaway, C. C., Wang, C.-X., Pittman, B., Yang, Y.-M., Schwartz, J. E., Tian, D., 
McIntee, E. J., Hecht, S. S. and Chung, F.-L. (2005). Phenethyl isothiocyanate and 
sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of 
lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Research 65: 
8548-8557. 
Cornelis, S., Bruynooghe, Y., Van Loo, G., Saelens, X., Vandenbeele, P. and Beyaert, 
R. (2005). Apoptosis of hematopoietic cells induced by growth factor withdrawal is 
associated with caspase-9 mediated cleavage of Raf-1. Oncogene 24: 1552-1562. 
Cross, J. V. and Templeton, D. J. (2004a). Thiol oxidation of cell signaling proteins: 
controlling an apoptotic equilibrium. Journal of Cellular Biochemistry 93: 104-111. 
Cross, J. V. and Templeton, D. J. (2004b). Oxidative stress inhibits MEKK1 by site-
specific glutathionylation in the ATP-binding domain. Biochemical Journal 381: 675-
683. 
Cuvillier, O., Edsall, L. and Spiegel, S. (2000). Involvement of sphingosine in 
mitochondria-dependent Fas-induced apoptosis of Type II Jurkat T cells. The Journal 
of Biological Chemistry 275: 15691-15700. 
Davies, J. and Jimenez, A. (1980). A new selective agent for eukaryotic cloning 
vectors. American Journal of Tropical Medicine and Hygiene 29: 1089-1092. 
Daxenbichler, M. E., Spencer, G. F., Carlson, D. G., Rose, G. B., Brinker, A. M. and 
Powell, R. G. (1991). Glucosinolate composition of seeds from 297 species of wild 
plants. Phytochemistry 30: 2623-2638. 
Devadas, S., Hinshaw, J. A., Zaritskaya, L. and Williams, M. S. (2003). Fas-
stimulated generation of reactive oxygen species or exogenous oxidative stress 
sensitize cells to Fas-mediated apoptosis. Free Radical Biology and Medicine 35: 
648-661. 
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., 
Katoh, Y., Yamamoto, M. and Talalay, P. (2002). Direct evidence that sulfhydryl 
groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect 
against carcinogens and oxidants. Proceedings of the National Academy of Sciences, 
USA 99: 11908-11913. 
Earnshaw, W. C., Martins, L. M. and Kaufmann, S. H. (1999). Mammalian caspases: 
structure, activation, substrates, and functions during apoptosis. Annual Reviews in 
Biochemistry 68: 383-424. 
Ellerby, L. M., Ellerby, M. H., Park, S. M., Holleran, A. L., Murphy, A. M., Fiskum, 
G., Kane, D. J., Testa, M. P., Kayalar, C. and Bredesen, D. E. (1996). Shift of the 
cellular oxidation-reduction potential in neural cells expressing Bcl-2. Journal of 
Neurochemistry 67: 1259-1267. 
Fahey, J. W., Zhang, Y. and Talalay, P. (1997). Broccoli sprouts: an exceptionally 
rich source of inducers of enzymes that protect against chemical carcinogens. 
Proceedings of the National Academy of Sciences, USA 94: 10367-10372. 
 Fahey, J. W., Zalcmann, A. T. and Talalay, P. (2001). The chemical diversity and 
distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 56: 
5-51. 
Ferreira, C. G., Epping, M., Kruyt, F. A. E. and Giaccone, G. (2002). Apoptosis: 
target of cancer therapy. Clinical Cancer Research 8: 2024-2034. 
Fesik, S. W. (2005). Promoting apoptosis as a strategy for cancer drug discovery. 
Nature Reviews Cancer 5: 876-885. 
Fimognari, C., Nusse, M., Berti, F., Iori, R., Cantelli-Forti, G. and Hrelia, P. (2002a). 
Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in 
non-transformed human T lymphocytes. Cellular and Molecular Life Sciences 59: 
2004-2012. 
Fimognari, C., Nusse, M., Cesari, R., Iori, R., Cantelli-Forti, G. and Hrelia, P. 
(2002b). Growth inhibition, cell cycle arrest and apoptosis in human T-cell leukemia 
by the isothiocyanate sulforaphane. Carcinogenesis 23: 581-586. 
Fimognari, C., Nusse, M., Berti, F., Iori, R., Cantelli-Forti, G. and Hrelia, P. (2004a). 
A mixture of isothiocyanates induces cyclin B1- and p53-mediated cell-cycle arrest 
and apoptosis of human T lymphoblastoid cells. Mutation Research 554: 205-214. 
Fimognari, C., Nusse, M., Berti, F., Iori, R., Cantelli-Forti, G. and Hrelia, P. (2004b). 
Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on 
human transformed and non-transformed cells. Biochemical Pharmacology 68: 1133-
1138. 
Fimognari, C., Nusse, M., Iori, R., Cantelli-Forti, G. and Hrelia, P. (2004c). The new 
isothiocyanate 4-(methylthio)butylisothiocyanate selectively affects cell-cycle 
progression and apoptosis induction of human leukemia cells. Investigational New 
Drugs 22: 119-129. 
Finnegan, N. M., Curtin, J. F., Prevost, G., Morgan, B. and Cotter, T. G. (2001). 
Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit 
Bak/Bcl-2 interactions. British Journal of Cancer 85: 115-121. 
Fischer, U., Janicke, R. U. and Schulze-Osthoff, K. (2003). Many cuts to ruin: a 
comprehensive update of caspase substrates. Cell Death and Differentiation 10: 76-
100. 
Fowke, J. H., Chung, F.-L., Jin, F., Qi, D., Cai, Q., Conaway, C., Cheng, J.-R., Shu, 
X.-O., Gao, Y.-T. and Zheng, W. (2003). Urinary isothiocyanate levels, brassica, and 
human breast cancer. Cancer Research 63: 3980-3986. 
Fuke, Y., Haga, Y., Ono, H., Nomura, T. and Ryoyama, K. (1997). Anti-carcinogenic 
activity of 6-methylsulfinylhexyl isothiocyanate, an active anti-proliferative principal 
of wasabi (Eutrema wasabi Maxim.). Cytotechnology 25: 197. 
 
 
 Gamet-Payrastre, L., Li, P., Lumeau, S., Cassar, G., Dupont, M.-A., Chevolleau, S., 
Gasc, N., Tulliez, J. and Terce, F. (2000). Sulforaphane, a naturally occurring 
isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer 
cells. Cancer Research 60: 1426-1433. 
Gao, X., Dinkova-Kostova, A. T. and Talalay, P. (2001). Powerful and prolonged 
protection of human retinal pigment epithelial cells, keratinocytes, and mouse 
leukemia cells against oxidative damage: the indirect antioxidant effects of 
sulforaphane. Proceedings of the National Academy of Sciences, USA 98: 15221-
15226. 
Garfin, D. E. (2003). Two-dimensional gel electrophoresis: an overview. Trends in 
Analytical Chemistry 22: 263-272. 
Getahun, S. M. and Chung, F.-L. (1999). Conversion of glucosinolates to 
isothiocyanates in humans after ingestion of cooked watercress. Cancer 
Epidemiology, Biomarkers and Prevention 8: 447-451. 
Ghezzi, P. (2005). Oxidoreduction of protein thiols in redox regulation. Biochemical 
Society Transactions 33: 1378-1381. 
Gingras, D., Gendron, M., Boivin, D., Moghrabi, A., Theoret, Y. and Beliveau, R. 
(2004). Induction of medulloblastoma cell apoptosis by sulforaphane, a dietary 
anticarcinogen from Brassica vegetables. Cancer Letters 203: 35-43. 
Goosen, T., C., Kent, U. M., Brand, L. and Hollenberg, P. F. (2000). Inactivation of 
Cytochrome P450 2B1 by benzyl isothiocyanate, a chemopreventive agent from 
cruciferous vegetables. Chemical Research and Toxicology 13: 1349-1359. 
Goosen, T., C., Mills, D. E. and Hollenberg, P. F. (2001). Effects of benzyl 
isothiocyanate on rat and human cytochromes P450: identification of metabolites 
formed by P450 2B1. The Journal of Pharmacology and Experimental Therapeutics 
296: 198-206. 
Gorman, A. M., Hirt, U. A., Zhivotovsky, B., Orrenius, S. and Ceccatelli, S. (1999). 
Application of a fluorimetric assay to detect caspase activity in thymus tissue 
undergoing apoptosis in vivo. Journal of Immunological Methods 226: 43-48. 
Graninger, W., Seto, M., Boutain, B., Goldman, P. and Korsmeyer, S. J. (1987). 
Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. 
Journal of Clinical Investigation 80: 1512-1515. 
Green, D. R. (1998). Apoptotic pathways: the roads to ruin. Cell 94: 695-698. 
Green, D. R. and Evan, G. I. (2002). A matter of life and death. Cancer Cell 1: 19-30. 
Gu, Q.-M. and Prestwich, G. D. (1997). Efficient peptide ladder sequencing by 
MALDI-TOF mass spectrometry using allyl isothiocyanate. Journal of Peptide 
Research 49: 484-491. 
Halkier, B. A. and Du, L. (1997). The biosynthesis of glucosinolates. Trends in Plant 
Science 2: 425-431. 
 Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100: 57-70. 
Hawker, J. R. (2003). Chemiluminescence-based BrdU ELISA to measure DNA 
synthesis. Journal of Immunological Methods 274: 77-82. 
Hecht, S. S. (1995). Chemoprevention by isothiocyanates. Journal of Cellular 
Biochemistry 59: 195-209. 
Hecht, S. S., Trushin, N., Rigotty, J., Carmella, S. G., Borukhova, A., Akerkar, S. and 
Rivenson, A. (1996). Complete inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone-induced rat lung tumorigenesis and favorable modification of biomarkers by 
phenethyl isothiocyanate. Cancer Epidemiology, Biomarkers and Prevention 5: 645-
652. 
Hecht, S. S. (1999). Chemoprevention of cancer by isothiocyanates, modifiers of 
carcinogen metabolism. Journal of Nutrition 129: 768S-774S. 
Hecht, S. S. (2000). Inhibition of carcinogenesis by isothiocyanates. Drug Metabolism 
Reviews 32: 395-411. 
Heil, J. and Reifferscheid, G. (1992). Detection of mammalian carcinogens with an 
immunological DNA synthesis-inhibition test. Carcinogenesis 13: 2389-2394. 
Heiss, E., Herhaus, C., Klimo, K., Bartsch, H. and Gerhauser, C. (2001). Nuclear 
factor kappa B is a molecular target of sulforaphane-mediated anti-inflammatory 
mechanisms. The Journal of Biological Chemistry 276: 32008-32015. 
Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature 407: 770-776. 
Hernandez-Triana, M., Kroll, J., Proll, J., Noack, J. and Petzke, K. J. (1996). Benzyl 
isothiocyanate (BITC) decreases quality of egg white proteins in rats. Journal of 
Nutrition and Biochemistry 7: 322-326. 
Hintze, K. J., Wald, K. A., Zeng, H., Jeffery, E. H. and Finley, J. W. (2003). 
Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by 
sulforaphane and other electrophiles via an antioxidant response element. The Journal 
of Nutrition 133: 2721-2727. 
Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J. 
(1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed 
cell death. Nature 348: 334-336. 
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L. and Korsmeyer, S. J. 
(1993). Bcl-2 Functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-
251. 
Holst, B. and Williamson, G. (2004). A critical review of the bioavailability of 
glucosinolates and related compounds. Natural Product Reports 21: 425-447. 
Holtzclaw, W. D., Dinkova-Kostova, A. T. and Talalay, P. (2004). Protection against 
electrophile and oxidative stress by induction of phase 2 genes: the quest for the 
elusive sensor that responds to inducers. Advances in Enzyme Regulation 44: 335-367. 
 Hong, F., Freeman, M. L. and Liebler, D. C. (2005a). Identification of sensor 
cysteines in human Keap1 modified by the cancer chemopreventive agent 
sulforaphane. Chemical Research and Toxicology 18: 1917-1926. 
Hong, F., Sekhar, K. R., Freeman, M. L. and Liebler, D. C. (2005b). Specific patterns 
of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. The 
Journal of Biological Chemistry 280: 31768-31775. 
Hu, R., Kim, B. R., Chen, C., Habbar, V. and Kong, A.-N. T. (2003). The roles of 
JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 
colon adenocarcinoma cells. Carcinogenesis 24: 1361-1367. 
Huang, D. C. S., Adams, J. M. and Cory, S. (1998). The conserved N-terminal BH4 
domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction 
with CED-4. The EMBO Journal 17: 1029-1039. 
Hudson, B., Upholt, W. B., Devinny, J. and Vinograd, J. (1969). The use of an 
ethidium analogue in the dye-buoyant density procedure for the isolation of closed 
circular DNA: the variation of the superhelix density of mitochondrial DNA. 
Proceedings of the National Academy of Sciences, USA 62: 813-820. 
Hunter, J. J., Bond, B. L. and Parslow, T. G. (1996). Functional dissection of the 
human Bcl2 protein: sequence requirements for inhibition of apoptosis. Molecular 
and Cellular Biology 16: 877-883. 
Iball, J., Morgan, C. H. and Wilson, H. R. (1966). The crystal and molecular 
structures of 5-bromo-2'-deoxyuridine and 5-bromouridine. Proceedings of the Royal 
Society of London Series A - Mathematical and Physical Sciences 295: 320-333. 
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., 
Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M. and Nabeshima, Y.-i. (1997). 
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying 
enzyme genes through antioxidant response elements. Biochemical and Biophysical 
Research Communications 236: 313-322. 
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D. and 
Yamamoto, M. (1999). Keap1 represses nuclear activation of antioxidant responsive 
elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and 
Development 13: 76-86. 
Jackson, S. J. T. and Singletary, K. W. (2004). Sulforaphane: a naturally occurring 
mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. 
Carcinogenesis 25: 219-227. 
Jacob, C. and Sies, H. (2003). Sulfur and selenium: the role of oxidation state in 
protein structure and function. Angewandte Chemie International Edition 42: 4742-
4758. 
Jakubikova, J., Bao, Y. and Sedlak, J. (2005). Isothiocyanates induce cell cycle arrest, 
apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant 
cell lines. Anticancer Research 25: 3375-3386. 
 Jeong, W.-S., Kim, I.-W., Hu, R. and Kong, A.-N. T. (2004). Modulatory properties 
of various natural chemopreventive agents on the activation of NF-κB signaling 
pathways. Pharmaceutical Research 21: 661-670. 
Ji, Y. and Morris, M. E. (2003). Determination of phenethyl isothiocyanate in human 
plasma and urine by ammonia derivatization and liquid chromatography-tandem mass 
spectrometry. Analytical Biochemistry 323: 39-47. 
Jiao, D., Smith, T. J., Yang, C. S., Pittman, B., Desai, D., Amin, S. and Chung, F.-L. 
(1997). Chemopreventive activity of thiol conjugates of isothiocyanates for lung 
tumorigenesis. Carcinogenesis 18: 2143-2147. 
Johnstone, R. W., Ruefli, A. A. and Lowe, S. W. (2002). Apoptosis: a link between 
cancer genetics and chemotherapy. Cell 108: 153-164. 
Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D. and Reed, J. C. 
(1998). Bax directly induces release of cytochrome c from isolated mitochondria. 
Proceedings of the National Academy of Sciences, USA 95: 4997-5002. 
Kane, D. J., Sarafian, T. A., Anton, R., Hahn, H., Gralla, E. B., Valentine, J. S., Ord, 
T. and Bredesen, D. (1993). Bcl-2 inhibition of neural death - decreased generation of 
reactive oxygen species. Science 262: 1274-1277. 
Kassie, F., Rabot, S., Uhl, M., Huber, W., Qin, H. M., Helma, C., Schulte-Hermann, 
R. and Knasmuller, S. (2002). Chemoprotective effects of garden cress (Lepidium 
sativum) and its constituents towards 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ)-
induced genotoxic effects and colonic preneoplastic lesions. Carcinogenesis 23: 1155-
1161. 
Kaufmann, S. H. (1989). Induction of endonucleolytic DNA cleavage in human acute 
myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic 
anticancer drugs: a cautionary note. Cancer Research 49: 5870-5878. 
Kaufmann, S. H. and Earnshaw, W. C. (2000). Induction of apoptosis by cancer 
chemotherapy. Experimental Cell Research 256: 42-49. 
Kaufmann, S. H. and Hengartner, M. O. (2001). Programmed cell death: alive and 
well in the new millenium. Trends in Cell Biology 11: 526-534. 
Kaufmanna, M., Bozica, D., Brianda, C., Bodmerb, J., Zerbec, O., Kohla, A., 
Tschoppb, J. and Gruttera, M. G. (2002). Identification of a basic surface area of the 
FADD death effector domain critical for apoptotic signalling. FEBS Letters 527: 250-
254. 
Kawahara, A., Kobayashi, T. and Nagata, S. (1998). Inhibition of Fas-induced 
apoptosis by Bcl-2. Oncogene 17: 2549-2554. 
Kawakami, M., Harada, N., Hiratsuka, M., Kawai, K. and Nakamura, Y. (2005). 
Dietary isothiocyanates modify mitochondrial functions through their electrophilic 
reaction. Bioscience, Biotechnology and Biochemistry 69: 2439-2444. 
 Kerr, J. F. R. (1971). Shrinkage necrosis: a distinct mode of cellular death. Journal of 
Pathology 105: 13-20. 
Kerr, J. F. R., Wyllie, A. H. and Currie, A. R. (1972). Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. British Journal of 
Cancer 26: 239-257. 
Keum, Y.-S., Jeong, W.-S. and Kong, A. N. T. (2004). Chemoprevention by 
isothiocyanates and their underlying molecular signaling mechanisms. Mutation 
Research 555: 191-202. 
Khor, T. O., Keum, Y.-S., Lin, W., Kim, J.-H., Hu, R., Shen, G., Xu, C., 
Gopalakrishnan, A., Reddy, B., Zheng, X., Conney, A. H. and Kong, A.-N. T. (2006). 
Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth 
of human PC-3 prostate xenografts in immunodeficient mice. Cancer Research 66: 
613-621. 
Kim, J.-H., Xu, C., Keum, Y.-S., Reddy, B., Conney, A. H. and Kong, A.-N. T. 
(2005). Inhibition of EGFR signaling in human prostate cancer PC-3 cells by 
combination treatment with β-phenylethyl isothiocyanate and curcumin. 
Carcinogenesis 27: 475-482. 
Kim, J.-Y. and Park, J.-H. (2003). ROS-dependent caspase-9 activation in hypoxic 
cell death. FEBS Letters 549: 94-98. 
Kim, Y.-H., Park, J.-W., Lee, J.-Y., Surh, Y.-J. and Kwon, T. K. (2003). Bcl-2 
overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP 
and Akt degradation. Biochemical Pharmacology 66: 1779-1786. 
Kitada, S., Leone, M., Sareth, S., Zhai, D., Reed, J. C. and Pellecchia, M. (2003). 
Discovery, characterization, and structure-activity relationships studies of 
proapoptotic polyphenols targeting B-cell Lymphocyte/Leukemia-2 protein. Journal 
of Medicinal Chemistry 46: 4259-4264. 
Kluck, R. M., Bossy-Wetzel, E., Green, D. R. and Newmeyer, D. D. (1997). The 
release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of 
apoptosis. Science 275: 1132-1136. 
Korn, S. H., Wouters, E. F., Vos, N. and Janssen-Heininger, Y. M. (2001). Cytokine-
induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide 
through oxidative inactivation of IkappaB kinase. Journal of Biological Chemistry: 
35963-35700. 
Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W. and Reed, J. C. 
(1993). Investigation of the subcellular-distribution of the Bcl-2 oncoprotein - 
residence in the nuclear envelope, endoplasmic-reticulum, and outer mitochondrial-
membranes. Cancer Research 53: 4701-4714. 
Laemmli, U. K. (1970). Cleavage of structural proteins during assembly of head of 
bacteriophage-T4. Nature 227: 680-685. 
 Lee, J.-S. and Surh, Y.-J. (2005). Nrf2 as a novel molecular target for 
chemoprevention. Cancer Letters 224: 171-184. 
Letai, A., Beard, C., Sorcinelli, M. and Korsmeyer, S. J. (2004). Anti-apoptotic Bcl-2 
is required for maintenance of a model leukemia. Cancer Cell 6: 241-249. 
Letai, A. (2005). Pharmacological manipulation of Bcl-2 family members to control 
cell death. The Journal of Clinical Investigation 115: 2648-2655. 
Li, H., Zhu, J., Xu, C. and Yuan, J. (1998). Cleavage of BID by caspase-8 mediates 
mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501. 
Lin, C.-M., Kim, J., Du, W.-X. and Wei, C.-I. (2000). Bactericidal activity of 
isothiocyanates against pathogens on fresh produce. Journal of Food Protection 63: 
25-30. 
Liu, X., Kim, C. N., Yang, J., Jemmerson, R. and Wang, X. (1996). Induction of 
apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 
86: 147-157. 
Liu, Y. and Liang, S. (2001). Chemical carboxyl-terminal sequence analysis of 
peptides and proteins using tribenzylsilyl isothiocyanate. Journal of Protein 
Chemistry 20: 535-541. 
Lowe, S. W. and Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis 21: 485-
495. 
Lui, V. W. Y., Wentzel, A. L., Xiao, D., Lew, K. L., Singh, S. V. and Grandis, J. R. 
(2003). Requirement of a carbon spacer in benzyl isothiocyanate-mediated 
cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. 
Carcinogenesis 24: 1705-1712. 
Macho, A., Hirsch, T., Marzo, I., Marchetti, P., Dallaporta, B., Susin, S. A., Zamzami, 
N. and Kroemer, G. (1997). Glutathone depletion is an early and calcium elevation is 
a late event of thymocyte apoptosis. Journal of Immunology 158: 4612-4619. 
Maeda, H., Ishida, N., Kawauchi, H. and Tuzimura, K. (1969). Reaction of 
fluorescein-isothiocyanate with proteins and amino acids: I. covalent and non-
covalent binding of fluorescein-isothiocyanate and fluorescein to proteins. Journal of 
Biochemistry 65: 777-783. 
Maghni, K., Nicolescu, O. M. and Martin, J. G. (1999). Suitability of cell metabolic 
colorimetric assays for assessment of CD4+ T cell proliferation: comparison to 5-
bromo-2-deoxyuridine (BrdU) ELISA. Journal of Immunological Methods 223: 185-
194. 
Majno, G. (1995). Apoptosis, oncosis and necrosis: an overview of cell death. 
American Journal of Pathology 146: 3-15. 
Malumbres, M. and Barbacid, M. (2001). To cycle or not to cycle: a critical decision 
in cancer. Nature Reviews Cancer 1: 222-231. 
 Manesh, C. and Kuttan, G. (2003). Anti-tumour and anti-oxidant activity of naturally 
occurring isothiocyanates. Journal of Experimental Clinical Cancer Research 22: 
193-199. 
Manici, L. M., Lazzeri, L. and Palmieri, S. (1997). In vitro fungitoxic activity of some 
glucosinolates and their enzyme-derived products toward plant pathogenic fungi. 
Journal of Agricultural and Food Chemistry 45: 2768-2773. 
Martin, S. J. and Green, D. R. (1995). Apoptosis and cancer: the failure of controls on 
cell death and cell survival. Critical Reviews in Oncology/Hematology 18: 137-153. 
Maser, R. S., Antoku, K., Scully, W. J., Cho, R. L. and Johnson, D. E. (2000). 
Analysis of the role of conserved cysteine residues in the Bcl-2 oncoprotein. 
Biochemical and Biophysical Research Communications 277: 171-178. 
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P. and 
Korsmeyer, S. J. (1989). bcl-2-Immunoglobulin transgenic mice demonstrate 
extended B cell survival and follicular lymphoproliferation. Cell 57: 79-88. 
Milanesi, E., Costantini, P., Gambalunga, A., Colonna, R., Petronilli, V., Cabrelle, A., 
Semenzato, G., Cesura, A. M., Pinard, E. and Bernardi, P. (2006). The mitochondrial 
effects of small organic ligands of Bcl-2. Sensitization of Bcl-2-overexpressing cells 
to apoptosis by a pyrimidine-2,4,6-trione derivative. The Journal of Biological 
Chemistry 281: 10066-10072. 
Minn, A. J., Kettlun, C. S., Liang, H., Kelekar, A., Vander Heiden, M. G., Chang, B. 
S., Fesik, S. W., Fill, M. and Thompson, C. B. (1999). Bcl-xL regulates apoptosis by 
heterodimerization-dependent and independent mechanisms. EMBO Journal 18: 632-
643. 
Mirjolet, J. F., Barberi-Heyob, M., Didelot, C., Peyrat, J. P., Abecassis, J., Millon, R. 
and Merlin, J. L. (2000). Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity 
independently of p53 status. British Journal of Cancer 83: 1380-1386. 
Mirkovic, N., Voehringer, D. W., Story, M. D., McConkey, D. J., McDonnell, T. J. 
and Meyn, R. E. (1997). Resistance to radiation-induced apoptosis in Bcl-2-
expressing cells is reversed by depleting cellular thiols. Oncogene 15: 1461-1470. 
Mithen, R. F., Dekker, M., Verkerk, R., Rabot, S. and Johnson, I. T. (2000). The 
nutritional significance, biosynthesis and bioavailability of glucosinolates in human 
foods. Journal of the Science of Food and Agriculture 80: 967-984. 
Miyashita, T. and Reed, J. C. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced 
apoptosis in human leukemia cell line. Blood 81: 151-157. 
Miyoshi, N., Takabayashi, S., Osawa, T. and Nakamura, Y. (2004a). Benzyl 
isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: 
implication for prevention against inflammation-related carcinogenesis. 
Carcinogenesis 25: 567-575. 
 
 Miyoshi, N., Uchida, K., Osawa, T. and Nakamura, Y. (2004b). A link between 
benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of 
mitogen-activated protein kinases in Bcl-2 phosphorylation. Cancer Research 64: 
2134-2142. 
Mo, B., Li, J. and Liang, S. (1997). Chemical carboxy-terminal sequence analysis of 
peptides using acetyl isothiocyanate. Analytical Biochemistry 252: 169-176. 
Moreno, R. L., Kent, U. M., Hodge, K. and Hollenberg, P. F. (1999). Inactivation of 
cytochrome P450 2E1 by benzyl isothiocyanate. Chemical Research and Toxicology 
12: 582-587. 
Morse, M. A., Elkind, K. I., Hecht, S. S., Jordan, K. G., Choi, C. I., Desai, D. H., 
Amin, S. G. and Chung, F.-L. (1991). Structure-activity relationships for inhibition of 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis by arylalkyl 
isothiocyanates in A/J mice. Cancer Research 51: 1846-1850. 
Munday, R. and Munday, C. M. (2004). Induction of phase II detoxification enzymes 
in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with 
sulforaphane and related compounds. Journal of Agricultural and Food Chemistry 52: 
1867-1871. 
Muramoto, K., Kamiya, H. and Kawauchi, H. (1984). The application of fluorescein 
isothiocyanate and high-performance liquid chromatography for the microsequencing 
of proteins and peptides. Analytical Biochemistry 141: 446-450. 
Musk, S. R. and Johnson, I. T. (1993). Allyl isothiocyanate is selectively toxic to 
transformed cells of the human colorectal tumour line HT29. Carcinogenesis 14: 
2079-2083. 
Myzak, M. C., Karplus, P. A., Chung, F.-L. and Dashwood, R. H. (2004). A novel 
mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. 
Cancer Research 64: 5767-5774. 
Myzak, M. C., Dashwood, W. M., Orner, G. A., Ho, E. and Dashwood, R. H. (2006a). 
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in 
Apcmin mice. FASEB Journal 20: 506-508. 
Myzak, M. C., Hardin, K., Wang, R., Dashwood, R. H. and Ho, E. (2006b). 
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate 
epithelial cells. Carcinogenesis 27: 811-819. 
Nakajima, M., Yoshida, R., Shimada, N., Yamazaki, H. and Yokoi, T. (2001). 
Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl 
isothiocyanate. Drug Metabolism and Disposition 29: 1110-1113. 
Nakamura, Y., Kawakami, M., Yoshihiro, A., Miyoshi, N., Ohigashi, H., Kawai, K., 
Osawa, T. and Uchida, K. (2002). Involvement of the mitochondrial death pathway in 
chemopreventive benzyl isothiocyanate-induced apoptosis. Journal of Biological 
Chemistry 277: 8492-8499. 
 NCI (1996). Clinical development plan: phenethyl isothiocyanate. Journal of Cellular 
Biochemistry 63: 149-157. 
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, 
M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. 
M., Smulson, M. E., Yamin, T. T., Yu, V. L. and Miller, D. K. (1995). Identification 
and inhibition of the Ice/Ced-3 protease necessary for mammalian apoptosis. Nature 
376: 37-43. 
Nicholson, D. W. and Thornberry, N. A. (1997). Caspases: killer proteases. Trends in 
Biochemical Sciences 22: 299-306. 
Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. and Riccardi, C. (1991). A 
rapid and simple method for measuring thymocyte apoptosis by PI staining and flow 
cytometry. Journal of Immunological Methods 139: 271-279. 
Nishikawa, A., Lee, I.-S., Uneyama, C., Furukawa, F., Kim, H.-C., Kasahara, K.-I., 
Huh, N. and Takahashi, M. (1997). Mechanistic insights into chemopreventive effects 
of phenethyl isothiocyanate in N-nitrosobis(2-oxopropyl)amine-treated hamsters. 
Japanese Journal of Cancer Research 88: 1137-1142. 
Nonn, L., Berggren, M. and Powis, G. (2003). Increased expression of mitochondrial 
peroxiredoxin-3 (thioredoxin-peroxidase-2) protects cancer cells against hypoxia and 
drug-induced hydrogen peroxide-dependent apoptosis. Molecular Cancer Research 1: 
682-689. 
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., 
Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., 
Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., 
Nettesheim, D., Ng, S., Nimmer, P. M., O'Connor, J. M., Oleksijew, A., Petros, A. 
M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., 
Wendt, M. D., Zhang, H., Fesik, S. W. and Rosenberg, S. H. (2005). An inhibitor of 
Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. 
Oltvai, Z., N., Milliman, C. L. and Korsmeyer, S. J. (1993). Bcl-2 heterodimerizes in 
vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74: 
609-619. 
Park, J.-W., Choi, Y.-J., Suh, S.-I., Baek, W.-K., Suh, M.-H., Jin, I.-N., Min, D. S., 
Woo, J.-H., Chang, J.-S., Passaniti, A., Lee, Y. H. and Kwon, T. K. (2001). Bcl-2 
overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of 
caspase-3 activity. Carcinogenesis 22: 1633-1639. 
Pellecchia, M. and Reed, J. C. (2004). Inhibition of anti-apoptotic Bcl-2 family 
proteins by natural polyphenols: new avenues for cancer chemoprevention and 
chemotherapy. Current Pharmaceutical Design 10: 1387-1398. 
Peter, M. E. and Krammer, P. H. (2003). The CD95(APO-1/Fas) DISC and beyond. 
Cell Death and Differentiation 10: 25-35. 
 
 Petros, A. M., Medek, A., Nettesheim, D. G., Kim, D. H., Yoon, H. S., Swift, K., 
Matayoshi, E. D., Oltersdorf, T. and Fesik, S. W. (2001). Solution structure of the 
antiapoptotic protein Bcl-2. Proceedings of the National Academy of Sciences, USA 
98: 3012-3017. 
Petros, A. M., Olejniczak, E. T. and Fesik, S. W. (2004). Structural biology of the 
Bcl-2 family of proteins. Biochimica et Biophysica Acta 1644: 83-94. 
Podhradsky, D., Drobnica, L. and Kristian, P. (1979). Reactions of cysteine, its 
derivatives, glutathione coenzyme A, and dihydrolipoic acid with isothiocyanates. 
Experientia 35: 154-155. 
Powolny, A., Takahashi, K., Hopkins, R. G. and Loo, G. (2003). Induction of GADD 
gene expression by phenethylisothiocyanate in human colon adenocarcinoma cells. 
Journal of cellular biochemistry 90: 1128-1139. 
Pullar, J. M., Thomson, S. J., King, M. J., Turnbull, C. I., Midwinter, R. G. and 
Hampton, M. B. (2004). The chemopreventive agent phenethyl isothiocyanate 
sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 25: 765-772. 
Raghupathi, R., Graham, D. I. and McIntosh, T. K. (2000). Apoptosis after traumatic 
brain injury. Journal of Neurotrauma 17: 927-938. 
Reed, J. C., Tsujimoto, Y., Alpers, J. D., Croce, C. M. and Nowell, P. C. (1987). 
Regulation of Bcl-2 protooncogene expression during normal human-lymphocyte 
proliferation. Science 236: 1295-1299. 
Rhee, S. G., Chae, H. Z. and Kim, K. (2005). Peroxiredoxins: a historical overview 
and speculative preview of novel mechanisms and emerging concepts in cell 
signaling. Free Radical Biology and Medicine 38: 1543-1552. 
Rose, P., Faulkner, K., Williamson, G. and Mithen, R. F. (2000). 7-
Methylsulfinylheptyl and 8-methylsulfinyloctyl isothiocyanates from watercress are 
potent inducers of phase II enzymes. Carcinogenesis 21: 1983-1988. 
Rose, P., Whiteman, M., Huang, S. H., Halliwell, B. and Ong, C. N. (2003). β-
Phenethyl isothiocyanate-mediated apoptosis in hepatoma HepG2 cells. Cellular and 
Molecular Life Sciences 60: 1489-1503. 
Rose, P., Armstrong, J. S., Chua, Y. L., Ong, C. N. and Whiteman, M. (2005). Beta-
phenylethyl isothiocyanate mediated apoptosis; contribution of Bax and the 
mitochondrial death pathway. The International Journal of Biochemistry and Cell 
Biology 37: 100-119. 
Rudin, C. M., Kozloff, M., Hoffman, P. C., Edelman, M. J., Karnauskas, R., Tomek, 
R., Szeto, L. and Vokes, E. E. (2004). Phase I study of G3139, a bcl-2 antisense 
oligonucleotide, combined with carboplatin and etoposide in pateints with small-cell 
lung cancer. Journal of Clinical Oncology 22: 1110-1117. 
Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, 
M., Miyazono, K. and Ichijo, H. (1998). Mammalian thioredoxin is a direct inhibitor 
of apoptosis signal-regulating kinase (ASK) 1. EMBO Journal 17: 2596-2606. 
 Saraste, A. and Pulkki, K. (2000). Morphologic and biochemical hallmarks of 
apoptosis. Cardiovascular Research 45: 528-537. 
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Matthias, E., 
Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., Thompson, C. B. and Fesik, S. 
W. (1997). Structure of Bcl-XL-Bax peptide complex: recognition between regulators 
of apoptosis. Science 275: 983-986. 
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. 
M., Krammer, P. H. and Peter, M. E. (1998). Two CD95 (APO-1/Fas) signaling 
pathways. EMBO Journal 17: 1675-1687. 
Schafer, F. Q. and Buettner, G. R. (2001). Redox environment of the cell as viewed 
through the redox state of the glutathione disulfide/glutathione couple. Free Radical 
Biology and Medicine 30: 1191-1212. 
Schimmer, A. D., Pedersen, I. M., Kitada, S., Eksioglu-Demiralp, E., Minden, M. D., 
Pinto, R., Mah, K., Andreef, M., Kim, Y., Suh, W. S. and Reed, J. C. (2003). 
Functional blocks in caspase activation pathways are common in leukemia and predict 
patient response to induction chemotherapy. Cancer Research 63: 1242-1248. 
Schmidt, E. V., Christoph, G., Zeller, R. and Leder, P. (1990). The cytomegalovirus 
enhancer: a pan-active control element in transgenic mice. Molecular and Cellular 
Biology 10: 4409-4411. 
Scorrano, L. and Korsmeyer, S. J. (2003). Mechanisms of cytochrome c release by 
proapoptotic Bcl-2 family members. Biochemical and Biophysical Research 
Communications 304: 437-444. 
Seow, A., Yuan, J.-M., Sun, C.-L., Van Den Berg, D., Lee, H.-P. and Yu, M. C. 
(2002). Dietary isothiocyanates, glutathione S-transferase polymorphisms and 
colorectal cancer risk in the Singapore Chinese health study. Carcinogenesis 23: 
2055-2061. 
Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P. and 
Korsmeyer, S. J. (1988). Alternative promoters and exons, somatic mutation and 
deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO Journal 7: 123-131. 
Shangary, S. and Johnson, D. E. (2003). Recent advances in the development of 
anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 
17: 1470-1481. 
Singh, S. V., Herman-Antosiewicz, A., Singh, A. V., Lew, K. L., Srivastava, S. K., 
Kamath, R., Brown, K. D., Zhang, L. and Baskaran, R. (2004). Sulforaphane-induced 
G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation 
of cell division cycle 25C. The Journal of Biological Chemistry 279: 25813-25822. 
Singh, S. V., Srivastava, S. K., Choi, S., Lew, K. L., Antosiewicz, J., Xiao, D., Zeng, 
Y., Watkins, S. C., Johnson, C. S., Trump, D. L., Lee, Y. J., Xiao, h. and Herman-
Antosiewicz, A. (2005). Sulforaphane-induced cell death in human prostate cancer 
cells is initiated by reactive oxygen species. Journal of Biological Chemistry 280: 
19911-19924. 
 Smith, T. J., Guo, Z., Li, C., Ning, S. M., Thomas, P. E. and Yang, C. S. (1993). 
Mechanisms of inhibition of 4-methylnitrosamino)-1-(3-pyridyl)-1-butanone 
bioactivation in mouse by dietary phenethyl isothiocyanate. Cancer Research 53: 
3276-3282. 
Solt, D. B., Chang, K.-W., Helenowski, I. and Rademaker, A. W. (2003). Phenethyl 
isothiocyanate inhibits nitrosamine carcinogenesis in a model for study of oral cancer 
chemoprevention. Cancer Letters 202: 147-152. 
Spitz, M. R., Duphorne, C. M., Detry, M. A., Pillow, P. C., Amos, C. I., Lei, L., de 
Andrade, M., Gu, X., Hong, W., K. and Wu, X. (2000). Dietary intake of 
isothiocyanates: evidence of a joint effect with glutathione S-transferase 
polymorphisms in lung cancer risk. Cancer Epidemiology, Biomarkers and 
Prevention 9: 1017-1020. 
Srivastava, S. K., Xiao, D., Lew, K. L., Hershberger, P., Kokkinakis, D. M., Johnson, 
C. S., Trump, D. L. and Singh, S. V. (2003). Allyl isothiocyanate, a constituent of 
cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in 
vivo. Carcinogenesis 24: 1665-1670. 
Srivastava, S. K. and Singh, S. V. (2004). Cell cycle arrest, apoptosis induction and 
inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl 
isothiocyanate against human pancreatic cancer cells. Carcinogenesis 25: 1701-1709. 
Steinman, H. M. (1995). The Bcl-2 oncoprotein functions as a pro-oxidant. Journal of 
Biological Chemistry 270: 3487-3490. 
Steinmetz, K. A. and Potter, J. D. (1991). Vegetables, fruit and cancer. I. 
Epidemiology. Cancer Causes and Control 2: 325-357. 
Steinmetz, K. A. and Potter, J. D. (1996). Vegetables, fruit and cancer prevention. 
Journal of the American Dietetic Association 96: 1027-1039. 
Strasser, A., Harris, A. W., Bath, M. L. and Cory, S. (1990). Novel primitive 
lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. 
Nature 348: 331-333. 
Sun, S. Y., Hail, N. and Lotan, R. (2004). Apoptosis as a novel target for cancer 
chemoprevention. Journal of the National Cancer Institute 96: 662-672. 
Sun, X. Z., Vinci, C., Makmura, L., Han, S., Tran, D., Nguyen, J., Hamann, M., 
Grazziani, S., Sheppard, S., Gutova, M., Zhou, F., Thomas, J. and Momand, J. (2003). 
Formation of a disulfide bond in p53 correlates with inhibition of DNA binding and 
tetramerization. Antioxidants and Redox Signalling 5: 655-665. 
Tang, C. S. and Tang, W.-J. (1976). Inhibition of papain by isothiocyanates. 
Biochimica et Biophysica Acta 452: 510-520. 
Tang, L. and Zhang, Y. (2004). Dietary isothiocyanates inhibit the growth of human 
bladder carcinoma cells. The Journal of Nutrition 134: 2004-2010. 
 Tang, L. and Zhang, Y. (2005). Mitochondria are the primary target in isothiocyanate-
induced apoptosis in human bladder cancer cells. Molecular Cancer Therapeutics 4: 
1250-1259. 
Thomson, S. J., Brown, K. K., Pullar, J. M. and Hampton, M. B. (2005). Phenethyl 
isothiocyanate triggers apoptosis in Jurkat cells made resistant by the overexpression 
of Bcl-2. Cancer Research Article in Press. 
Thornalley, P. J. (2002). Isothiocyanates: mechanism of cancer chemopreventive 
action. Anti-Cancer Drugs 13: 331-338. 
Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-
Calvo, M., Houtzager, V. M., Nordstrom, P. A., Royl, S., Vaillancourt, J. P., 
Chapman, K. T. and Nicholson, D. W. (1997). A combinatorial approach defines 
specificities of members of the caspase family and granzyme B. The Journal of 
Biological Chemistry 272: 17907-17911. 
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. and Croce, C. M. (1984). 
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) 
chromosome translocation. Science 226: 1097-1099. 
Twomey, C. and McCarthy, J. V. (2005). Pathways of apoptosis and importance in 
development. Journal of Cellular and Molecular Medicine 9: 345-359. 
Ueda, S., Masutani, H., Nakamura, H., Tanaka, T., Ueno, M. and Yodoi, J. (2002). 
Redox control of cell death. Antioxidants and Redox Signaling 4: 405-414. 
van den Dobbelsteen, D. J., Nobel, C. S. I., Schlegel, J., Cotgreave, I. A., Orrenius, S. 
and Slater, A. F. (1996). Rapid and specific efflux of reduced glutathione during 
apoptosis induced by anti-Fas/APO-1 antibody. The Journal of Biological Chemistry 
271: 15420-15427. 
Vander Heiden, M. G. and Thompson, C. B. (1999). Bcl-2 proteins: regulators of 
apoptosis or of mitochondrial homeostasis. Nature Cell Biology 1: E209-E216. 
Vaux, D. L., Cory, S. and Adams, J. M. (1988). Bcl-2 gene promotes haemopoietic 
cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-
442. 
Veis, D. J., Sorenson, C. M., Shutter, J. R. and Korsmeyer, S. J. (1993). Bcl-2-
Deficient Mice Demonstrate Fulminant Lymphoid Apoptosis, Polycystic Kidneys, 
and Hypopigmented Hair. Cell 75: 229-240. 
Vermeulen, M., van Rooijen, H. J. M. and Vaes, W. H. J. (2003). Analysis of 
isothiocyanate mercapturic acids in urine: a biomarker for cruciferous vegetable 
intake. Journal of Agricultural and Food Chemistry 51: 3554-3559. 
Visanji, J. M., Duthie, S. J., Pirie, L., Thompson, D. G. and Padfield, P. J. (2004). 
Dietary isothiocyanates inhibit Caco-2 cell proliferation and induce G2/M phase cell 
cycle arrest, DNA damage, and G2/M checkpoint activation. The Journal of Nutrition 
134: 3121-3126. 
 Voehringer, D. W. and Meyn, R. E. (1998). Reversing drug resistance in Bcl-2-
expressing tumor cells by depleting glutathione. Drug Resistance Updates 1: 345-351. 
von Weymarn, L. B., Chun, J. A. and Hollenberg, P. F. (2005). Effects of benzyl and 
phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in 
smokers. Carcinogenesis 27: 782-790. 
Weiller, M., Latta, M., Kresse, M., Lucas, R. and Wendel, A. (2004). Toxicity of 
nutritionally available selenium compounds in primary and transformed hepatocytes. 
Toxicology 201: 21-30. 
Wonsey, D. R., Zeller, K. I. and Dang, C. V. (2002). The c-Myc target gene PRDX3 
is required for mitochondrial homeostasis and neoplastic transformation. Proceedings 
of the National Academy of Sciences, USA 99: 6649-6654. 
Wrobel, K., Claudio, E., Segade, F., Ramos, S. and Lazo, P. S. (1996). Measurement 
of cytotoxicity by propidium iodide staining of target cell DNA. Application to the 
quantification of murine TNF-α. Journal of Immunological Methods 189: 243-249. 
Wu, S.-J., Ng, L. T. and Lin, C.-C. (2005). Effects of antioxidants and caspase-3 
inhibitor on the phenethyl isothiocyanate-induced apoptotic signaling pathways in 
human PLC/PRF/5 cells. European Journal of Pharmacology 518: 96-106. 
Xiao, D., Srivastava, S. K., Lew, K. L., Zeng, Y., Hershberger, P., Johnson, C. S., 
Trump, D. L. and Singh, S. V. (2003). Allyl isothiocyanate, a constituent of 
cruciferous vegetables, inhibits proliferation of human prostate cancer cells by 
causing G2/M arrest and inducing apoptosis. Carcinogenesis 24: 891-897. 
Xiao, D., Choi, S., Lee, Y. J. and Singh, S. V. (2005a). Role of mitogen-activated 
protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate 
cancer cells. Molecular Carcinogenesis 43: 130-140. 
Xiao, D., Zeng, Y., Choi, S., Lew, K. L., Nelson, J. B. and Singh, S. V. (2005b). 
Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous 
vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. 
Clinical Cancer Research 11: 2670-2679. 
Xu, C., Li, C. Y.-T. and Kong, A.-N. T. (2005a). Induction of phase I, II and III drug 
metabolism/transport by xenobiotics. Archives of Pharmacal Research 28: 249-268. 
Xu, C., Shen, G., Chen, C., Gelinas, C. and Kong, A.-N. T. (2005b). Suppression of 
NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through 
IκBα, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24: 4486-4495. 
Xu, K. and Thornalley, P. J. (2000a). Antitumour activity of sphingoid base adducts 
of PEITC. Bioorganic and Medicinal Chemistry Letters 10: 53-54. 
Xu, K. and Thornalley, P. J. (2000b). Studies on the mechanism of the inhibition of 
human leukemia cell growth by dietary isothiocyanates and their cysteine adducts in 
vitro. Biochemical Pharmacology 60: 221-231. 
 Xu, K. and Thornalley, P. J. (2001a). Signal transduction activated by the cancer 
chemopreventive isothiocyanates: cleavage of BID protein, tyrosine phosphorylation 
and activation of JNK. British Journal of Cancer 84: 670-673. 
Xu, K. and Thornalley, P. J. (2001b). Involvement of glutathione metabolism in the 
cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human 
leukaemia cells in vitro. Biochemical Pharmacology 61: 165-177. 
Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T.-I., Jones, D. 
P. and Wang, X. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c 
from mitochondria blocked. Science 275: 1129-1132. 
Yang, L., Cao, Z., Yan, H. and Wood, W. C. (2003). Coexistence of high levels of 
apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: 
implication for cancer specific therapy. Cancer Research 63: 6815-6824. 
Yang, Y.-M., Conaway, C. C., Chiao, J. W., Wang, C.-X., Amin, S., Whysner, J., Dai, 
W., Reinhardt, J. and Chung, F.-L. (2002). Inhibition of Benzo(a)pyrene-induced lung 
tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and 
phenethyl isothiocyanates during the postinitiation phase is associated with activation 
of mitogen-activated protein kinases and p53 activity and induction of apoptosis. 
Cancer Research 62: 2-7. 
Yang, Y.-M., Meena, J.-U., Schwartz, J., E., Conaway, C. C., Halicka, H. D., 
Traganos, F. and Chung, F.-L. (2005). N-Acetylcysteine conjugate of phenethyl 
isothiocyanate enhances apoptosis in growth-stimulated human lung cells. Cancer 
Research 65: 8538-8547. 
Ye, L. and Zhang, Y. (2001). Total intracellular accumulation levels of dietary 
isothiocyanates determine their activity in elevation of cellular glutathione and 
induction of phase 2 detoxification enzymes. Carcinogenesis 22: 1987-1992. 
Yin, X.-M., Oltvai, Z. N. and Korsmeyer, S. J. (1994). BH1 and BH2 domains of Bcl-
2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 
369: 321-323. 
Yu, R., Mandlekar, S., Harvey, K. J., Ucker, D. S. and Kong, A. N. (1998). 
Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease 
activity. Cancer Research 58: 402-408. 
Zamzami, N., Brenner, C., Marzo, I., Susin, S. A. and Kroemer, G. (1998). 
Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. 
Oncogene 16: 2265-2282. 
Zeiss, C. J. (2003). The apoptosis-necrosis continuum: insights from genetically 
altered mice. Veterinary Pathology 40: 481-495. 
Zhang, Y., Kolm, R. H., Mannervik, B. and Talalay, P. (1995). Reversible 
conjugation of isothiocyanates with glutathione catalyzed by human glutathione 
transferases. Biochemical and Biophysical Research Communications 206: 748-755. 
 Zhang, Y. and Talalay, P. (1998). Mechanism of differential potencies of 
isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. Cancer Reseach 58: 
4632-4639. 
Zhang, Y. (2001). Molecular mechanism of rapid cellular accumulation of 
anticarcinogenic isothiocyanates. Carcinogenesis 22: 425-431. 
Zhang, Y. and Callaway, E. C. (2002). High cellular accumulation of sulforaphane, a 
dietary anticarcinogen, is followed by rapid transporter-mediated export as 
dithiocarbamates. Biochemical Journal 364: 301-307. 
Zhang, Y., Tang, L. and Gonzalez, V. (2003). Selected isothiocyanates rapidly induce 
growth inhibition of cancer cells. Molecular Cancer Therapeutics 2: 1045-1052. 
Zhang, Y., Li, J. and Tang, L. (2005). Cancer-preventive isothiocyanates: 
dichotomous modulators of oxidative stress. Free Radical Biology and Medicine 38: 
70-77. 
Zhang, Y., Yao, S. and Li, J. (2006). Vegetable-derived isothiocyanates: anti-
proliferative activity and mechanism of action. Proceedings of the Nutrition Society 
65: 68-75. 
Zheng, G.-Q., Kenney, P. M. and Lam, L. K. T. (1992). Phenylalkyl isothiocyanate-
cysteine conjugates as glutathione S-transferase stimulating agents. Journal of 
Medical Chemistry 35: 185-188. 
Zou, H., Li, Y., Liu, X. and Wang, X. (1999). An APAF-1:cytochrome c multimeric 
complex is a functional apoptosome that activates procaspase-9. The Journal of 
Biological Chemistry 274: 11549-11556. 
 
 
 
